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ABSTRACT 
Background: Utility values reflect people’s preferences for health states. The 
development of a value set, which assigns utility values to all possible health states 
described by a health state utility instrument, involves research participants valuing 
a number of health states. Previous studies have shown that valuation of disease-
specific health states can be affected by adding a disease label on their descriptions. 
However, the impact of a label on generic health states is not clear. Another long-
debated issue is whether value sets should be based on patients’ or the general 
population’s preferences. This matters if there are systematic differences in their 
valuations, for which limited research has been done. Another important but rarely 
studied issue is the sample size determination for value set studies.  
Aims: (i) To evaluate how the most severe health state (a generic health state) 
labelled as “All-worst” is valued by the general population, (ii) to compare values for 
hypothetical health states elicited from patients with chronic disease and from the 
general population, and (iii) to propose methods for determining the sample size for 
value set studies for the latest version of EQ-5D health state utility instrument.  
Materials: Data from three studies, referred to as A, B and C, were used. The 
analyses for aims (i), (ii), and (iii) were based on study A, A & B, and C, respectively. 
All studies were cross-sectional, face-to-face surveys of health state valuation 
conducted in participants from Singapore. Study A involved valuation for SF-6D 
and EQ-5D health states using the visual analog method in the general population 
(n = 1034). Study B involved valuation for EQ-5D health states using the composite 
time trade-off method in general population (n = 175), heart diseases patients (n = 
175), and cancer patients (n = 175). Study C involved valuation for EQ-5D using 
the composite time trade-off method in the general population (n = 1000). 
Methods: An ordinary least-square (OLS) regression model was performed to 
compare the valuation score between the most severe health states labelled as “All-
worst” and other health states, adjusting for health state descriptors. Similar model 
with addition of socio-demographic covariates was performed to compare the 
valuation score given by patient populations and the general population. Finally, I 
proposed four approaches for determining the sample size for the EQ-5D value set 
studies. The first approach was based on acheiving the desired width of prediction 
interval for valuation scores using an OLS model. The second approach empirically 
determined a sample size based on mean absolute error in predicting valuation scores 
using empirical data. The last two approaches were based on assessing the statistical 
significance and estimating regression coefficients with a desired width of confidence 
interval in the OLS model.  
Results: In Study A (general population sample), about 50% of participants were 
female, and 12% eldrely (above 60 years). About 43% of participants self-reported 
having chronic diseases (14% rheumatism, 13% hypertension, 9% diabetes, 4% heart 
disese, and 4% lung disesaes). Participants in the patient's groups were older 
compared to healthy participants. In Study B sample, patient populations had a 
higher proportion of elderly (53% in heart disease and 33% in cancer vs 17% in 
general population). The heart disease group had a lower proportion of female (34% 
in heart disease vs 58% in cancer and 53% in general population). Study C (general 
population sample) had about 53% female, and 17% elderly participants.  
Using data from Study A, I found that the valuation of the health state labelled as 
“All-worst” was significantly lower than the value expected according to its 
descriptors. I compared the valuation of health states by participants with chronic 
diseases and a general population in Studies A and B. Values of mild and severe 
states elicited by patients with heart disease were significantly different from the 
general population. No such difference was found between any other patient groups 
and the general population. Finally, I developed and demonstrated the four 
approaches for determining the sample size for value set studies using required 
parameters estimated from Study C.  
Conclusions: A labelling effect is plausible in value set studies, and therefore 
labelling health states should be avoided. Patients with chronic diseases may differ 
from the general population in the strength of their preferences for hypothetical 
health states. Cost-utility analysis based on utility values derived from the general 
population may not accurately evaluate healthcare interventions for certain type of 
diseases, such as heart diseases. Finally, my methods proposed for sample size 
determination can help to decide on an appropriate sample size for value set studies. 
 
TIIVISTELMÄ 
Taustaa: Ihmisten terveydentilan arvostus heijastuu hyötyarvoihin. Jos halutaan 
muodostaa arvojoukko, jossa nimetään hyötyarvot kaikille mahdollisille 
terveyskyselyssä kuvatuille terveydentiloille, tutkimukseen osallistujien on arvioitava 
erilaisia terveydentiloja. Aiempien tutkimusten mukaan sairauskohtaisten 
terveydentilojen arviointiin voidaan vaikuttaa lisäämällä kuvaukseen sairauden nimi. 
Nimeämisen vaikutus yleisiin terveydentiloihin on kuitenkin epäselvää. Lisäksi 
keskustelua on käyty pitkään siitä siitä, pitäisikö arvojoukkojen perustua vain 
potilaiden vai yleisemmin koko valtaväestön mielipiteisiin. Tämä on olennaista, jos 
arvioinneissa on järjestelmällisiä eroja, joita on tutkittu vasta vähän. Toinen tärkeä, 
joskin harvoin tutkittu, aihe on arvojoukkotutkimusten otoskoon määrittäminen.  
Tavoitteet: 1) Tutkia, miten valtaväestö arvioi kaikista vakavinta, pahimmaksi 
nimettyä (yleistä) terveydentilaa, 2) vertailla kroonisista sairauksista kärsivien 
potilaiden ja valtaväestön hypoteettisten terveystilojen arviointeja, sekä 3) ehdottaa 
keinoja EQ-5D-elämänlaatumittaria hyödyntävien arvojoukkotutkimusten otoskoon 
määrittämiselle.  
Materiaalit: Tutkimuksessa käytettiin aineistoja kolmesta tutkimuksesta, joihin 
viitataan tutkimuksina A, B ja C. Tavoitteiden 1, 2 ja 3 analyysit perustuivat 
järjestyksessä tutkimuksiin A, A+B ja C. Kaikki tutkimukset olivat kasvotusten 
suoritettuja poikittaistutkimuksia, joissa singaporelaiset osallistujat arvioivat 
terveydentilaansa. Tutkimuksessa A arvioitiin SF-6D- ja EQ-5D-mittarien mukaisia 
terveydentiloja visuaalisella analogisella metodilla valtaväestön keskuudessa (n = 
1 034). Tutkimuksessa B arvioitiin valtaväestön (n = 175), sydänsairaiden (n = 175) 
ja syöpäpotilaiden (n = 175) EQ-5D-mittarin mukaisia terveydentiloja yhdistetyllä 
laatupainotettujen elinvuosien tutkimuksella. Tutkimuksessa C arvioitiin 
valtaväestön (n = 1 000) EQ-5D-mittarin mukaisia terveydentiloja yhdistetyllä 
laatupainotettujen elinvuosien tutkimuksella. 
Menetelmät: Aineiston analyysissa käytettiin regressioanalyysiä pienimmän 
neliösumman menetelmällä (PNS) pahimman ja muiden terveydentilojen arviointien 
vertailemiseksi. Menetelmää mukautettiin terveydentilojen kuvaajien mukaan. 
Potilasryhmien ja valtaväestön arvioiden vertailua varten suoritettiin vastaava 
analyysi, johon oli lisätty sosiaalisia ja demografisia taustamuuttujia. Lopuksi 
esitetään neljä lähestymistapaa EQ-5D-arvojoukkotutkimusten otoskoon 
määrittämiseksi. Ensimmäisessä lähestymistavassa pyritään saavuttamaan haluttu 
ennustusväli arvioinneille PNS-mallin avulla. Toisessa lähestymistavassa otoskoko 
määritetään empiirisesti perustuen keskimääräiseen absoluuttiseen virheeseen 
arviointien ennustamisessa empiiristen tulosten perusteella. Kolmas ja neljäs 
lähestymistapa perustuvat tilastollisen merkitsevyyden ja regressiokertointen 
arvioinnille sekä PNS-mallin halutulle luottamusvälille.  
Tulokset: Tutkimuksessa A väestöotoksesta noin 50 % vastaajista oli naisia ja 12 % 
yli 60-vuotiaita. Noin 43 % vastaajista ilmoitti kärsivänsä kroonisista sairauksista 
(14 % reuma, 13 % kohonnut verenpaine, 9 % diabetes, 4 % sydänsairaus, 4 % 
keuhkosairaus). Potilasryhmien vastaajat olivat terveitä vastaajia vanhempia. 
Tutkimuksen B otoksesta potilasryhmissä oli enemmän ikääntyneitä ihmisiä kuin 
valtaväestössä (sydänsairaat: 53 %, syöpäpotilaat: 33 %, valtaväestö: 17 %). 
Sydänsairaiden ryhmässä naisten osuus oli pienempi kuin muissa ryhmissä (34 %, vs. 
58 % syöpäsairaissa ja 53 % valtaväestössä). Tutkimuksen C väestöotoksesta noin 
53 % oli naisia ja 17 % ikääntyneitä.  
Tutkimuksen A tuloksista kävi ilmi, että kaikista huonoimmaksi nimetyn 
terveydentilan arviointi oli merkittävästi matalampi kuin mitä oli odotettavissa 
kuvaajien perusteella. Tässä tutkimuksessa verrattiin tutkimusten A ja B kroonisesti 
sairaiden vastaajien terveydentila-arvioita samojen tutkimusten väestöotoksiin. 
Sydänsairaiden vastaajien lievien ja vakavien tilojen vastaukset poikkesivat 
merkittävästi valtaväestön vastauksista. Tällaista eroa ei löytynyt minkään muun 
potilasryhmän ja valtaväestön välillä. Lopuksi kehitettiin ja esiteltiin neljä tapaa 
määrittää arvojoukkotutkimuksen otoskoko tutkimuksen C pohjalta esitetyin 
parametrein.  
Johtopäätökset: Sairauden tai terveydentilan nimeäminen saattaa vaikuttaa 
arvojoukkotutkimuksen tuloksiin, joten sitä tulisi välttää. Kroonisesti sairaiden 
potilaiden vastaukset saattavat poiketa valtaväestöstä hypoteettisten terveydentilojen 
suosimisen voimakkuudessa. Valtaväestön vastauksista saatujen hyötyarvojen 
kustannus-hyötyanalyysin avulla ei välttämättä voida arvioida terveydenhuollon 
toimia tarkasti joidenkin sairaustyyppien, kuten sydänsairauksien, osalta. Otoskoon 
määrittämiseen ehdottamani tavat saattavat auttaa sopivan otoskoon valitsemisessa 
arvojoukkotutkimuksiin. 
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1 INTRODUCTION 
Patients with chronic diseases and their families do not single-mindedly pursue 
increased survival when deciding between treatments. They also take into 
consideration other factors such as the cost of care and quality of life 
(QoL).(Malhotra et al., 2015) Hence, a QoL value in conjunction with cost and 
improvement in survival is important for choosing fairly between different 
treatments. Cost-utility analysis (CUA) is a special form of cost-effectiveness analysis 
used for the health technology assessment (HTA) in which the result is presented in 
cost per quality-adjusted life year (QALY) gained. QALY is the product of the time 
spent in a health state and its preference (also called utility). A treatment that requires 
less cost per QALY gained is considered more cost-effective. 
CUA requires a value set having utility values of all possible health states according 
to a health state utility instruments, such as EuroQol-5Dimension (EQ-5D) and 
Short Form-6Dimension (SF-6D). It is developed by surveying in a patient 
population or general population which asks participants to rate their preferences 
for different health states, including the most severe health state and dead state, 
presented to them. The preference rating can be performed in various ways such as 
visual analog scale (VAS), time trade-off (TTO) and standard gamble (SG) 
methods.(Xie et al., 2014) A higher utility value indicates the health state is preferred.  
Despite past successes in developing and applying CUA methods and its 
components, various methodological issues and uncertainties have remained. They 
can hinder the accuracy and appropriateness of CUA and methodological 
development for health outcome valuation.  
One of the key concerns during the health state valuation is – how to minimize 
impact of external factors including survey research procedures so that the derived 
utility value reflects participant’s true preference for the given health state, but not 
the artifact effect of external factors. For example, it is not uncommon to label the 
most severe health state as ‘all worst’ or ‘pits’ in addition to its description in value 
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set studies.(Ratcliffe et al., 2016, Craig et al., 2013, Wee et al., 2006) But the impact 
of such labeling on its value is unknown.  
Another key concern is the sample size requirement for developing a value 
set, specifically for many low-resourced and/or small countries. However, methods 
for determining an appropriate sample size for value set studies is rarely studied. The 
sample size methods used in previous value set studies were either not aligned with 
the analysis strategy and/or not capitalized for the valuation protocol used. The 
majority of such sample size determination method studies were based on the 
landmark Measurement and Valuation of Health (MVH) study protocol for 3-level 
EQ-5D (EQ-5D-3L) utilizing the conventional TTO method.(Dolan, 1997) 
However, so far, no statistically justified sample size determination method has been 
proposed for any other valuation protocol, even for the recent standard protocol for 
5-level EQ-5D (EQ-5D-5L) value set studies adopting the composite TTO method. 
Therefore, what should be the sample size for a value set study is an open question.  
A long-debated issue that is increasingly getting attention is – how to 
incorporate patient preferences in the HTA.(Brazier et al., 2017a, Underwood, 2016, 
Bridges and Jones, 2007) Many countries across the world are promoting patient-
centric approaches in healthcare management. This includes involvement of patients 
in the treatment decision. The question of whose preferences (utility), patient or the 
general population, should be used in the clinical decision making, and 
reimbursement for healthcare cost have not reached consensus.(Zhang et al., 2017, 
McTaggart-Cowan, 2011, Stamuli, 2011) Furthermore, it is not entirely clear whether 
patients have different preferences than the general population.(Ogorevc et al., 2017, 
Karimi et al., 2017a, Peeters and Stiggelbout, 2010) Limited research has been done 
in this direction. The issue is particularly important for countries where healthcare 
cost is not heavily subsidized by the government.  
The issues mentioned above are just some of many issues to be resolved in the 
field of CUA and health state valuation. In this thesis, I investigated three 
methodological issues in health state valuation and provided recommendations to 
improve the valuation process. These issues are discussed in detail in the next 
chapter.  
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2 REVIEW OF LITERATURE 
2.1 Approach to the Literature Review 
The objective of the literature reivew is to summarize the previous research done 
related to the aims of my research presented in this thesis. Primarily, the review 
included literature on labeling effect on valuation of health states, impact of chronic 
disease experience on valuation of hypothetical health states, and sample size 
determination methods used in value set studies.  
The literature search was performed for electronic publications indexed in 
PubMed. Publications were indentified using combination of key words such as 
health state valuation, general population, patient population, hypothetical health 
states, sample size, value set, labeling health state/health condition. Relevent 
publications were shortlisted from reviewing the publication titles and abstracts. 
Relevent references cited in the shortlisted publication were also included in the 
literature review. Additional literatue such as reports published by governments, and 
non-goverment or research organizations were included from known sources. The 
last search was performed on February 2018 with emphasize to include recent 
publications.  
2.2 Health State Utility Instruments 
A value set provides utility values for all possible health states described by a health 
state utility instrument. As value sets are generally used for CUA for comparing cost-
benefit ratio of health products across different therapeutic areas, health states for 
value sets are usually described using generic (not specific to any disease) health state 
utility instruments. The most commonly used generic health state utility instruments 
are EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D).(Brazier 
et al., 2017a)  
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2.2.1 EQ-5D 
The EQ-5D is the most widely used generic health state utility instruments for 
CUA.(Wisløff et al., 2014) It comprises of five dimensions (mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression) plus a visual analog scale (EQ-
VAS) of the overall health status. There are many language versions of the EQ-5D 
validated in various disease groups in many countries including Singapore.(Devlin 
and Brooks, 2017) It is the health state utility instrument (characterized by its 
descriptive system and valuation technique) preferred by the National Institute for 
Health and Care Excellence (NICE), United Kingdom, for eliciting utility 
values.(NICE, 2013) The original version of the EQ-5D (EQ-5D-3L) has 3 response 
levels (no problem, moderate problems, and extreme problems) for each of the five 
dimensions (see Appendix 1). EQ-5D-3L health states are defined by combining 
the five dimensions at different response levels. For example, the health state ‘11211’ 
indicates no problem on any of the five dimensions, except ‘moderate problems’ 
with doing ‘usual activities’ (3rd dimension at response level 2). A total of 243 health 
states can be described using the EQ-5D-3L. 
Recently, the EQ-5D’s response levels have been revised from 3-level to 5-level 
(no problem, slight problems, moderate problems, severe problems, and extreme 
problems) (see Appendix 2). This revision has been shown to increase measurement 
precision. A total of 3125 health states can be described using the 5-level EQ-5D 
(EQ-5D-5L).  
2.2.2 SF-6D 
The Short Form-36 is 36 items health survey questionnaire used to assess patient 
health.(Ware Jr and Sherbourne, 1992) Short Form-36 has six dimensions – physical 
functioning, role limitations, social functioning, pain, mental health, and vitality. 
Each dimension has 4 to 6 levels. The Short Form-36 is available in many languages 
and also validated in several countries for a variety of disease populations.(Kwan et 
al., 2016, Thumboo et al., 2013, Thumboo et al., 2001) The SF-6D health state 
descriptive system represents one item from each of the 6 dimension of the SF-36 
(see Appendix 3).(Brazier et al., 2002) Thus, a total of 18,000 health states can be 
described using the SF-6D.  
 21 
2.3 Valuation Methods 
Preference values elicited for health states are called utility or index values. A set of 
preference values elicited for all possible health states based on a given health state 
utility instrument is called a preference set, utility set, value set or index set. Utility 
values for different health states are determined by surveying patients or the general 
population which asks participants to rate their preferences for different health states 
presented to them. There are several valuation methods such as the VAS, TTO, 
standard gamble, and the like.(Brazier et al., 2017a, Gudex et al., 1996) Furthermore, 
there are several variants of these methods are also available and used to develop 
value sets. I used the VAS and TTO methods in my studies described in this thesis. 
The variants used in my studies are explained here.  
2.3.1 Visual Analog Scale Method 
This method involves two steps. In the first step, the participant is presented with a 
hypothetical scenario by showing ‘immediate death’ and the most severe health state 
(e.g., ‘33333’ for EQ-5D-3L) and then asked whether he/she prefers to die now 
(immediate death) or live rest for the rest of life in the most severe health state. The 
state that the participant considered less desirable is assigned a value 0 on a 100-
point VAS scale (similar to a thermometer) with two ends 100 (most desirable) and 
0 (least desirable).(Gudex et al., 1996) Figure 1 shows the VAS scale used in one of 
the studies (Study A described in section  4.2) used in this thesis. There could be 
possibility of using the EQ-VAS (Appendices 1 and 2) as the VAS scale. In the 
second step, the participant is asked to value a unique set of health states (e.g., 10 
health states) from a pre-defined subset of all possible states (e.g., 243 health states 
for the EQ-5D-3L). In addition, the most severe or dead state, which one is not 
valued earlier at 0, is asked to value along with other states. The participant is asked 
imagining him/herself in the given health states for the rest of the life without 
changing and indicate health state positions for valuing health states on the VAS 
scale. Multiple health states can assign same value. Usually, the VAS valuation score 
is rescaled using an appropriate transformation function to get utility value 
representing 1 for perfect health, 0 for dead state, and negative values for worse than 
death states.  
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Figure 1. Visual analog scale for health state valuation 
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2.3.2 Time Trade-Off Method 
Like the VAS method, the participant is asked to value a unique set of health states 
from a pre-defined subset of states in the TTO method. The TTO method involves 
an iterative procedure for each of the health states. The participant is asked how 
many years (x) in full health he/she would consider equivalent to a given amount of 
time (t) in an (unhealthy) health state.(Oppe et al., 2016, Oppe et al., 2014) The time 
t is generally set at 10 years. At the start, the number of years in full health is set at 
10 and then reduced gradually to the point at which the participant is indifferent 
about the choice between the health state (e.g., ‘21121’ EQ-5D-5L health state in 
Figure 2) in 10 years and full health for a shorter period (x). The utility of a health 
state is calculated as x/10.   
 
Figure 2. The time trade-off method with a 10-year time frame to value states worse than death 
If a health state is very severe (e.g., ‘35554’ EQ-5D-5L health state in Figure 3), 
the participant may consider experiencing this for 10 years so distasteful that he/she 
would consider it worse than death and prefer immediate death (i.e., x ≤ 0). Such 
health states are valued using the lead-time TTO method.(Oppe et al., 2016, Oppe 
et al., 2014) In this approach, the health state is measured by asking the participant 
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to imagine a life of 20 years, in which the ﬁrst 10 are in full health (i.e., lead time) 
and the remaining 10 in the health state, and then searching for the indifference point 
between this life and x years of full health. The utility of such health states is 
calculated as (x-10)/10. 
 
Figure 3. The lead-time time trade-off method with a 20-year time frame to value states worse than 
death 
In the composite TTO method, the participant is first asked whether he/she 
considers the given health state better or worse than death. The health states better 
than death are valued using the conventional TTO (Figure 2), and the health states 
worse than death are valued using the lead-time TTO (Figure 3). The composite 
TTO method ensures that the utility value of each health state is bounded at -1 and 
1, with 0 represents value for the ‘dead’ state. This approach is recommended by the 
EuroQol Research Foundation (the developer of EQ-5D) in the EuroQol Valuation 
Technology (EQ-VT) protocol for EQ-5D-5L value sets (explained later with more 
details).(Oppe et al., 2014) 
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2.4 Current Methodological Issues in Cost-Utility Analysis and 
Health State Valuation Methods 
Over the last three decade methodologies for performing CUA and its components 
such as health state valuation are evolving. There is growing interest in evaluating 
health outcomes using QALY, and such approaches are adopted in policy guidelines 
by several regulatory agencies.(ISPOR, 2018) The research on developing health 
state utility instruments and valuation methodology assigning weights to health 
states/conditions described by such questionnaires has been a great success. It 
enabled to compare health benefits across different symptoms and diseases. 
Nevertheless, various methodological issues and uncertainties have remained, which 
can hamper the accuracy and appropriateness of CUA and health state valuation.  
The widely used valuation methods such as the TTO and standard gamble, 
are complex, cognitively demanding, and time-consuming which make them difficult 
to implement in elderly and participants with low education level.(Karimi et al., 
2017b, Brazier et al., 2017b) These methods are also vulnerable to external factors 
such as interviewer effect and survey research procedures. The newly emerging 
discrete choice experiment method is still in the exploratory stage, and several issues 
remain to be resolved before it can potentially replace the existing valuation 
methods.(Bansback et al., 2014)  
In addition to these issues, sample size requirement for developing a value 
set is a major constraint for many low-resourced countries. However, methods for 
determining an appropriate sample size for value set studies is rarely studied. For 
example, the landmark Measurement and Valuation of Health (MVH) study in 1993 
for EQ-5D-3L value set was conducted with a sample size of over 3000 participants 
from the United Kingdom.(Dolan, 1997) However, subsequently, a value set study 
in The Netherlands in late 2006 showed that a sample size of 300 participants could 
be sufficient.(Lamers et al., 2006) These sample size methods were based on the 
MVH study protocol for EQ-5D-3L value set studies using the conventional TTO 
method. The majority of sample size methods were also not aligned with the planned 
statistical analysis for developing the value set and/or capitalized on the valuation 
protocol. So far, no statistically justified method has been proposed for any other 
valuation protocol, even for the recent standard protocol for EQ-5D-5L value set 
studies. Therefore, what should be the sample size for a value set study is an open 
question. On another note, recently some research has been initiated to optimize 
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health states selection for direct valuation to improve the precision in predicting 
utility values and ultimately to reduce the number of health states to be valued 
and/or reduce the required sample size.(Yang et al., 2017) However, this research is 
based on the EQ-5D-3L health states using the VAS method. It will require being 
generalized for other valuation methods as well as health state utility instruments. 
Similarly, researchers in this field are actively trying different statistical models for 
enhancing the predictive ability and gain precision through modeling techniques, but 
so far limited success has been achieved.(Rand-Hendriksen et al., 2017, Ramos-Goñi 
et al., 2017) 
Another long-debated issue which is increasingly getting attention is – how 
to incorporate patient preferences in the HTA.(Zhang et al., 2017, Underwood, 
2016, Bridges and Jones, 2007) Many countries across the world are promoting 
patient-centric approaches in healthcare management. This includes involvement of 
patients in the treatment decision. The question of whose preferences (utility), 
patient or the general population, should be used in the clinical decision making, and 
reimbursement for healthcare cost have not reached consensus.(Brazier et al., 2017a, 
Stamuli, 2011, McTaggart-Cowan, 2011) Furthermore, it is not entirely clear whether 
patients have different preferences than the general population.(Ogorevc et al., 2017, 
Karimi et al., 2017a, Peeters and Stiggelbout, 2010) Limited research has been done 
in this direction. The issue is specifically important for countries where healthcare 
cost is not heavily subsidized by the government.  
Along the line of incorporating patient preferences in HTAs, CUAs based 
on generic health state utility instruments may also be considered suboptimal for 
certain patient populations in which an essential dimension of QoL affected by the 
disease or its treatment is not adequately incorporated. For example, the EQ-5D 
lacks dimension related to vision, and speech. So, a CUA based on the EQ-5D utility 
values for evaluating treatment options in patients with cataracts or patients with 
stroke may be criticized. Therefore, research on adding extra items as “bolt-on” in 
the EQ-5D and developing its value set will be needed.(Yang et al., 2015) 
Consequently, the issue of comparability of such value sets with the existing value 
sets requires being addressed.  
The issues mentioned above are just some of many issues to be resolved in the 
field of CUA and health state valuation. In this thesis, I investigated three 
methodological issues in health state valuation and provided recommendations to 
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improve the valuation process. These issues are discussed in detail in the subsequent 
sections.  
2.4.1 Issue with Labeling of the Most Severe Health State 
The most severe health state (e.g., ‘33333’ for EQ-5D-3L and ‘645655’ for SF-6D) 
described in a health state utility instrument is an important health state in the 
valuation process. Usually, either the most severe health state or dead state is valued 
lowest among all health states in valuation studies.(Green et al., 2000) The lower 
bound of utility values is therefore determined by them. Some previous studies have 
shown that valuation of severe health states can be affected by the survey research 
procedure and that their utility values are difficult to predict.(Al Sayah et al., 2016, 
Luo et al., 2007, Wee et al., 2006, Brazier et al., 2002) 
Among the other factors that can affect the valuation of the most severe health 
state, special attention is required as to how its value can be affected if a label is 
added in its description. It is not uncommon to label the most severe health state as 
‘all worst’ or ‘pits’ in value set studies.(Ratcliffe et al., 2016, Craig et al., 2013, Wee et 
al., 2006) There is an opinion that adding a disease label in disease-specific health 
state descriptions can have an impact on health state value, possibly due to prior 
knowledge or preconception of the disease.(Green et al., 2017, Robinson and Bryan, 
2013) However, no study to our knowledge has investigated the impact of labeling a 
generic health state. Therefore, how the most severe health state (in the presence of 
a label) is valued needs attention.  
2.4.2 Issue with Valuation by the General Population or a Patient 
Population 
Panel on Cost-Effectiveness in Health and Medicine in the United States and the 
National Institute for Health and Care Excellence in England and Wales recommend 
using value sets elicited by a general population for CUA.(Sanders et al., 2016, NICE, 
2013) A general population-derived utility is desirable when the utility is needed to 
inform decisions that allocate societal (taxpayer) resources.(Stamuli, 2011) However, 
a value set elicited by patients is preferred in clinical decision making from a patient-
centered perspective. If the treatment costs are mostly paid by patients themselves, 
the patient-derived utility is also relevant for CUA for the comparison of treatment 
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within the given patient population. A systematic review reported that less than one-
third of published CUAs use a general-population-derived utility; the remaining 
CUAs use a patient, clinician- or expert-derived utility, or authors’ judgments.(Brauer 
et al., 2006) Patient-derived utility values are believed to be more accurate as patients 
who have experienced the disease conditions can appraise their condition(s) more 
accurately than individuals who have not experienced such conditions.(Karimi et al., 
2017a, Russell et al., 1996) A meta-analysis reported that patients give higher values 
to their own health state than the individuals without such experience.(Peeters and 
Stiggelbout, 2010) However, there is conflicting evidence on whether patients with 
chronic diseases value hypothetical health states differently than individuals without 
chronic disease experience.(Ogorevc et al., 2017, Wang et al., 2014, Pickard et al., 
2013, Krabbe et al., 2011) The conflicting results could be because the patients might 
have adapted to their condition or because individuals with no disease experience 
overestimate the impact of disease or disability on QoL.(Wang et al., 2014) Other 
factors such as the type of condition, the severity of the condition, and valuation 
method may also contribute to the differences in valuation. For example, a study 
conducted by Suarez-Almazor et al.(Suarez-Almazor and Conner-Spady, 2001) 
showed that individuals with arthritis value health states similar to individuals 
without arthritis when the VAS method is used. However, individuals with and 
without arthritis gave different valuations when the TTO method is used. It should 
also be noted that most of the studies evaluating differences in valuations between 
the chronic disease patients and the general population were conducted in the 
western population, with only one study being conducted in Asian 
population.(Ogorevc et al., 2017, Wang et al., 2014, Pickard et al., 2013, Krabbe et 
al., 2011, Peeters and Stiggelbout, 2010) Furthermore, the majority of the studies 
have compared valuation of patients own health state being experienced at the time 
of survey with hypothetical health states. Several studies have shown that cultural 
differences affect the valuation.(Luo et al., 2014, Johnson et al., 2005) There are 
several Asian countries including Singapore, China, and India where the majority of 
healthcare cost is paid by patients themselves.(WHO, 2014) In such scenarios, it is 
important to evaluate CUA using patients’ ‘experienced-based’ value set. However, 
developing ‘experienced-based’ value set is challenging due to several reasons. It is 
difficult to ask patients who are experiencing very severe health states to provide 
value of their own health states. In some cases, it could be even impossible for health 
states such as ‘55555’ for the EQ-5D-5L. Therefore, usually, the sample size for 
valuation of severe health states are limited and their validity could be sub-optimal. 
Furthermore, the patient own health should also be valued using a disease-specific 
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health state utility instrument to describe the current health state accurately. 
However, in reality, it is uncommon to have such validate instrument that can be 
used for valuation. An alternative is to use a generic health state utility instrument 
and ask patients to value hypothetical health states from their own perspective. It is 
likely that patients have experience more of such health states than the general 
population. So far there is little evidence is available about differences in hypothetical 
health state valuation between patients with chronic diseases and the general 
population to decide on whose value set should be used.  
The question of whether patients and the general population have similar 
preferences for hypothetical health states has important implications on the use of 
the value set. If the answer is ‘yes,’ the use of utility values which reflects the health 
state preferences of the general population to inform medical decision making 
should be encouraged because they also reflect patients’ preferences. If the answer 
is ‘no,’ caution should be exercised when using utility values, based on general 
population preferences to evaluate the treatment benefit of clinical interventions or 
quality of care. Nevertheless, the answer to this question is still elusive given the 
seemingly contradicting findings in previous studies. 
2.4.3 Issue with Sample Size Determination of the EQ-5D-5L Value Set 
Studies 
With the revision of the response levels from 3-levels to 5-levels in the EQ-5D, a 
new value set for the EQ-5D-5L health states is needed. The EQ-5D-3L value set 
studies were either mostly conducted using the VAS or TTO method with no 
standard protocol.(Szende et al., 2007) Therefore, value sets developed for different 
countries with different valuation protocols were not comparable. Nevertheless, the 
previous value set studies provided information on pros and cons of different 
variants of these two valuation methods. After conducting a few pilot studies to 
optimize the valuation method, the EuroQol Research Foundation proposed a 
revised TTO method, called composite TTO method for EQ-5D-5L value sets. The 
protocol is named the EuroQol Valuation Technology (EQ-VT) protocol (Oppe et 
al., 2014, Oppe et al., 2016) and considered the ‘standard’ for uniformly developing 
EQ-5D-5L value sets. It has been used for developing EQ-5D-5L value sets for 
several countries including England (Devlin et al., 2017), China (Luo et al., 2017), 
Canada (Xie et al., 2016), Netherlands (Versteegh et al., 2016), Germany (Ludwig et 
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al., 2018), Japan (Ikeda et al., 2015), Korea (Kim et al., 2016), Indonesia (Purba et 
al., 2017), and Singapore.  
This standard protocol recommends a sample size of 1000 participants for a value 
set.(Oppe et al., 2014) The recommendation is based on some assumptions, such as 
10 valuations per health state is sufficient, with limited theoretical justification. 
Furthermore, there is no empirical evaluation performed based on the data from the 
EQ-5D-5L value set studies on the appropriateness of the sample size. The selection 
of an optimal sample size is very important from both statistical and feasibility points 
of view. A study with insufficient sampler size lacks precision, and the use of 
unnecessarily large sample size leads to waste of resources and time. Although CUA 
is getting popularity and evidence of cultural differences in valuation is growing, 
many countries do not have country-specific value sets, possibly due to resource 
constraint for conducting a large-scale value set study. If a method allowing to 
estimate the sample size for desired precision or evaluating the impact of a sample 
size on the precision of predicted utility values is available, it will be very useful for 
planning value set studies according to study team’s requirements.  
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3 AIMS 
The research aims to provide recommendations for improving valuation techniques, 
development of value sets as well as the use of value sets. The specific aims were: 
1. To evaluate how the most severe health state is valued by the general 
population.  
 
2. To compare values for hypothetical health states elicited by patients with 
chronic disease and the general population. This has two sub-aims:  
2.1 To compare values for EQ-5D-3L health states elicited using the 
VAS method by individuals with self-reported chronic diseases 
(diabetes, rheumatism, hypertension, heart disease, lung disease) 
and by individuals with no chronic disease in the general 
population. 
2.2    To compare values for EQ-5D-5L health states elicited using the 
composite TTO method by individuals who were clinically 
diagnosed with chronic diseases (heart disease and cancer) and by 
individuals from the general population. 
 
3. To propose methods for estimating the sample size for EQ-5D-5L value set 
studies according to the standardized procedure of the EQ-VT protocol. 
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4 METHODS 
Data from three studies, referred to as A, B and C in this thesis for brevity, were 
used to achieve the research aims. The analyses for aims 1 and 2.1 were based on 
study A data. This study data was already available prior to the start of this thesis 
research. Study B was conducted to achieve aim 2.2. Study C data was used to 
demonstrate the methods proposed in aim 3. All three studies were conducted in 
Singapore.  
4.1 Demography of Singapore 
Singapore is a sovereign city-state in Southeast Asia with a land area of 719 km2. It 
is ranked highly in GDP per capita (USD 52961), healthcare, life expectancy, quality 
of life, personal safety, housing and education.(Wikipedia, 2017) Singapore 
comprises of 5.5 million residents with 74.3% of Chinese descent, 13.4% Malay, 
9.1% Indian, and 3.2% of other descent.(DOS, 2010) English is the most common 
language (80% literacy). Due to the scarcity of land, more than 80% of residents live 
in subsidized, high-rise, housing apartments (called “HDB” flats) built by the 
Housing and Development Board (HDB) of the government. Table 1 shows some 
key sociodemographic and health indicators for Singapore.  
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Table 1. Basic sociodemographic and health indicators for Singapore 
Indicator Measure 
Total area (km2) 719 
Total population (million) 5.54 
Population density (per km2) 7697 
Population annual growth rate (%) 1.2 
Average household size (persons) 3.39 
Per capita gross domestic product (USD) 52961 
Median household monthly income (USD) 6367 
Literacy rate (%) 99.5 
Life expectancy (years) 82.7 
Population aged 65 years and above (%) 11.8 
Ethnicity (%)  
     Chinese 74.3 
     Malays 13.4 
     Indians 9.1 
     Others 3.2 
Language most frequently spoken at home (%)  
     English 62.4 
     Mandarin & Chinese dialects 4.7 
     Malay 4.3 
     Tamil 0.1 
     Others 28.6 
Distribution of disability-adjusted life years (%)  
     Cardiovascular diseases 20 
     Cancer 19 
     Neurological, vision and hearing disorders 14 
     Diabetes mellitus 10 
     Others 37 
Source: Singapore Census 2010 (DOS, 2010) and Burden of Disease Study 2010 (MOH, 2010) 
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4.2 Study A: EQ-5D-3L and SF-6D Valuation Study in the 
Singapore General Population 
4.2.1 Study Design and Participants 
A cross-sectional, face-to-face survey of health state valuation for SF-6D and EQ-
5D-3L using the VAS method was conducted in 2009 from a representative sample 
of the general population of Singapore. A multi-stage quota sampling approach was 
used to randomly select residential blocks, within which households were selected, 
within which one person per household was selected. Quota for ethnicity (400 
Chinese, 400 Malay, and 234 Indian), gender (50% Female) and age (30% for 21–34 
years, 40% for 35–49 years, 30% for 50+ years) set. Half of the participants within 
each ethnicity were interviewed in English and the remaining half in their native 
languages, i.e., Mandarin for Chinese, Malay for Malays and Tamil for Indians. 
4.2.2 Valuation Procedure 
Two separate samples of 1034 participants each were selected for the SF-6D and 
EQ-5D-3L value sets using the VAS method (explained in section 1.3.1). A subset 
of 249 SF-6D states (Appendix 4) was selected (out of 18,000) based on the protocol 
of Brazier et al.(Brazier et al., 2002) Each participant was first presented to a 
hypothetical scenario by showing ‘immediate death,’ and the most severe health 
states (e.g. ‘645655’ for SF-6D) and then asked whether he/she prefers to die now 
(immediate death) or live rest for the rest of life in the most severe health state. Then, 
the participant was asked to value a unique set of 6 states from the subset of 249 SF-
6D states and either dead or the most severe health state, depending on which one 
was not valued earlier at 0. The unique set of 6 health states were assigned to each 
participant in a way that they include health states of varying severity from mild to 
severe. The valuation of EQ-5D-3L health states was carried out similarly as SF-6D. 
A subset of 42 EQ-5D-3L health states (Appendix 5) was selected based on the 
protocol of Dolan.(Dolan, 1997) The most severe health states (‘645655’ for SF-6D 
and ‘33333’ for EQ-5D-3L) were labeled as ‘all-worst.’ Unconscious state was also 
valued in addition to the other 6 assigned states.  
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4.2.3 Other Details 
The study collected information about self-reported chronic diseases. The data 
collection form had a pre-defined list of chronic diseases which included diabetes, 
high blood pressure/hypertension, heart diseases, stroke, asthma or other lung 
diseases, cancer, rheumatism/back pain or other bone or muscle illness, mental 
illness (e.g., depression, anxiety neurosis, schizophrenia) and other illness (e.g., 
kidney problems or dialysis). 
The study was approved by SingHealth Centralized Institutional Review Board. 
4.3 Study B: EQ-5D-5L Valuation Study in the Singapore 
General and Patient Populations 
4.3.1 Study Design and Participants 
A cross-sectional, face-to-face survey of health state valuation for the EQ-5D-5L 
using the composite TTO method was conducted in 2016 in Singapore. Heart 
disease and cancer patients attending outpatient clinics at the National Heart Centre 
Singapore and the National Cancer Centre Singapore, respectively, were invited to 
participate in their routine visits. The National Heart Centre Singapore and the 
National Cancer Centre Singapore are the largest capacity specialty centers in 
Singapore for heart disease and cancer patients, respectively. The main eligibility 
criterion for the heart disease patients was hospitalization primarily for heart disease 
in the last 5 years; this criterion was used to screen out patients with mild heart 
conditions. The primary eligibility criterion for the cancer patients was to have 
histologically confirmed cancer of any type and stage in the last 5 years; this criterion 
was used to screen out cancer survivors. The study also included a sample from the 
general population recruited from three shopping malls. Shopping malls in Singapore 
(including ones used in this study) are located in proximity to local bus and train 
stations as well as food centers, which are part of the general population’s daily 
routines. According to a lifestyle survey conducted by the Urban Redevelopment 
Authority of Singapore(URA, 2009), shopping malls are the third most regularly used 
facilities in Singapore. Therefore, sampling from shopping malls in Singapore is a 
good approximation of the general population. All participants were between 21 and 
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80 years old, able to read and communicate in English or Chinese (Mandarin), and 
well enough for an interview. A quota sampling based on age and gender 
distributions similar to the Singapore census was used to generate the general 
population sample. 
4.3.2 Valuation Procedure 
All interviews were conducted by the same trained interviewer using a computer 
program designed for the composite TTO method (see section 2.3.2) according to 
the EQ-VT protocol.(Oppe et al., 2014) Interviews were conducted in either English 
or Chinese according to participant’s preference. The interviews with the patients 
were conducted in the hospitals in a quiet waiting area. The general population 
participants were interviewed in a quiet place of the malls where they were recruited.  
The interviews started with some warm-up questions asking the participants to 
describe their own health using the EQ-5D-5L questionnaire. Subsequently, the 
composite TTO-based valuation task was explained to participants using the state of 
‘‘in a wheelchair’’ as an example, after which three practice EQ-5D-5L health states 
were administered to familiarize participants with the task and EQ-5D-5L health 
states of varying severity. The practice states were followed by the composite TTO 
valuation of 10 EQ-5D-5L health states. The interviews ended with some feedback 
and background questions. A detailed description of the EQ-VT protocol can be 
found elsewhere.(Oppe et al., 2014) 
In this study, all participants were asked to value the same set of 10 health states, 
in random order. The 10 health states were 11122, 21121, 21222, 21232, 32232, 
32333, 22224, 31242, 53343, and 33453.  
4.3.3 Other Details 
In addition to the valuation interview, all the clinical information was collected 
directly from patients’ medical records except information on functional 
classifications/status (listed below) were evaluated from patients by the interviewer. 
Clinical information included diagnoses, year of diagnosis, and clinical assessments 
such as New York Heart Association (NYHA) functional classification and Canadian 
Cardiovascular Society (CCS) functional classification of angina for heart disease 
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patients; and cancer stage and Eastern Cooperative Oncology Group (ECOG) 
performance status for cancer patients. All participants were also asked to self-report 
their current and past chronic diseases. 
The study was approved by the SingHealth Centralized Institutional Review Board. 
4.4 Study C: EQ-5D-5L Valuation Study in the Singapore 
General Population 
4.4.1 Study Design and Participants 
A cross-sectional, face-to-face national survey of health state valuation for EQ-5D-
5L using the composite TTO method was conducted in 2016 in Singapore general 
population. A multi-stage quota sampling approach was used to randomly select 
residential blocks, within which households were selected, within which one person 
per household was selected. Sampling quotas were used to make the resultant sample 
resembling the general adult Singaporean population in distributions of age, gender, 
and ethnic groups. The eligibility criteria were aged 21 years or above; able to 
communicate and read in English, Chinese, or Malay. 
4.4.2 Valuation Procedure 
All interviews were conducted by trained interviewers using a computer program 
designed for the composite TTO method (EQ-VT protocol) similar to the one used 
in Study B. Interviews were conducted in either English, Chinese or Malay according 
to participant’s preference. The interviews also included warm-up questions asking 
the participants to describe their own health using the EQ-5D-5L questionnaire, 
practice questions using wheelchair examples followed by composite TTO valuation 
of 10 EQ-5D-5L health states.  
According to the EQ-VT protocol, each participant values a randomly allocated 
set (called a block) of 10 EQ-5D-5L health states.(Oppe et al., 2014) Each block 
includes one very mild health state from five pre-specified ones (21111, 12111, 
11211, 11121, 11112), the most severe health state (55555), and eight health states 
from 80 pre-specified health states (from the remaining 3119 possible health states) 
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(Appendix 6). The protocol contains a total of 10 unique blocks. Simple random 
sampling is used to select one of the 10 blocks for each participant; hence the equal 
probability of each block being chosen. 
4.4.3 Other Details 
The study was approved by the National University of Singapore’s Institutional 
Review Board. 
4.5 Statistical Considerations 
4.5.1 Sample Size Considerations 
The sample size for study A was 2068 participants (1034 for SF-6D, and 1034 for 
EQ-5D-3L). It was decided for developing EQ-5D-3L and SF-6D value sets. As 
aims 1 and 2.1 were secondary analyses of study data already available, the entire 
sample was used for the research aim 1 and 1034 participants of the EQ-5D-3L 
sample for the research aim 2.1. 
The sample size for study B was decided based on the research aim 2.2. The 
sample size was 525 participants (175 heart disease patients, 175 cancer patients, and 
175 participants from the general population). It was estimated, to detect a difference 
of 0.1 standardized effect size in mean utility value of the 10 elicited health states, 
from a group of patients and general population using a two-sided test for 5% Type-
I error rate and 80% power, assuming 10% participants may provide a logically 
inconsistent valuation or do not complete the interviews. 
The sample size for study C was decided according to the recommendation of 
the EQ-VT protocol to use 1000 participants for the EQ-5D-5L value set studies. 
The study data was used to demonstrate sample size methods proposed in the 
research aim 3.  
 39 
4.5.2 Analysis Populations 
For research aim 1:  
All participants enrolled in the study A except those who met the following criteria: 
a) valued less than 3 health states, b) did not value dead or the ‘all-worst’ state, c) 
valued dead or the ‘all-worst’ state or unconscious state higher than all the other 
states, d) gave the same valuation score to all the health states, e) self-reported or 
rated by the interviewers as having a poor understanding of health states description 
or valuation tasks. 
For research aim 2:  
Research aim 2.1: All participants enrolled for the EQ-5D-3L  value set in the study A 
except those who met the following criteria: a) valued less than 3 health states, b) did 
not value dead or the ‘all-worst’ state, c) valued dead or the ‘all-worst’ state or 
unconscious state higher than all the other health states, d) gave the same valuation 
score to all the health states, e) self-reported or rated by the interviewers as having a 
poor understanding of health states description or valuation tasks. Furthermore, 
participants with chronic diseases other than diabetes, high blood 
pressure/hypertension, heart diseases, asthma/lung diseases, rheumatism/back 
pain/other bone-muscle illness were excluded as the number of participants with 
other chronic diseases were small (<10).  
For research aim 2.2: All participants enrolled in the study B except those who met the 
following criteria: a) gave the same utility value to all the health states, b) gave 
negative or zero utility value to all health states (i.e., considered all health states worse 
than or equal to death).  
For research aim 3:  
All participants enrolled in the study C.  
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4.5.3 Analyses 
4.5.3.1 General Considerations 
All P-values (p) were two-sided. A p less than 0.05 was considered statistically 
significant. All confidence intervals (CI) were at 95% level. Regression models 
involving more than one records from a participant used the Eicker-Huber-White 
robust standard error (SE) for cluster data for statistical inference.(Williams, 2000) 
Minimally important differences (MID) of 4 points for EQ-5D-3L and 3.3 points 
for SF-6D on the 100-point VAS were considered to be of practical 
significance.(Walters and Brazier, 2003, Wee et al., 2007, Luo et al., 2010) Similarly, 
a MID of 0.05 points for the EQ-5D-5L utility values was considered to be of 
practical significance.(McClure et al., 2017, Nolan et al., 2016) All the analyses were 
carried out using Stata/MP version 10.1 or 13.1 for Windows. 
4.5.3.2 Analyses for Research Aim 1 
The analysis used untransformed raw valuation score (range 0: least desirable to 100: 
most desirable) to avoid any impact of transformation on the utility values. So far 
there is no consensus on which transformation is the most appropriate.(Lamers, 
2007) 
As the selection of whether the most severe health state is worse or better than 
dead in the first step of the VAS method can potentially affect the valuation of health 
states, the impact of labeling of the most severe health was studied separately among 
participants who considered it better or worse than dead. Accordingly, the mean 
valuation scores were presented separately using line graphs for these two group of 
participants.  
An ordinary least-square (OLS) regression model was performed for the 
valuation score with 10 indicator variables representing 2 severity levels in 5 
dimensions of the EQ-5D-3L referencing severity level 1 (no problem) and an 
intercept. The model also included an indicator variable (N3) to take into account 
additional disutility when a severe problem (level 3) is reported on at least one 
dimension.(Szende et al., 2007) In addition to the above commonly used variables, 
the model included two indicator variables D1 and D2 and their interaction: D1 
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represented the participant who considered the ‘all-worst’ state worse than dead, and 
D2 represented the ‘all-worst’ state. This model helped to assess whether there was 
a deficit in the valuation score for the most severe state even after taking the 
descriptors (levels in each dimension) into account. It also assessed the potential 
impact of considering the most severe state worse than death on its valuation. Similar 
OLS model was used to study the SF-6D valuation score. For the variable N3, the 
severe level was defined as levels 4–6 for physical functioning, levels 3–4 for role 
limitation, level 4–5 for social functioning, mental health and vitality, and level 5–6 
for pain.(Brazier et al., 2002) 
Perfect health state was not included in the models, as it was assigned a fixed 
value of 100 on VAS. The dead and unconscious states were also excluded from the 
models as they did not represent any health states/dimensions of SF-6D or EQ-5D-
3L.  
4.5.3.3 Analysis for Research Aim 2 
The analysis for the research aim 2.1 was based on study A using the untransformed 
VAS valuation score whereas the analysis for the research aim 2.2 was performed 
using the data from the study B based on the composite TTO utility values.  
 
We defined the control group as the individual without any chronic disease in 
study A and participants from the general population (of whom some may have 
chronic diseases) in study B.  
Key sociodemographic characteristics of the patient and control groups were 
compared using either the Fisher’s exact test or two-sample independent t-test.  
EQ-5D-3L health states (total 42 states) in study A were classified as ‘severe’ (28 
states) if at least one dimension was at level 3, and the remaining states (42 – 28 = 
14 states) were classified as ‘non-severe.’ Similarly, 10 EQ-5D-5L health states in 
study B were classified as ‘mild’ (3 states: 11122, 21121, 21222) if all dimensions at 
level 1 or 2, ‘severe’ (4 states: 22224, 31242, 53343, 33453) if at least one dimension 
was at level 4 or 5, and remaining states as ‘moderate’ (3 states: 21232, 32232, 32333).  
A separate analysis was performed to compare the valuations by each of the 
patient groups with those of the control group. Each analysis included an OLS 
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regression model (say core model) for the comparison of the overall difference in 
valuation (including all the health states) between a patient and the control groups. 
As in study A, different health states were valued by the participants; the core model 
also included indicator variables for health state descriptors (10 variables for severity 
levels in 5 dimensions of the EQ-5D-3L). The comparisons of valuation between a 
patient and the control groups for the non-severe and severe health states were 
performed by including an interaction term between the indicator variable for severe 
health state (reference: non-severe health state) and the indicator variable for the 
specific patient group (reference: the control group) in the core model. On the other 
hand, as the same 10 health states were valued by all participants in study B, indicator 
variables for health state descriptors were not included in the core model. The 
comparisons of valuation between a patient and the control groups for the mild, 
moderate and severe health states were performed by fitting the core model 
separately for each of the three types of health states. Each of the models for study 
A as well for study B was adjusting for key sociodemographic characteristics - 
Ethnicity, gender, age, marital status, education level, religion, house type or 
household income, and employment status of accounting for differences in the 
sociodemographic characteristics between the patients and control groups.  
An exploratory analysis was performed based on study B. The differences in 
utility values between the health states valued by the same person were compared 
between the patients and control groups. As the difference in utility values of two 
health states is usually used to approximate utility gained from transitions between 
the two health states,(Sonnenberg and Beck, 1993) this comparison helped us to 
assess whether the different sets of utility values would give similar estimates when 
used to determine utility gained from health state transitions. First, differences in 
utility were calculated separately for each of the patient groups (heart disease and 
cancer), and the control group for 45 pairs of health states, where each pair has one 
health state better than the other in at least one of five dimensions. Second, 
differences in the differences between a patient group and the control group were 
presented using a line graph and tested by OLS models. The graph also presented 
the differences in differences adjusted for participants’ sociodemographic 
characteristics, calculated using the OLS models performed separately for each pair 
of health states.  
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4.5.3.4 Analysis for Research Aim 3 
4.5.3.4.1 Statistical Models for Estimating Utility Values 
A value set provides an algorithm for deriving a utility value for each health state. A 
value set study conducted using the EQ-VT protocol provides values for only 86 
directly valued health states (Appendix 6). These values are used to estimate values 
for all 3125 health states of the EQ-5D-5L, by regression analysis relating the elicited 
values to the health state descriptors. There are various ways to achieve it using an 
appropriate statistical model such as an OLS model, OLS model with cluster-robust 
SE, random effects (RE) model, interval regression model, and so on.(Rand-
Hendriksen et al., 2017, Feng et al., 2017, Luo et al., 2014) Currently, there is no 
consensus on which model is ideal for predicting utility values. Usually, a study team 
performs several models and decides upon a final model based on the models’ 
performance for consistency, bias, precision, and parsimony.  
As an initial choice, an OLS model for estimating utility values can be specified 
as:  
 𝑦𝑦 =  𝑋𝑋β +  𝜀𝜀.              (1) 
We call this model as the Basic OLS model. Here, 𝑦𝑦 = (𝑦𝑦1,𝑦𝑦2, … ,𝑦𝑦𝑛𝑛)′, where 𝑦𝑦𝑖𝑖 =(𝑦𝑦𝑖𝑖1,𝑦𝑦𝑖𝑖2, … ,𝑦𝑦𝑖𝑖10)′ is a vector of utility values of 10 health states elicited from the ith 
participant (𝑖𝑖 = 1, 2, … ,𝑛𝑛), and 𝑛𝑛 is the number of participants; 𝛽𝛽 =(𝛽𝛽0,𝛽𝛽1, … ,𝛽𝛽20)′ is a vector of regression coefficients to be estimated, corresponding 
to the intercept and 20 indicator variables representing the four severity levels (2 to 
5 levels) of the five dimensions (dummy coding scheme); X is an 10𝑛𝑛 ×  21 design 
matrix with the first column being an identity vector for the intercept and the 
remaining 20 columns for the indicator variables; 𝜀𝜀 is an 10𝑛𝑛 ×  1 vector of errors. 
It is assumed that 𝜀𝜀𝑖𝑖𝑖𝑖 (error for utility value of jth health state in ith participant) ~ 
i.i.d. 𝑁𝑁(0,𝜎𝜎2), where i.i.d. stands for independent and identically distributed and 
𝑁𝑁(0,𝜎𝜎2) denotes a normal distribution with mean 0 and variance 𝜎𝜎2.  
As each participant values 10 health states, values of health states elicited by the 
same participant might be correlated. Furthermore, the variance may not be 
constant. Thus, it is advisable to use cluster-robust SE (considering each participant 
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as a cluster) to make valid statistical inference about the coefficients of the 
model.(Williams, 2000)   
Alternatively, one can use an RE model for utility values specified as:(Verbeke, 
2000)  
𝑦𝑦 = 𝑋𝑋𝛽𝛽 + 𝛾𝛾 + 𝜀𝜀.    (2) 
We call this model as the Basic RE model. Here, 𝑦𝑦, 𝑋𝑋, and 𝛽𝛽 are vectors as 
mentioned in equation (1); 𝛾𝛾 = (𝛾𝛾1, 𝛾𝛾2, … , 𝛾𝛾𝑛𝑛)′, where 𝛾𝛾𝑖𝑖 = (𝛾𝛾𝑖𝑖1, 𝛾𝛾𝑖𝑖2, … , 𝛾𝛾𝑖𝑖10)′, 
𝛾𝛾𝑖𝑖𝑖𝑖 = 𝛾𝛾𝑖𝑖𝑖𝑖 for all 𝑗𝑗 ≠ 𝑘𝑘,  represents a 10 × 1 vector of ith participant-specific random 
intercept which underlines the intra-participant correlation among the 10 health 
states; 𝜀𝜀 is an 10𝑛𝑛 ×  1 vector of errors. It is assumed that 𝛾𝛾𝑖𝑖𝑖𝑖~𝑁𝑁(0,𝜎𝜎𝛾𝛾2), 
𝜀𝜀𝑖𝑖𝑖𝑖~𝑁𝑁(0,𝜎𝜎𝑒𝑒2), and 𝛾𝛾𝑖𝑖’s and 𝜀𝜀𝑖𝑖𝑖𝑖 ’s are independent. Here, 𝜎𝜎𝛾𝛾2 represents the between-
participant variance, 𝜎𝜎𝑒𝑒2 is the within-participant variance, 𝐶𝐶𝐶𝐶𝐶𝐶�𝑦𝑦𝑖𝑖𝑖𝑖 ,𝑦𝑦𝑖𝑖𝑖𝑖� = 𝜎𝜎𝛾𝛾2 for 
all 𝑗𝑗 ≠ 𝑘𝑘, 𝐶𝐶𝐶𝐶𝐶𝐶�𝑦𝑦𝑖𝑖𝑖𝑖 , 𝑦𝑦𝑙𝑙𝑖𝑖� = 0 for all 𝑖𝑖 ≠ 𝑙𝑙 and 𝑉𝑉𝑉𝑉𝑉𝑉�𝑦𝑦𝑖𝑖𝑖𝑖� = 𝜎𝜎𝛾𝛾2 + 𝜎𝜎𝑒𝑒2 = 𝜎𝜎2. In other 
words, within-participant utility values are correlated, but between-participant utility 
values are uncorrelated. Furthermore, intra-participant correlation does not depend 
on order of health states being valued.  
The models in equations (1) and (2) may be extended to include additional 
variables, to indicate whether a health state is mild (e.g., all dimensions at severity 
level 1 or 2) or severe (e.g., at least one dimension at severity level 4 or 5), and 
possibly adding interactions between the health state descriptor variables to improve 
model performance for the country-specific valuation data.(Szende et al., 2007) 
Furthermore, indicator variables for health state descriptor may be coded with 
backward difference coding scheme,(Chen et al., 2003) so that regression coefficients 
of each dimension represent estimated mean differences in the utility values 
compared to their previous level of severity. In this thesis, the methodologies are 
presented for the dummy coding scheme for illustration as it is widely used. 
However, relevant information regarding the differential coding scheme is provided 
in Publication Paper IV.  
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4.5.3.4.2 Prerequisite Parameters for Sample Size Estimation 
Inverse of cross-product of design matrix 
As will be shown in the subsequent sections, the inverse of the cross-product of the 
design matrix 𝐶𝐶 = (𝑋𝑋′𝑋𝑋)−1, where 𝑋𝑋 is as defined in equation (1), plays an 
important role in the sample size determination. Thus, this piece of generic 
information was derived before discussing specific sample size determination 
methods.  
It is intuitive to begin with considering the sample size as a multiple of 10. Since 
the valuation protocol has only 10 unique blocks of health states (Appendix 6), each 
block has 10 health states, and the blocks have equal probability of being selected, 
for 𝑁𝑁𝑠𝑠 = 10 × 𝑀𝑀 participants, each of the 10 blocks on average is to be valued 𝑀𝑀 
times. Thus, for 𝑁𝑁𝑠𝑠 participants, the matrix 𝑋𝑋 is expected to be 𝑋𝑋 =
�𝑋𝑋𝑢𝑢(1),𝑋𝑋𝑢𝑢(2), … ,𝑋𝑋𝑢𝑢(𝑀𝑀)�′, where 𝑋𝑋𝑢𝑢(𝑖𝑖) = 𝑋𝑋𝑢𝑢 is the ith replicate of the 100 ×  21 
design matrix based on the 10 unique blocks. Therefore, 
𝐸𝐸(𝐶𝐶|𝑁𝑁𝑠𝑠 = 10𝑀𝑀) = (𝑋𝑋𝑢𝑢′ 𝑋𝑋𝑢𝑢)−1 𝑀𝑀⁄ = 𝐷𝐷 𝑀𝑀⁄ = 10 𝐷𝐷 𝑁𝑁𝑠𝑠⁄ ,  (3) 
where 𝐷𝐷 = (𝑋𝑋𝑢𝑢′ 𝑋𝑋𝑢𝑢)−1.  
As such, 
𝐸𝐸�𝐶𝐶𝑖𝑖𝑖𝑖� = 𝐷𝐷𝑗𝑗𝑗𝑗𝑀𝑀 = 10𝐷𝐷𝑗𝑗𝑗𝑗𝑁𝑁𝑠𝑠 ,          (4) 
where 𝐶𝐶𝑖𝑖𝑖𝑖 and 𝐷𝐷𝑖𝑖𝑖𝑖 are the jth diagonal element of the 21×21 matrices 𝐶𝐶 and 𝐷𝐷, 
respectively.    
The matrix 𝐷𝐷 for the dummy coding scheme is shown in Table 2.  
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Design effect 
Standard sample size estimation approaches, as well as those described in the 
subsequent sections, assume (or begin with assuming) independent observations. 
However, the EQ-VT protocol requires each participant to value 10 health states. 
Such clustering of observations within participants impacts the variance of the 
estimates. On the one hand, utility values (outcome variable) elicited by the same 
participant are likely positively correlated, as some people may generally give higher 
(or lower) values to health states no matter what these health states are. On the other 
hand, the EQ-VT protocol is developed to ensure that the 10 health states (exposure 
variables) are diverse within each participant, leading to negative correlation in the 
exposure. Given positive correlation in outcomes, the variances of the regression 
estimates are inflated if the exposures are positively correlated (e.g., cluster 
randomized trials), or deflated if the exposures are negatively correlated (e.g., 
crossover drug trials).(Kahan and Morris, 2013, Parzen et al., 1998) The sample size 
should be increased (or decreased) by the ‘design effect’ factor (DE)(Kahan and 
Morris, 2013, Donner and Klar, 2000, Parzen et al., 1998) to compensate for the 
variance inflation or deflation. The sample size adjusted for the design effect is 
calculated as, 
𝑁𝑁 = 𝑁𝑁𝑠𝑠 × 𝐷𝐷𝐸𝐸 .      (5) 
For a randomized controlled trial that has one exposure variable, there are 
formulas for estimation of design effect and therefore sample size using the intra-
class correlation coefficients as inputs.(Kahan and Morris, 2013, Donner and Klar, 
2000, Parzen et al., 1998) However, currently, there is no such formula for the 
complex case of multivariable regression analysis. Therefore, it was proposed to 
empirically estimate the design effect using data from a large-scale study, as will be 
shown below.  
The design effect for predicted utility value of a particular health state HS0 is 
calculated as  
𝐷𝐷𝐸𝐸𝑦𝑦0 =  𝑉𝑉𝐶𝐶𝐶𝐶𝐶𝐶𝑠𝑠𝐶𝐶𝐶𝐶𝐶𝐶(𝑦𝑦�0)𝑉𝑉(𝑦𝑦�0) ,     (6)  
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where 𝑉𝑉𝐶𝐶𝑙𝑙𝑢𝑢𝑠𝑠𝐶𝐶𝑒𝑒𝐶𝐶(𝑦𝑦�0) and 𝑉𝑉(𝑦𝑦�0) are cluster-robust and OLS variances, respectively, 
for the predicted utility value of HS0. For simplicity, one may consider using simple 
or weighted mean of 𝐷𝐷𝐸𝐸𝑦𝑦0 values (𝐷𝐷𝐸𝐸����𝑦𝑦) of directly valued health states, where 
weights can be chosen proportional to probability of occurrence of the health states. 
According to the valuation protocol, probabilities of occurrences of very mild health 
states (21111, 12111, 11211, 11121, and 11112), the most severe health state (55555) 
and the remaining 80 directly valued health states are 0.02, 1.0, and 0.01, respectively 
(Appendix 6). 
Similar to equation (6), the design effect for a regression coefficient, 𝛽𝛽𝑖𝑖 , is 
calculated as 
𝐷𝐷𝐸𝐸𝛽𝛽𝑗𝑗 =  𝑉𝑉𝐶𝐶𝐶𝐶𝐶𝐶𝑠𝑠𝐶𝐶𝐶𝐶𝐶𝐶(𝛽𝛽�𝑗𝑗)𝑉𝑉(𝛽𝛽�𝑗𝑗) ,     (7) 
where 𝑉𝑉𝐶𝐶𝑙𝑙𝑢𝑢𝑠𝑠𝐶𝐶𝑒𝑒𝐶𝐶(?̂?𝛽𝑖𝑖) and 𝑉𝑉(?̂?𝛽𝑖𝑖) are cluster-robust and OLS variances of 𝛽𝛽𝑖𝑖 , 
respectively. Similar to 𝐷𝐷𝐸𝐸����𝑦𝑦, one may consider using simple or weighted mean of 
𝐷𝐷𝐸𝐸𝛽𝛽𝑗𝑗values (𝐷𝐷𝐸𝐸����𝛽𝛽). For example, if we are interested in coefficients of health state 
descriptors (i.e., 𝛽𝛽1 to 𝛽𝛽20), weights proportional to probability of occurrence of 
respective severity levels in a sample of randomly allocated blocks can be used for 
𝐷𝐷𝐸𝐸����𝛽𝛽. According to the valuation protocol, the probability of occurrences of severity 
levels 2 to 5 in different dimensions range from 0.13 to 0.26 (Appendix 6). 
As an alternative to 𝑉𝑉𝐶𝐶𝑙𝑙𝑢𝑢𝑠𝑠𝐶𝐶𝑒𝑒𝐶𝐶(𝑦𝑦�0) and 𝑉𝑉𝐶𝐶𝑙𝑙𝑢𝑢𝑠𝑠𝐶𝐶𝑒𝑒𝐶𝐶�?̂?𝛽𝑖𝑖� in equations (6) and (7) 
respectively, one can use variances estimated for predicted utility value of HS0, 
𝑉𝑉𝑅𝑅𝑅𝑅(𝑦𝑦�0), and 𝛽𝛽𝑖𝑖 , 𝑉𝑉𝑅𝑅𝑅𝑅�?̂?𝛽𝑖𝑖�, respectively, from the Basic RE model in equation (2). 
Empirical estimates of design effects from the study C will be given in Results 
section.  
4.5.3.4.3 Sample Size Estimation Approaches for Value Set Studies 
Approach 1 - To achieve desired precision for an estimated mean utility value for a particular health 
state 
The primary objective of value set studies is to predict utilities for health states with 
acceptable precision. Suppose the study team would like to predict utility value of a 
particular health state HS0 with a tolerated margin of error 𝛿𝛿, where 𝛿𝛿 is a sufficiently 
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small value (e.g., MID for utility values).(Coretti et al., 2014) That is, the maximum 
allowable difference between the predicted value and the true value should be less 
than 𝛿𝛿 with sufficiently high probability 100 × (1 − α)%, 0 < α < 1. This is 
equivalent to targeting the 100 × (1 − α)% prediction interval (PI) to be ± 𝛿𝛿. 
Consider the Basic OLS model for estimating the mean utility value of a particular 
health state, HS0. The 100 × (1 − α)% PI for mean utility value of HS0  
is:(Montgomery et al., 2012) 
�𝑦𝑦�0 − 𝑍𝑍1−𝛼𝛼
2
�𝜎𝜎�2 𝑥𝑥0′𝐶𝐶𝑥𝑥0,  𝑦𝑦�0 + 𝑍𝑍1−𝛼𝛼
2
�𝜎𝜎�2 𝑥𝑥0′𝐶𝐶𝑥𝑥0�,  (8) 
where 𝑦𝑦�0 is the predicted utility value for HS0,  𝑥𝑥0′ = (1, 𝑥𝑥01, 𝑥𝑥02, … , 𝑥𝑥020) is the 
vector representing values of indicator variables for health state descriptor of HS0, 
σ�2 is the estimate of error variance, and 𝐶𝐶 = (𝑋𝑋′𝑋𝑋)−1. 
Thus, for the objective of estimating mean utility value of HS0 with desired 
precision, say 100 × (1 − α)% PI of 𝑦𝑦�0 equal to 𝑦𝑦�0 ± 𝛿𝛿, the sample size 𝑁𝑁𝑠𝑠 can be 
calculated by solving equation, 𝛿𝛿 = 𝑍𝑍1−𝛼𝛼
2
�𝜎𝜎�2 𝑥𝑥0′𝐶𝐶𝑥𝑥0. It can be solved using 
equation (3) as 𝛿𝛿 = 𝑍𝑍1−𝛼𝛼
2
× 𝜎𝜎� × �10 𝑥𝑥0′𝐷𝐷𝑥𝑥0 𝑁𝑁𝑠𝑠⁄  giving: 
                     𝑁𝑁𝑠𝑠 = 10 𝜎𝜎�2 𝑥𝑥0′𝐷𝐷𝑥𝑥0  𝑍𝑍1−𝛼𝛼/22𝛿𝛿2  .    (9) 
This approach provides different sample sizes for different health states. The 
study team may choose the mean of these sample sizes. Using the matrix 𝐷𝐷 (Table 
2) and 𝑥𝑥0 vectors of the directly valued health states in the EQ-VT protocol, it can 
be shown that  𝑥𝑥0′𝐷𝐷𝑥𝑥0 has mean, standard deviation (SD) and coefficient of variation 
(CV) of 0.210, 0.062, and 29.3%, respectively.  
Lastly, as equation (9) also assumes independent observations, it needs to be 
adjusted for the design effect 𝐷𝐷𝐸𝐸����𝑦𝑦 using equation (5), and replacing 𝑥𝑥0′𝐷𝐷𝑥𝑥0 by mean 
of 𝑥𝑥0′𝐷𝐷𝑥𝑥0 values (𝐷𝐷�𝑥𝑥0) of directly values health states, gives 
𝑁𝑁 = 𝑁𝑁𝑠𝑠 × 𝐷𝐷𝐸𝐸 = 10 𝜎𝜎�2 𝐷𝐷�𝑥𝑥0  𝐷𝐷𝑅𝑅����𝑦𝑦  𝑍𝑍1−𝛼𝛼/22𝛿𝛿2  .               (10) 
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Approach 2 - Empirical approach to achieve desired mean absolute error in prediction of utility 
values relative to a reference study 
This is an empirical approach in which mean absolute error (MAE)(Lamers et al., 
2006) defined as,  
𝑀𝑀𝑀𝑀𝐸𝐸𝑁𝑁𝑠𝑠 = 110𝑁𝑁 ∑ ∑ �𝑦𝑦�𝑖𝑖𝑖𝑖(𝑁𝑁𝑠𝑠) − 𝑦𝑦𝑖𝑖𝑖𝑖�10𝑖𝑖=1𝑁𝑁𝑖𝑖=1 ,   (11) 
is calculated, where 𝑦𝑦�𝑖𝑖𝑖𝑖(𝑁𝑁𝑠𝑠) denote predicted utility values based on a regression 
model fitted with sample size 𝑁𝑁𝑠𝑠, and 𝑦𝑦𝑖𝑖𝑖𝑖 denote observed utility values in a reference 
study with a larger sample size 𝑁𝑁, where 𝑁𝑁 > 𝑁𝑁𝑠𝑠. 𝑀𝑀𝑀𝑀𝐸𝐸𝑁𝑁𝑠𝑠is to be estimated for a 
large number of replications of random sampling (with replacement) of 𝑁𝑁𝑠𝑠 number 
of subjects within a reference study with sample size 𝑁𝑁 conducted according to the 
EQ-VT protocol. A plot of mean 𝑀𝑀𝑀𝑀𝐸𝐸𝑁𝑁𝑠𝑠over sample size 𝑁𝑁𝑠𝑠  can provide a visual 
presentation of how the MAE is reduced with an increase in sample size for the 
model. A sample size 𝑁𝑁𝑠𝑠∗ corresponding to desired MAE, or desired marginal gain 
in MAE as sample size increases, is selected for the study. 
Approach 3 - To assess significance of a regression coefficient of health state descriptors 
A value set study is expected to show that individual regression coefficients of health 
state descriptors (i.e., 𝛽𝛽1 to 𝛽𝛽20) are not different from zero by chance. That is, it 
requires to test the null hypothesis 𝐻𝐻0: β𝑖𝑖 = 0 against the alternative hypothesis 
𝐻𝐻1: β𝑖𝑖 ≠ 0, for all 𝑗𝑗 = 1, 2. . . , 20, with sufficient statistical power (1 − 𝛽𝛽) and 
type-I error rate (𝛼𝛼). 
Considering the Basic OLS model in equation (1), the SE of ?̂?𝛽𝑖𝑖 is 𝑆𝑆𝐸𝐸(?̂?𝛽𝑖𝑖) =
�𝜎𝜎�2𝐶𝐶𝑖𝑖𝑖𝑖, where σ�
2 is the estimate of error variance, and 𝐶𝐶𝑖𝑖𝑖𝑖 is the jth diagonal 
element of 𝐶𝐶 = (𝑋𝑋′𝑋𝑋)−1 matrix [15]. Using equation (4), 𝑆𝑆𝐸𝐸�?̂?𝛽𝑖𝑖� = �𝜎𝜎�2𝐷𝐷𝑖𝑖𝑖𝑖 𝑀𝑀⁄ =
�10𝜎𝜎�2𝐷𝐷𝑖𝑖𝑖𝑖 𝑁𝑁𝑠𝑠⁄ , where 𝐷𝐷𝑖𝑖𝑖𝑖 are available from Table 2. Solving the equation, 
𝛽𝛽𝑖𝑖 𝑆𝑆𝐸𝐸(?̂?𝛽𝑖𝑖)⁄ = 𝛽𝛽𝑖𝑖 �10𝜎𝜎�2𝐷𝐷𝑖𝑖𝑖𝑖 𝑁𝑁𝑠𝑠⁄⁄ = (𝑍𝑍1−𝛼𝛼/2 + 𝑍𝑍1−𝛽𝛽) will give sample size: 
𝑁𝑁𝑠𝑠 = 10𝜎𝜎�2𝐷𝐷𝑗𝑗𝑗𝑗(𝑍𝑍1−𝛼𝛼/2+𝑍𝑍1−𝛽𝛽)2𝛽𝛽𝑗𝑗2 ,     (12) 
where 𝑍𝑍1−𝛼𝛼 2⁄   and 𝑍𝑍1−𝛽𝛽  are values of standard normal distribution at 1 − 𝛼𝛼 2⁄  and 1 − 𝛽𝛽, respectively. The σ�2 can be obtained from a reference study (e.g., study C).  
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The target β𝑖𝑖 in sample size determination can be a smallest desired value for the 
coefficient (e.g., MID for utility values) that the study team would consider 
meaningful. It is clear that the sample size may be different for different coefficients; 
one can choose the mean of coefficients �?̅?𝛽�for simplicity in the sample size 
estimation. Substituting ?̅?𝛽 for β𝑖𝑖  and 𝐷𝐷� for 𝐷𝐷𝑖𝑖𝑖𝑖 in equation (12) gives,  
𝑁𝑁𝑠𝑠 = 10 𝜎𝜎�2 𝐷𝐷� (𝑍𝑍1−𝛼𝛼/2+𝑍𝑍1−𝛽𝛽)2𝛽𝛽�2 .    (13) 
Since the sample size formula assumes independent observations, it needs to be 
adjusted for the design effect 𝐷𝐷𝐸𝐸����𝛽𝛽 using equations (5), which gives, 
𝑁𝑁 = 10 𝜎𝜎�2 𝐷𝐷� 𝐷𝐷𝑅𝑅����𝛽𝛽 (𝑍𝑍1−𝛼𝛼/2+𝑍𝑍1−𝛽𝛽)2
𝛽𝛽�2
 .    (14) 
Approach 4 - To estimate a regression coefficient of health state descriptors with a desired precision 
Alternative to Approach 3, the study team may desire to estimates the regression 
coefficients with certain precision, say requiring the 100 × (1 − 𝛼𝛼)% CI of β𝑖𝑖 to 
be ?̂?𝛽𝑖𝑖 ± 𝛿𝛿𝑖𝑖 , where 𝛿𝛿𝑖𝑖 is a sufficiently small number (e.g., MID for utility values). For 
this objective, the sample size is obtained by solving 𝛿𝛿𝑖𝑖 = 𝑍𝑍1−𝛼𝛼
2
𝑆𝑆𝐸𝐸�?̂?𝛽𝑖𝑖� = 𝑍𝑍1−𝛼𝛼
2
�10𝜎𝜎�2𝐷𝐷𝑖𝑖𝑖𝑖 𝑁𝑁𝑠𝑠⁄  (Montgomery et al., 2012). It gives  
𝑁𝑁𝑠𝑠 = 10 𝜎𝜎�2𝐷𝐷𝑗𝑗𝑗𝑗𝑍𝑍1−𝛼𝛼/22𝛿𝛿𝑗𝑗2 .    (15) 
Alternatively, substituting 𝛿𝛿𝑖𝑖  by 𝛿𝛿̅ = mean of 𝛿𝛿𝑖𝑖 (𝑗𝑗 = 1, 2, . . , 20), 𝐷𝐷𝑖𝑖𝑖𝑖 by 𝐷𝐷� in 
equation (15) gives  
𝑁𝑁𝑠𝑠 = 10  𝜎𝜎�2 𝐷𝐷�𝑍𝑍1−𝛼𝛼/22𝛿𝛿�2  .     (16) 
Finally, adjusting the sample size for the design effect 𝐷𝐷𝐸𝐸����𝛽𝛽 using equation (5), gives 
𝑁𝑁 = 10 𝜎𝜎�2 𝐷𝐷� 𝐷𝐷𝑅𝑅����𝛽𝛽 𝑍𝑍1−𝛼𝛼/22
𝛿𝛿�2
.    (17) 
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5 RESULTS 
5.1 Results for Research Aim 1 
In the sample for the SF-6D value set in study A, 7 participants valued dead higher 
than all the other states; 1 participant valued the ‘all-worst’ state higher than all the 
other states, and 5 participants were observed to have a poor understanding of health 
states description and/or valuation tasks. Hence, these 13 participants were excluded 
from the SF-6D-related analysis. Table 3 shows sociodemographic and health 
characteristics of 1021 participants for the SF-6D valuation that were included in the 
analysis. Due to the pre-specified quota for gender, age and ethnicity, the 
demographic characteristics of enrolled participants were similar to what was 
planned. The majority of the SF-6D participants were married (n = 765, 75%), 
employed/self-employed (n = 659, 65%), had at least secondary education (n = 844, 
83%), and self-reported good to excellent general health (n = 947, 93%). 
Similarly, in the EQ-5D-3L sample, 12 participants valued dead higher than all 
the other states; 2 participants valued the unconscious state higher than all the other 
states; 1 participant did not value the ‘all-worst’ state, and 4 participants were 
observed to have a poor understanding of health states description and/or valuation 
tasks. Hence, 19 participants were excluded from the EQ-5D-3L-related analysis. 
The sociodemographic and health characteristics of the EQ-5D-3L participants were 
similar to the SF-6D participants (Table 3). 
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Table 3. Sociodemographic and health characteristics of study A participants 
Characteristics SF-6D sample (N = 1021) 
EQ-5D-3L sample 
(N = 1015) 
Female, n (%) 521 (51.0) 512 (50.4) 
Age (years), n (%)   
     21-59 890 (87.2) 891 (87.8) 
     60+ 131 (12.8) 124 (12.2) 
Ethnicity, n (%)   
     Chinese 392 (38.4) 387 (38.1) 
     Malay 396 (38.8) 399 (39.3) 
     Indian 233 (22.8) 229 (22.6) 
Education level, n (%)   
     Primary (6 years) or less 177 (17.3) 190 (18.7) 
     Secondary (11 years) 562 (55.0) 576 (56.8) 
     Diploma/degree or higher 282 (27.6) 249 (24.5) 
Married/partner, n (%) 765 (74.9) 761 (75.0) 
Employed or self-employed, n (%) 659 (64.5) 643 (63.4) 
Self-reported health on VAS, Mean (SD) 84.5 (11.2) 83.0 (12.1) 
VAS Visual analog scale (100: Best imaginable health state, 0: Worst imaginable health state); SD Standard 
deviation. 
In the SF-6D valuation, except the ‘all-worst’ state, no other health state was 
valued worse than dead state. The mean valuation scores for selected SF-6D health 
states are shown in Figure 4. For the participants who considered the ‘all-worst’ 
state worse than dead, there was a difference of more than 30 points in the mean 
valuation score between the ‘all-worst’ state (‘645655’) and its adjacent health states, 
which are only one level different in one dimension (‘545655’ and ‘645555’). For the 
participants who considered the ‘all-worst’ state better than dead, the corresponding 
difference ranged from 9 to 17 points. Similar to the SF-6D results, only the ‘all-
worst’ state was valued worse than dead, and the majority of participants (n = 753, 
74%) considered the ‘all-worst’ state worse than dead in the EQ-5D-3L valuation. 
Similar to Figure 4, Figure 5 also shows a difference of 25 points in the mean 
valuation score between the ‘all-worst’ state (‘33333’) and its adjacent state ‘33323’ 
for the participants who considered the ‘all-worst’ worse than dead. For the 
participants who considered the ‘all-worst’ better than dead the corresponding 
difference was 11 points. 
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Figure 4. Mean valuation scores of SF-6D health states elicited by participants who considered the 
‘All-worst’ state better and worse than dead  
# Some health states were systematically skipped for the graphical presentation, except the lowest ten health 
states with the least valuation scores near the dead state. 
 
 
 
Figure 5. Mean valuation scores of EQ-5D-3L health states elicited by participants who considered 
the ‘All-worst’ state better and worse than dead 
# Some health states were systematically skipped for the graphical presentation, except the lowest ten health states 
with the least valuation scores near the dead state. 
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In the OLS model for SF-6D valuation score (Table 4), the coefficient D1 
showed that the participants who considered the ‘all-worst’ state worse than death, 
scored higher in the other health states by 2 points (95% CI: 0.2, 3.8); compared to 
the participants who considered the ‘all-worst’ state better than dead. The 
participants who considered the ‘all-worst’ state better than dead scored the ‘all-
worst’ state 12.3 points lower (D2 coefficient 95% CI: −15.8, −8.8; p <0.001) than 
expected by its descriptors. Furthermore, the participants who considered the ‘all-
worst’ state worse than dead scored the ‘all-worst’ state 27.0 points lower 
(coefficient: −12.3 - 14.7 = 27.0; 95% CI: −30.2, −24.0; p <0.001) than expected. 
For the EQ-5D-3L valuation, the participants who considered the ‘all-worst’ state 
better than dead did not score the ‘all-worst’ state statistically significantly different 
from what is expected by its descriptors (coefficient = -2.1 points; 95% CI: −5.4, 
−1.1; p = 0.201). The participants who considered the ‘all-worst’ state worse than 
dead scored the ‘all-worst’ state 15.8 points lower (coefficient = −2.1-13.7 = −15.8; 
95% CI: −18.8, −12.7; p <0.001) than expected (Table 5). 
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Table 4. Summary of ordinary least-square regression model for SF-6D valuation score 
Regressor Coefficient (95% Confidence interval) 
The most severe state worse than dead (D1) 2.0 (   0.2,     3.8) * 
The most severe state (D2) -12.3 (-15.8,   -8.8) *** 
Interaction of D1 and D2 -14.7 (-16.6, -12.9) *** 
At least one severe level (N3)                  -2.3 (  -4.3,   -0.4) * 
Physical functioning level 2 -7.5 (-16.6, -12.9) *** 
Physical functioning level 3 -7.9 (  -9.7,   -6.0) *** 
Physical functioning level 4 -13.8 (-15.8, -11.7) *** 
Physical functioning level 5 -13.9 (-15.9, -11.9) *** 
Physical functioning level 6 -22.1 (-24.4, -19.9) *** 
Role limitations level 2 -3.7 (  -5.2,   -2.2) *** 
Role limitations level 3 -3.1 (  -4.6,   -1.6) *** 
Role limitations level 4 -2.7 (  -4.3,   -1.0) ** 
Social functioning level 2 -3.1 (  -4.6,   -1.5) *** 
Social functioning level 3                  -2.1 (  -3.8,   -0.4) * 
Social functioning level 4 -2.9 (  -4.8,   -1.1) ** 
Social functioning level 5 -3.2 (  -5.1,   -1.4) ** 
Pain level 2 -3.9 (  -5.7,   -2.2) *** 
Pain level 3 -6.3 (  -8.1,   -4.5) *** 
Pain level 4 -6.8 (  -8.6,   -4.9) *** 
Pain level 5 -7.5 (  -9.2,   -5.7) *** 
Pain level 6 -11.1 ( -13.0,  -9.2) *** 
Mental health level 2                   -2.1 (  -3.8,   -0.4) * 
Mental health level 3 -2.8 (  -4.7,   -1.0) ** 
Mental health level 4 -4.0 (  -5.9,   -2.1) *** 
Mental health level 5                  -3.0 (  -4.9,   -1.1) ** 
Vitality level 2                  -0.3 (  -2.1,    1.6) 
Vitality level 3 -5.0 (  -6.9,   -3.2) *** 
Vitality level 4 -5.6 (  -7.6,   -3.6) *** 
Vitality level 5 -10.6 (-12.6,   -8.6) *** 
Intercept 80.2 ( 77.3,   83.1) *** 
R2  = 0.519  
* p < 0.05, ** p < 0.01, *** p<0.001. 
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Table 5. Summary of ordinary least-square regression model for EQ-5D-3L valuation score 
Regressor Coefficient (95% Confidence interval) 
The most severe state worse than dead (D1)                    2.2 (  -0.0,    4.5) 
The most severe state (D2)                   -2.1 (  -5.4,    1.1) 
Interaction of D1 and D2 -13.7 (-15.8, -11.6) *** 
At least one severe level (N3) -14.8 (-17.4, -12.1) *** 
Mobility level 2 -8.2 (  -9.4,   -6.9) *** 
Mobility level 3 -15.0 (-17.0, -13.0) *** 
Self-care level 2   -5.1 (  -6.5,   -3.7) *** 
Self-care level 3 -13.9 (-15.7, -12.2) *** 
Usual activities level 2                   -1.6 (  -3.5,    0.3) 
Usual activities level 3 -4.2 (  -6.3,   -2.0) *** 
Pain/discomfort level 2 -5.1 (  -6.3,   -3.9) *** 
Pain/discomfort level 3 -12.4 (-13.6, -11.1) *** 
Anxiety/depression level 2                   -0.3 (  -1.8,    1.2) 
Anxiety/depression level 3 -6.1 (  -7.9,   -4.2) *** 
Intercept 79.9 ( 77.5,  82.3) *** 
R2  = 0.642  
* p < 0.05, ** p < 0.01, *** p<0.001. 
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5.2 Results for Research Aim 2 
In the sample for the EQ-5D value set in study A, 9 participants had chronic diseases 
other than diabetes, high blood pressure/hypertension, heart disease, asthma/lung 
disease or rheumatism/back pain/other bone-muscle illness; 34 participants valued 
‘dead’ state higher than all the other states; 3 participants valued ‘unconscious’ state 
higher than all the other states; 1 participant did not value the ‘all-worst’ state, and 4 
participants were observed to have a poor understanding of valuation tasks. Hence, 
a total of 51 participants were excluded from the analysis (i.e., included 1034 – 51 = 
983 participants). Table 6 shows the comparison of sociodemographic and health 
characteristics of the patient groups with the control group. Participants in the 
patient's groups were older, had a lower education level, and lower self-reported 
general health, compared to participants in the control group. 
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Of 525 participants who completed the interview in study B, 30 were excluded 
from analyses: 24 participants assigned the same value to all 10 health states, and six 
participants valued all the health states worse than or equal to death. Table 7 shows 
the sociodemographic and health characteristics of the 495 participants included in 
the analyses (169 in the control group, 157 in the heart disease patients group, and 
169 in the cancer patients group). Participants in the patient groups were older, had 
lower education level, and poor self-reported general health, compared to 
participants in the control group. A total of 62 (37%) participants in the control 
group self-reported to have one or more chronic diseases, such as hypertension 
(15%), hyper/dyslipidemia (12%), and lung diseases (10%). The majority of 
sociodemographic characteristics of the control group were similar to the census 
population (DOS, 2010). Only 5% of patients in the heart disease group self-
reported to have had cancer. Similarly, 4% of patients in the cancer group had had 
heart disease, and less than 5% of participants in the control group had either heart 
disease or cancer. More details on heart disease and cancer patients’ disease 
characteristics are presented in the Online Appendix Tables 3 and 4 of 
Publication Paper III, respectively.  
 
 
 
 
 
 
 
 
 
 
 61 
Table 7. Sociodemographic and health characteristics of study B participants 
Characteristic 
Control 
(N = 169) 
Heart disease 
(N = 157) 
Cancer 
(N = 169) 
n (%) n (%) p n (%) p 
Female 89 (52.7) 54 (34.4) 0.001 98 (58.0) 0.381 
Age (years)   <0.001  <0.001 
     21-40 75 (44.4) 13 (8.3)  20 (11.8)  
     41-60 65 (38.5) 61 (38.9)  93 (55.0)  
     >60 29 (17.2) 83 (52.9)  56 (33.1)  
Ethnicity   0.029  0.079 
     Chinese 140 (82.8) 110 (70.1)  123 (72.8)  
     Malay 10  (5.9) 12 (7.6)  22(13.0)  
     Indian 10 (5.9) 23 (14.7)  10 (5.9)  
     Others 9 (5.3) 12 (7.6)  14 (8.3)  
Education level   <0.001  <0.001 
     Primary (6 years) or less 12 (7.1) 35 (22.3)  25 (14.8)  
     Secondary (7-11 years) 54 (32.0) 88 (56.1)  91 (53.9)  
     Diploma, University or higher 103 (61.0) 34 (21.7)  53 (31.4)  
Married/living with partner 104 (61.5)      101 (64.3) 0.647 113 (66.9) 0.364 
Employed 109 (64.5) 84 (53.5) 0.055 95 (56.2) 0.148 
Household earnings per month   <0.001  0.010 
     <S$4000 60 (35.5) 98 (62.4)  87 (51.5)  
     ≥S$4000 91 (53.9)    44 (28.0)  65 (38.5)  
     Don’t know/refused 18 (10.7) 15 (9.6)  17 (10.1)  
Religion   0.693  <0.001 
     No religious belief 37 (21.9) 26 (16.6)   15 (8.9)  
     Buddhism/Taoism 55 (32.5) 54 (34.4)  66 (39.1)  
     Islam 15 (8.9) 19 (12.1)  34 (20.1)  
     Christians 44 (26.0) 43 (27.4)  46 (27.2)  
     Others 18 (10.7) 15 (9.6)  8 (4.7)  
Self-reported health on VAS, Mean (SD) 82.6 (10.4) 73.8 (14.5) <0.001 76.3 (17.3) <0.001 
VAS Visual analog scale (100: Best imaginable health state, 0: Worst imaginable health state); SD Standard 
deviation. 
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Table 8 summarizes the comparison of health state valuation scores between the 
patient groups and the control group in Study A. After taking health state descriptors 
and covariates into account in the regression models, the mean differences between 
the patient groups and the control group regarding valuation scores of all the health 
states ranged from −2.5 to 1.6 (each p >0.05), except for the heart disease group. 
The adjusted mean valuation score of all the health states for the heart disease group 
was 4.6 points higher (95% CI: 0.4 to 8.9; p = 0.032) than that of the control group. 
Similarly, the mean differences between the patient groups and the control group 
regarding severe health state valuation scores ranged from −2.4 to 1.8 (each p >0.05), 
except for the heart disease group. The adjusted mean valuation score of severe 
states for the heart disease group was 5.4 points higher (95% CI: 0.7 to 10.1; p = 
0.025) than that of the control group. There was no practically significant difference 
in the mean valuation scores of non-severe health states between any patient group 
and the control group.  
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Table 9 summarizes the comparison of utility values between the patient groups 
and the control group in study B. After taking sociodemographic variables into 
account in the regression models, the mean utility value based on heart disease 
patients was lower by 0.05 (p = 0.534) for severe health states, and higher by 0.08 
points (p = 0.007) and 0.09 points (p = 0.176) for mild and moderate health states, 
respectively, than that based on the control group. Unlike heart disease patients, 
there was no statistically significant difference in mean utility value for all health 
states including mild, moderate, and severe health states between cancer patient 
group and the control group.  
Among all the covariates adjusted for the analysis, age had the strongest 
association with utility (Wald test p <0.0001; see Online Appendix Table 5 of 
Publication Paper III). Older age was associated with lower utility value.  
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Table 9. Comparison of utility values between the patients and the control groups in study B 
EQ-5D-5L health states# Heart disease (N=157) 
Cancer 
(N=169) 
Control 
(N=169) 
All health states    
     Mean (SD) 0.291 (0.807) 0.336 (0.723) 0.398 (0.657) 
     Adjusted mean difference (95% CI) 0.031 (-0.067, 0.130) -0.007 (-0.058, 0.045)  
Mild health states    
     Mean (SD) 0.875 (0.345) 0.829 (0.362) 0.842 (0.255) 
     Adjusted mean difference (95% CI) 0.076 (0.021, 0.131) ** -0.009 (-0.072, 0.054)  
Moderate health states    
     Mean (SD) 0.452 (0.704) 0.417 (0.651) 0.505 (0.545) 
     Adjusted mean difference (95% CI) 0.091 (-0.041, 0.223) -0.011 (-0.132, 0.111)  
Severe health states    
     Mean (SD) -0.267 (0.764) -0.096 (0.719) -0.016 (0.693) 
     Adjusted mean difference (95% CI) -0.048 (-0.198, 0.103) -0.002 (-0.137, 0.133)  
# Health states with all dimensions at severity level either 1 or 2 are considered ‘mild,’ health states with at least 
one dimension at severity level either 4 or 5 are considered ‘severe,’ and remaining are considered ‘moderate.’  
Adjusted mean difference: mean scores of the patient groups minus mean scores of the control group 
estimated by the ordinary least-square regression model, with adjustment for sociodemographic covariates 
(see Methods section). 
* p <0.05; ** p <0.01. 
SD Standard deviation; CI Confidence interval. 
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Mean (unadjusted and adjusted) differences between the heart disease patients 
and the general population group in differences between selected health states are 
presented in Figure 6. It shows that the covariate-adjusted differences in differences 
were higher than 0.05, a possible MID for utility values, for 23 of 45 pairs of health 
states (51%; p <0.05 for 11 pairs), and lower than 0.05 for 13 pairs of health states 
(29%; p <0.05 for 3 pairs) in heart disease patients than the control group. A similar 
analysis comparing cancer patients and the control group, (Figure 7) showed that 
adjusted differences in differences were greater than 0.05 for 7 of 45 pairs of health 
states (16%; p >0.05 for all), and lower than 0.05 for 4 pairs (9%; p >0.05 for all). 
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5.3 Results for Research Aim 3 
5.3.1 Estimates of Useful Parameters 
Based on the utility values from study C for the Basic OLS model in equation (1), 
the estimate of error variance (𝜎𝜎�2) was 0.365. The mean (β�) of regression 
coefficients (?̂?𝛽1, ?̂?𝛽2, … , ?̂?𝛽20) of health state descriptor defined using the dummy 
coding scheme was −0.196. Using the Basic RE model in equation (2), the estimate 
of between-participant variance (𝜎𝜎�𝛾𝛾2) and the within-participant variance (𝜎𝜎�𝑒𝑒2) were 
0.203 and 0.162, respectively. The Basic RE model gave β�  −0.204, which was similar 
to the -0.196 from the Basic OLS model.  
Simple and weighted means of design effects �𝐷𝐷𝐸𝐸����𝛽𝛽� for ?̂?𝛽1, ?̂?𝛽2, … , ?̂?𝛽20, using 
equation (7) for cluster-robust variances, were 0.82 and 0.84, respectively, or 
approximately 0.8. The Basic RE model was more efficient, in the sense that the 
variance estimates were smaller. Simple and weighted mean design effects based on 
RE variances were both 0.47, or approximately 0.5. Design effects for the intercept, 
?̂?𝛽0, were 1.27 and 0.92 based on cluster-robust and RE variances, respectively. 
Detailed results of the Basic OLS and RE models are presented in Electronic 
Supplementary Material Table A.2 of Publication Paper IV.  
Pearson’s correlation between predicted utility values based on the Basic OLS 
and RE models was 0.999 in study C, and mean absolute error in prediction using 
both the models was 0.499. Mean design effects �𝐷𝐷𝐸𝐸����𝑦𝑦0� for predicted values using 
equation (6) were approximately 1.15 and 0.75 based on cluster-robust and RE 
variances respectively. Weighted means of design effects were similar to their 
unweighted mean design effects. Mean utility values of individual health states in 
study C along with their predicted values and their standard errors (square root of 
variances) using the Basic OLS and RE models are presented in Electronic 
Supplementary Material Table A.4 of Publication Paper IV. 
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5.3.2 Numerical Illustration 
For illustration, a MID of 0.05 is considered for utility values and regression 
coefficients of health state descriptors.   
Approach 1 - To achieve desired precision of an estimated mean utility value for a particular health 
state 
Suppose the study team is interested in calculating a sample size such that the 
predicted utility value of ‘12334’ health state, which has 𝑥𝑥0′𝐷𝐷𝑥𝑥0 value approximately 
equal to the mean of 𝑥𝑥0′𝐷𝐷𝑥𝑥0 values (i.e., 𝐷𝐷�𝑥𝑥0 = 0.210) of all directly valued health 
states in the EQ-VT protocol, is not far from its true value by more than an MID 
for utility values. That is, the half-width of the 95% PI of the estimated utility value 
equal to δ = 0.05 (MID). The sample size can be calculated using equation (10), 
assuming 𝜎𝜎�2 = 0.365 and design effect 𝐷𝐷𝐸𝐸����𝑦𝑦 = 0.75 (based on the Basic RE model), 
as 𝑁𝑁 = 10 𝜎𝜎�2 𝐷𝐷�𝑥𝑥0𝐷𝐷𝐸𝐸����𝑦𝑦 𝑍𝑍1−𝛼𝛼/22 𝛿𝛿2⁄   = 10×0.365×0.210×0.75×(1.960)2/(0.05)2 = 
2.2084/0.0025 ≈ 883 participants. 
The solid line in Figure 8 shows the sample sizes calculated as illustrated above 
for Approach 1 for different MID (y-axis on the left). It shows a rapid decline in the 
curve with an increase in sample size from 100 to 400 participants. However, it 
decreases by a trivial magnitude with further increase of sample size after 400.  
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Approach 2 - Empirical approach to achieve desired mean absolute error in prediction of utility 
values relative to a reference study 
For this approach, Figure 8 shows the mean of 𝑀𝑀𝑀𝑀𝐸𝐸𝑁𝑁𝑠𝑠 (y-axis on right) for 100 
random samples (with replacement) of sample sizes 100 to 900 participants based 
on the Basic OLS model using the study C data (N = 1000). The MAE decreased 
rapidly between the sample sizes of 100 to 300. After that, reduction in the slope is 
trivial beyond the sample size of 300. That is, gain in prediction accuracy was trivial 
when the sample size was more than 300 participants.  
Approach 3 - To assess significance of a regression coefficient of health state descriptors 
The sample size required to test 𝐻𝐻0: β� = 0 against 𝐻𝐻1: β� ≠ 0, assuming the true value 
of ?̅?𝛽 = 0.05 (MID) and 𝜎𝜎�2 = 0.365, at 5% two-sided level of significance (α) and 
80% statistical power (1−β), can be calculated using equation (14), by inserting value 
of (𝑍𝑍1−𝛼𝛼/2 + 𝑍𝑍1−𝛽𝛽)2 = (1.960 + 0.842)2 = 7.851, 𝐷𝐷� = 0.131, and adjusting for 
design effect 𝐷𝐷𝐸𝐸����𝛽𝛽 = 0.5 (based on the Basic RE model), as  𝑁𝑁 =10 𝜎𝜎�2 𝐷𝐷� 𝐷𝐷𝐸𝐸����𝛽𝛽 (𝑍𝑍1−𝛼𝛼/2 + 𝑍𝑍1−𝛽𝛽)2 ?̅?𝛽2⁄  = 10×0.365×0.131×0.5×7.851/(0.05)2 = 
1.8770/0.0025 ≈ 751 participants. Figure 8 shows sample sizes corresponding to 
values of ?̅?𝛽 (y-axis on left) at 5% of α and 80% statistical power.  
Approach 4 - To estimate a regression coefficient of health state descriptors with a desired precision 
To estimate a regression coefficient with its 95% CI of half-width equal to 𝛿𝛿̅ = 0.05 
(MID), using equation (17) with 𝜎𝜎�2 = 0.365, 𝐷𝐷� = 0.131 and 𝐷𝐷𝐸𝐸����𝛽𝛽 = 0.5 (as in 
previous illustration), the required sample size is 𝑁𝑁 = 10 𝜎𝜎�2 𝐷𝐷� 𝐷𝐷𝐸𝐸����𝛽𝛽 𝑍𝑍1−𝛼𝛼/22 𝛿𝛿̅2⁄  = 
10×0.365×0.131×0.5×(1.960)2/(0.05)2 = 0.9184/0.0025 ≈ 367 participants. Figure 
8 shows sample sizes corresponding to values of 𝛿𝛿̅ (y-axis on left) for 95% CI of a 
regression coefficient. 
The backward difference coding scheme used for health state descriptors has no 
impact on sample size estimation in Approach 1 and 2, and only a trivial impact on 
Approach 3 and 4 (Results not shown). 
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6 DISCUSSION 
Several methodological issues in health state valuation were studied. Firstly, how the 
most severe state in the presence of a label, such as ‘all-worst’ is valued in a general 
population is explored using two of the most extensively utilized generic 
instruments, SF-6D and EQ-5D-3L, with the VAS method. This is the first study 
conducted to evaluate the impact of labeling a generic health state on its valuation. 
So far, all prior studies were conducted to study this aspect in disease-specific health 
states.(Green et al., 2017, Robinson and Bryan, 2013, Brazier et al., 2012, Rowen et 
al., 2012) Second, the impact of chronic disease experience on hypothetical health 
state valuation is studied in several patient populations using the EQ-5D-3L with 
the VAS method and the EQ-5D-5L with the composite TTO method. This issue 
was studied in two separate studies. The first study evaluated the impact of chronic 
disease experience on the valuation in patients with diabetes, rheumatism, 
hypertension, heart disease and lung disease. The study included a vast range of 42 
EQ-5D-3L health states. This is the first study evaluating the impact of chronic 
diseases on the valuation of hypothetical health states with several chronic disease 
patients in the Asian population. The second study was a follow-up study to further 
evaluate the findings of the first study in the two high disease burden chronic disease 
populations, heart disease and cancer patients, with the latest revised version of EQ-
5D-3L, EQ-5D-5L, using the standard protocol for the EQ-5D-5L value set based 
on the composite TTO method. In this study, the patients’ diagnoses were also 
confirmed clinically.  Finally, capitalizing on the standard valuation protocol for the 
EQ-5D-5L value set studies, statistical methods for estimating sample size for value 
set studies have been proposed. Previously used sample size methods in the EQ-
5D-3L value set studies were either not based on the primary objective and analysis 
strategy for developing a value set or not capitalized on health states directly valued 
as per the valuation protocol.(Chevalier and de Pouvourville, 2013, Lamers et al., 
2006, Dolan et al., 1994) My approaches will also help to evaluate the 
appropriateness of the currently recommended sample size of 1000 participants for 
the EQ-5D-5L value set studies. I hope my findings and recommendations on above 
methodological issues can contribute to improving health state valuation methods, 
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the scientific validity of value sets and guide selection of value sets for CUAs and 
medical decision making from a patient-centric approach.  
6.1 Impact of Labeling on the Most Severe Health State 
Valuation 
The most severe health state is one of the most important health states in value 
set studies. Usually, it is valued lowest among all the health states and determines the 
lower limit of the value set. It is often used to rescale utility values to get the value 
set with an appropriate range (e.g., 1 to -1).(Lamers, 2007) In this case, the value of 
the most severe health state has an impact on all the rescaled values. The majority 
of the value set studies include the most severe health state to be directly valued by 
each of the participants to increase the precision of its estimated value when 
considering its importance.(Szende et al., 2007) It is not uncommon to label the most 
severe health state such as ‘all-worst’ or ‘pits’ in value set studies.(Ratcliffe et al., 
2016, Craig et al., 2013, Wee et al., 2006) However, an impact of such labeling on its 
valuation is not studied.  
In my study, the most severe health state was labeled as ‘all-worst.’ I observed a 
deficit in the most severe state valuation which is unable to explain using its 
description (i.e., considering severity levels in each of the dimensions). This was, 
however, not observed in other least valued health states which are better by just 
severity level in one of the dimensions. The deficit in the valuation of the most severe 
health state was observed in valuation using both the commonly used health state 
utility instruments, EQ-5D-3L and SF-6D. The deficit was larger than the MID of 
the respective health state utility instruments as well as statistically significant, which 
indicates that the deficit has a practically significant impact.  
One of the possible reasons for the deficit in the valuation of the most severe 
health state could that participants might have valued the most severe state based on 
the ‘all-worst’ label without fully based on its description according to the health 
state utility instrument. A few studies evaluating the impact of labeling on disease-
specific health states in cancer, mental health and sclerosis also observed a lower 
valuation in the presence of labeling.(Green et al., 2017, Robinson and Bryan, 2013, 
Rabin et al., 1993) The current study showed a comparable labeling effect in a non-
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disease specific health state and a general population context. Thus, we suggest 
avoiding the use of labeling health states in valuation studies. 
Another possibility for the deficit in the valuation of the most severe health state 
could be due to end-aversion bias.(Torrance et al., 2001) That is, some participants 
could be systematically avoiding valuing any health state at the extreme end of the 
VAS. The VAS method involves deciding the least desirable health states from the 
most severe health state or dead state to be placed at the lower end of the VAS scale, 
and then rate the remaining health states between the perfect health the least valued 
health state. The health states near the lower end of the VAS scale might be valued 
at a distance from the most severe health state by the participants who consider the 
most severe health state worse than death, which could have created deficit in the 
valuation of the most severe health state. On the other hand, the participants who 
considered the most severe health state better than death, the end-aversion bias is 
not expected to affect the valuation of the most severe health state.  
In my study, the deficit in the valuation of the most severe health state was more 
prominent in the valuation using the SF-6D compared to EQ-5D-3L. This can be 
explained by the differences in these two descriptive systems. A previous study has 
shown that participant considers severe EQ-5D-3L health states more severe than 
severe SF-6D health states.(Brazier et al., 2004) Therefore, the most severe health 
state of EQ-5D-3L is expected to be valued lower than the SF-6D counterpart, 
which leaves less room for labeling effect on its valuation.  
6.2 Impact of Chronic Disease Experience on Health State 
Valuation 
There is growing interest in how to incorporate patient preferences in the 
healthcare decision making, including in the HTAs for new treatments.(Underwood, 
2016, Bridges and Jones, 2007) Some of the regulatory bodies recommend using the 
general population derived utility values for CUA aiming for reimbursement of the 
treatment using the societal resources.(Sanders et al., 2016, NICE, 2013) However, 
the targeted patient population derived utility values are relevant for medical decision 
making from a patient-centric approach.(Stamuli, 2011) Nevertheless, whose utility 
values should be used depends on whether the utility values derived by the general 
population and the patient population differ significantly. There are only a few 
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studies available comparing the utility of hypothetical health states between patient 
populations and the general population.(Ogorevc et al., 2017, Wang et al., 2014, 
Pickard et al., 2013, Krabbe et al., 2011) Furthermore, these studies have shown 
mixed findings. I compared the utility values of hypothetical health states described 
by the most widely used generic health state utility instrument, EQ-5D, between 
several patient populations and the general population (potentially without chronic 
diseases) in two separate studies.  
In the first study (study A), the mean value of EQ-5D-3L health states based on 
the VAS method was compared between participants with self-reported chronic 
diseases (diabetes, rheumatism, hypertension, heart disease and lung disease) and 
participants without any chronic diseases. The strength of the study was that it used 
a vast range of 42 health states for valuation and included several chronic disease 
patient populations.  
The study showed that heart disease patients value hypothetical health states, 
mainly severe health states, higher than participants with no chronic disease. The 
mean difference in the values between heart disease patients and participants with 
no chronic disease was statistically significant and also larger than the MID for EQ-
5D-3L values. This reflects the practically significant impact of the heart disease 
experience on the health state valuation. No such difference was observed in the 
valuation of other chronic diseases - diabetes, rheumatism, hypertension, and lung 
disease - and participants with no chronic disease.  
In the second study (study B), similar to study A, I compared the mean value of 
hypothetical health states described by the revised version of EQ-5D-3L, EQ-5D-
5L, valued using the currently recommended valuation method - the composite TTO 
method, by patients with heart disease and cancer with participants from the general 
population. The strength of the study was that patient diagnosis was medically 
confirmed, a fixed set of health states were valued by patients and the general 
population participants, the same interviewer conducted all the interviews (to 
minimize interviewer effect).   
The study showed that heart disease patients value hypothetical health states, 
mainly mild health states, higher than participants from the general population. The 
mean difference in the values between heart disease patients and participants from 
the general population was statistically significant and also larger than the MID for 
EQ-5D-5L values. This reflects the practically significant impact of the heart disease 
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experience on the health state valuation. No such difference was observed in the 
valuation of patients with cancer and participants from the general population. 
A post-hoc analysis of study A, comparing values of mild health states between 
patients with heart disease and participants with no chronic disease, also showed that 
heart disease patients value mild health states statistically significantly higher than 
the no chronic disease participants, and the difference was larger than the MID for 
the EQ-5D-3L (see Appendix 7 for more details). This concurs with the findings 
of study B.  
A possible reason for heart disease patients giving higher valuation scores could 
be that a more significant proportion of heart disease patients might have 
experienced health states of varying severity, and this might have changed their 
perception regarding the severity of health problems. That is, heart disease patients 
are more likely to have adapted to health issues demarcated by EQ-5D states than 
healthy ones. Consequently, patients do not distinguish those health states as 
unbearable or unwanted as the general population. This might not be the case with 
other chronic disease patients, or it could at least be various levels of adaptation.  
There is another conceivable reason for why heart disease and other chronic 
disease patients, such as cancer patients, were dissimilar in the valuation of EQ-5D 
health states in contrast to the general population. It is possible that, as opposed to 
the general population and patients with heart disease of a similar age, those with 
cancer are more prone to perceiving their actual life expectancy to be less than 10 
years and are consequently more generous when trading the ‘extra’ years. This 
tendency may lead to lower utility values for all severities of health states. It could 
offset the result of adaptation and as a consequence, make patients with cancer 
similar to the general population in the valuation of health states using the TTO 
method. The finding that older age is associated with lower utility value in study B 
may be evidence for the effect of self-professed life expectancy on TTO-based 
valuation using a fixed time frame.  
The absence of meaningful differences in the valuation between some chronic 
disease patients and the general population might also be because several 
hypothetical health states included in my studies might not be actually experienced 
by patients in real life. Hence, they value these health states similar to participants 
with no chronic disease.  
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The findings from study B are consistent with the study reported by Pickard et 
al.(Pickard et al., 2013) based on the TTO values for EQ-5D-3L health states. 
Pickard et al. reported no meaningful difference in utility values between patients 
with chronic diseases (arthritis, diabetes, depression, hay fever, cancer) and 
participants with no chronic disease, except for heart failure patients. The study 
showed that patients with heart failure only, and patients with heart failure and at 
least one other chronic disease, gave values higher by 0.25 points and 0.07 points, 
respectively, which is larger than the MID for EQ-5D-3L, compared to participants 
with no chronic disease.  
In another study conducted by Krabbe et al.(Krabbe et al., 2011) comparing VAS 
and TTO values for EQ-5D-3L health states between patients with rheumatoid 
arthritis and cancer with participants from the general population, showed no 
meaningful difference in VAS values between patients with rheumatoid arthritis and 
participants from the general population. However, he showed that cancer patients 
give higher TTO values compared to participants from the general population. It 
should be noted that this study did not adjust for any sociodemographic 
characteristics, including age. Patients in this study were much older (mean age 63 
years and 65 years for cancer and rheumatoid arthritis patients, respectively) 
compared to participants from the general population (mean age 44 years). As age 
can also affect the valuation (shown in my study B), the results of this study are not 
fully comparable with my study results.  
6.3 Determination of Sample Size for Value Set Studies  
The standard valuation protocol, EQ-VT, based on the composite TTO method 
for the EQ-5D-5L value sets recommends a sample size of 1000 participants.(Oppe 
et al., 2014) The recommended sample size lacks sound statistical justification as well 
as empirical evidence for its appropriateness. The determination of a suitable sample 
size is very important: a sample size that is too small will not allow achieving the 
research purpose, whereas a sample size that is too large will compromise feasibility 
of the study. I propose four approaches for determining the sample size for the EQ-
5D-5L value set studies according to the standardized protocol. 
Four approaches for determining sample size were proposed and illustrated for 
the valuation studies of health states using EQ-VT protocol—the first two are based 
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on achieving desired precision in predicting utility values, and remaining two on 
regression coefficients for a model predicting utility values. Useful sample size 
parameters are estimated from a Singaporean study. Amid the first two approaches 
which are directly associated with the primary aim of value set studies to predict 
utility values with desired precision, Approach 1 (based on prediction intervals of 
predicted utility values) has certain advantages over Approach 2 (based on mean 
absolute errors in predicted utility values). In the Approach 1, the study team can 
choose the desired level of precision (prediction error) with the desired level of 
confidence (probability), whereas in Approach 2 is based on achieving the mean 
level of precision (prediction error). Moreover, it also requires data from a similar 
value set study with a larger sample size and the sample size of a new study be 
selected proportionate to the larger study. The remaining two approaches are also 
associated with the analysis plan for developing a value set with acceptable precision. 
Previous sample size estimation methods used in the EQ-5D-3L value set studies 
were based on comparing mean utility values of two directly valued health states or 
estimating utility values of directly valued health states with the desired precision 
(confidence interval)(Chevalier and de Pouvourville, 2013, Lamers et al., 2006, 
Dolan et al., 1994). These methods have either not incorporated regression model 
used to predict utility values or capitalized the method based on the directly valued 
health states. In other words, these sample size approaches were not directly based 
on the study’s primary objective, analysis plan or protocol. Hence, the precision of 
predicted utility values using these sample size methods cannot be assured. An 
approach based on the study protocol, primary aim, outcome, and analysis plan 
should be chosen by the study team. 
Two approaches commonly used in clustered data for statistical inference - 
cluster-robust estimation and random-effects model – were studied to evaluate how 
they influence the sample size estimation. Both methods exhibited deflation in the 
variances for regression coefficients of model predicting utility values when adjusted 
for within-person correlation. This was expected as each block involves health states 
from varying severity from mild to severe; as such, the within-person correlation 
among allocated health states is negative.(Kahan and Morris, 2013, Parzen et al., 
1998) Apropos the choice between the clustered-robust estimator and random-
effects model methods for estimating the design effect, is not straightforward and 
rests on the preference of the study team for the model selection and also on data. 
The approach of the cluster-robust estimator needs fewer assumptions in contrast 
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to that of the random-effects model approach.(Cameron and Miller, 2015) 
Nonetheless, it is less efficient. Better efficiency is seen with the random-effects 
model which gives smaller standard errors and design effect estimate contrary to the 
other approach. However, there is no assurance that the model assumptions in the 
random-effects model hold for given data. Nonetheless, as is conveyed in the Results 
section, the Pearson’s correlation between utility values predicted using the ordinary 
least-square model (with cluster-robust standard errors) and the random-effects 
models in the Singapore study, was close to 1, signifying both models provided 
almost identical results. 
6.4 Limitations 
 
There are several limitations in my studies. All my studies were conducted in 
Singapore. As the cultural differences affect the health state valuation, the 
generalizability of the findings is limited. Nonetheless, as the Singapore is a multi-
ethnic country with three major ethnicities – Chinese, Malay, and Indian. The study 
findings have potential to generalize in the Asian population. Further research will 
be required in western countries to generalize the findings in the western population.   
The main limitation of the study evaluating the labeling effect on the most severe 
health state was that the labeling effect was evaluated in the absence of a control 
arm, without a label for the most severe health state. Therefore, the findings of the 
study required to be confirmed in a randomized controlled study with and without 
labeling arms. This study used the VAS method for valuation. As the valuation 
method could impact the health state valuation, further studies will be required to 
evaluate the labeling effect using other valuation methods. 
Both the studies comparing valuation using the EQ-5D-3L (study A) and EQ-
5D-5L (study B) have a few common limitations. First, the study samples did not 
incorporate inpatients or patients at a severe or unstable stage of chronic diseases. 
As such, inpatients are likely to be in the worse functional state and might be 
associated with a lower valuation. For example, heart disease outpatients in the EQ-
5D-5L study (study B), whose functional state was associated with a lower valuation 
(data not shown). Therefore, the difference in valuation between chronic disease 
patients and the general population could be under-estimated. Nonetheless, it is 
challenging to conduct the highly demanding cognitive valuation interviews with 
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extremely severe patients. Second, the studies involved only two life-threatening 
chronic diseases (cardiovascular diseases and cancers). Further studies in other life-
threatening chronic conditions will be required to generalize the findings to a wider 
group of chronic conditions. Third, separate statistical tests were performed for 
comparing valuation of health states with varying severity between each of the 
patient populations and the control population without multiplicity adjustment. The 
studies were not powered for these analyses. Therefore, the statistical significance 
observed in these studies might be due to inflated Type-I error probability and 
findings require further confirmation. Lastly, because of the sample size constraint, 
it was impossible to evaluate the effect of chronic disease experience on the valuation 
of individual dimensions of EQ-5D health states.  
In the study comparing the EQ-5D-3L valuation (study A), the chronic diseases 
were self-reported by participants. Therefore, I cannot rule out the possibility of 
misclassification as they were not clinically confirmed. Nevertheless, there could be 
less possibility of participants with no disease to report having a disease than patients 
with a disease reporting having no disease. A study conducted in Finnish 
population(Oksanen et al., 2010) showed that the sensitivity of self-reporting 
chronic conditions such as diabetes, hypertension, heart disease, asthma and 
rheumatoid arthritis could range from 78 to 96%, whereas the specificity could range 
from 96 to 99%. That is, the difference in valuation between patients and 
participants with no chronic disease might be under-estimated, but fewer chances 
that it is over-estimated.  
In the study comparing the EQ-5D-5L valuation (study B), the general 
population sample was enlisted from shopping malls. Although malls are a 
commonly visited place by the Singaporeans(URA, 2009), shopping is typically an 
enjoyable leisure activity which might influence the valuation of health states. 
Therefore, the extent of the difference observed in valuation by patients and general 
population could also be affect by this sample selection.  
It should be noted that while developing methodologies for sample size 
estimation for EQ-5D-5L value set studies, my objective was not to recommend any 
analysis strategy or model, nor offer a value set. Therefore, no attempt to optimize 
the model fitting has been made, except for incorporating 20 indicator variables and 
an intercept intended for health state descriptors. No interaction terms have been 
included in these basic models, which could be valuable for the model assumptions 
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and performance validity. It could also be the likely reason why when using 
Approach 2, the mean absolute error has a high value, even when the sample size of 
participants is 1000. By what method the analysis models can be improved and the 
prediction error to be reduced, is a complex problem beyond the scope of the 
current research, and in theory, is associated with valuation methodology in addition 
to modeling technique. This may necessitate additional research. Moreover, when 
illustrating the sample size determination approaches, a minimally important 
difference of 0.05 was used for utility values simply with the intent to illustrate the 
numerical applications. In certain realistic circumstances, for example, the 
illustration in Approaches 1 and 3, 1000 participants as a sample size was more or 
less right. Nevertheless, they were based on certain assumptions and a particular 
level of precision, which could differ according to the study team’s requirements. 
The sample size should be determined by the study team as per its requirements. 
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7 SCIENTIFIC CONCLUSIONS 
1. The most severe state with label ‘all-worst’ is valued significantly lower than 
expected, according to its descriptors. Labels in addition to health state 
description should be avoided to minimize the impact of unintended factors 
on health state valuation. (Publication Paper I) 
2. Chronic disease patients might vary from those of the general population 
when it came to the strength of their preferences for hypothetical health 
states. The difference in preferences may depend on the type of the disease, 
the patient’s age, and how severe the health state being valued is. 
Consequently, using utility values originated from the general population 
might undervalue or overvalue the comparative effectiveness of healthcare 
interventions for specific kinds of diseases, for example, heart diseases. 
(Publication Papers II and III) 
3. The proposed four sample size estimation approaches and the relevant 
parameter estimates can help to decide an appropriate sample size for a value 
set study. (Publication Paper IV) 
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8 IMPLICATIONS AND FUTURE RESEARCH 
NEEDS 
 
The present research findings provide several recommendations for improvement 
in health state valuation techniques and selection of value sets in CUA and 
comparative effectiveness from a patient-centric approach. 
The findings based on the first research aim suggest avoiding using any labels 
(e.g., ‘all-worst’ for the most severe health state) in addition to health state 
description. In the presence of labeling, the valuation of health states might be 
affected by prior belief or emotions associated with the label. Specifically, if a label 
is attached to the anchoring health states, such as the most severe health state which 
often decides lower bound of utility value sets, may have major implications. As the 
current study was a single-arm observational study with all participants exposed to a 
health state with a label, a randomized controlled study with participants exposed to 
health states with and without a label will be needed to confirm the findings.  
The findings from the second research aims indicated that some specific chronic 
disease experience might affect how individuals with such experience perceive 
different health conditions. For example, my studies showed patients with heart 
disease experience may not consider a health condition with mild impairment as 
worse compared to individuals with no such experience may consider. Similarly, 
severe health conditions were also perceived differently by heart disease patients. 
Such systemic differences in perception might lead to differences in health state 
valuation derived from the patient and the general populations, which could 
ultimately lead to under-estimation or over-estimation of the effectiveness of a 
healthcare intervention if the general population derived value set is used. This 
finding may have implications in clinical decision making as to which healthcare 
intervention is preferable for patients with the disease. If a patient-centered 
approach is to be adopted to guide patient care to ensure that targeted patient 
population preferences and values are incorporated, the patient-derived utility value 
set should be considered. As such, patient-derived utility value set will be needed for 
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the evaluative effectiveness of available healthcare interventions. As our studies were 
limited to a few chronic diseases and limited sample sizes, further studies with larger 
sample sizes and patients with different chronic diseases and severity should be 
conducted to understand the implication of disease experience on health state 
valuation. If the patient valuation is found to be systematically different from the 
general population, a utility set targeted to the specific patient population should be 
developed for patient-centered clinical decision-making and effectiveness analysis.  
Lastly, the third research aim suggested multiple approaches for estimating 
required sample size for EQ-5D-5L value set studies. These approaches were 
capitalized on the latest internationally adopted protocol for EQ-5D-5L health state 
valuation. The suggested approaches can help to determine sample size for a 
country-specific value set for the general population as well as a value set specific to 
a particular patient population. The sample size approaches offer to determine 
sample sizes using given levels of precision with different objectives related to the 
development of value set studies. Further research will be needed to generalize the 
sample size approaches for other multi-attribute descriptive systems with different 
valuation methodologies. 
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Appendix 1: EQ-5D-3L Questionnaire  
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Appendix 2: EQ-5D-5L Questionnaire  
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Appendix 3: SF-6D Questionnaire  
 
Source: www.sheffield.ac.uk 
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Appendix 4: SF-6D Health States Selected in Study A 
Serial Number Health state PH RL SF PN MH VT 
1 111111 1 1 1 1 1 1 
2 111112 1 1 1 1 1 2 
3 111212 1 1 1 2 1 2 
4 111215 1 1 1 2 1 5 
5 111222 1 1 1 2 2 2 
6 111453 1 1 1 4 5 3 
7 111621 1 1 1 6 2 1 
8 112111 1 1 2 1 1 1 
9 112221 1 1 2 2 2 1 
10 112521 1 1 2 5 2 1 
11 112543 1 1 2 5 4 3 
12 113411 1 1 3 4 1 1 
13 114212 1 1 4 2 1 2 
14 114244 1 1 4 2 4 4 
15 115653 1 1 5 6 5 3 
16 121111 1 2 1 1 1 1 
17 121112 1 2 1 1 1 2 
18 121122 1 2 1 1 2 2 
19 121212 1 2 1 2 1 2 
20 122112 1 2 2 1 1 2 
21 122211 1 2 2 2 1 1 
22 122233 1 2 2 2 3 3 
23 122425 1 2 2 4 2 5 
24 122622 1 2 2 6 2 2 
25 122653 1 2 2 6 5 3 
26 124114 1 2 4 1 1 4 
27 124314 1 2 4 3 1 4 
28 131542 1 3 1 5 4 2 
29 132425 1 3 2 4 2 5 
30 132524 1 3 2 5 2 4 
31 133132 1 3 3 1 3 2 
32 133511 1 3 3 5 1 1 
33 134322 1 3 4 3 2 2 
34 134352 1 3 4 3 5 2 
35 135332 1 3 5 3 3 2 
36 141653 1 4 1 6 5 3 
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Serial Number Health state PH RL SF PN MH VT 
37 142154 1 4 2 1 5 4 
38 142631 1 4 2 6 3 1 
39 143611 1 4 3 6 1 1 
40 144113 1 4 4 1 1 3 
41 144144 1 4 4 1 4 4 
42 144241 1 4 4 2 4 1 
43 144341 1 4 4 3 4 1 
44 145133 1 4 5 1 3 3 
45 145353 1 4 5 3 5 3 
46 211111 2 1 1 1 1 1 
47 211211 2 1 1 2 1 1 
48 211212 2 1 1 2 1 2 
49 211221 2 1 1 2 2 1 
50 212442 2 1 2 4 4 2 
51 212453 2 1 2 4 5 3 
52 213114 2 1 3 1 1 4 
53 213323 2 1 3 3 2 3 
54 213345 2 1 3 3 4 5 
55 214411 2 1 4 4 1 1 
56 214535 2 1 4 5 3 5 
57 215154 2 1 5 1 5 4 
58 221211 2 2 1 2 1 1 
59 221212 2 2 1 2 1 2 
60 221432 2 2 1 4 3 2 
61 221535 2 2 1 5 3 5 
62 222113 2 2 2 1 1 3 
63 222121 2 2 2 1 2 1 
64 222122 2 2 2 1 2 2 
65 222212 2 2 2 2 1 2 
66 223451 2 2 3 4 5 1 
67 223511 2 2 3 5 1 1 
68 224112 2 2 4 1 1 2 
69 224223 2 2 4 2 2 3 
70 224612 2 2 4 6 1 2 
71 232111 2 3 2 1 1 1 
72 233551 2 3 3 5 5 1 
73 234233 2 3 4 2 3 3 
74 234551 2 3 4 5 5 1 
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Serial Number Health state PH RL SF PN MH VT 
75 235224 2 3 5 2 2 4 
76 241531 2 4 1 5 3 1 
77 241545 2 4 1 5 4 5 
78 241635 2 4 1 6 3 5 
79 243432 2 4 3 4 3 2 
80 243634 2 4 3 6 3 4 
81 244313 2 4 4 3 1 3 
82 311222 3 1 1 2 2 2 
83 311233 3 1 1 2 3 3 
84 311655 3 1 1 6 5 5 
85 312255 3 1 2 2 5 5 
86 312332 3 1 2 3 3 2 
87 312455 3 1 2 4 5 5 
88 312552 3 1 2 5 5 2 
89 313532 3 1 3 5 3 2 
90 314631 3 1 4 6 3 1 
91 315515 3 1 5 5 1 5 
92 321122 3 2 1 1 2 2 
93 321144 3 2 1 1 4 4 
94 321221 3 2 1 2 2 1 
95 321335 3 2 1 3 3 5 
96 321455 3 2 1 4 5 5 
97 322134 3 2 2 1 3 4 
98 322635 3 2 2 6 3 5 
99 322644 3 2 2 6 4 4 
100 323135 3 2 3 1 3 5 
101 323153 3 2 3 1 5 3 
102 323333 3 2 3 3 3 3 
103 323431 3 2 3 4 3 1 
104 323433 3 2 3 4 3 3 
105 323443 3 2 3 4 4 3 
106 323632 3 2 3 6 3 2 
107 323644 3 2 3 6 4 4 
108 323645 3 2 3 6 4 5 
109 324125 3 2 4 1 2 5 
110 325455 3 2 5 4 5 5 
111 331244 3 3 1 2 4 4 
112 332113 3 3 2 1 1 3 
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Serial Number Health state PH RL SF PN MH VT 
113 332145 3 3 2 1 4 5 
114 332411 3 3 2 4 1 1 
115 333154 3 3 3 1 5 4 
116 333225 3 3 3 2 2 5 
117 333333 3 3 3 3 3 3 
118 333433 3 3 3 4 3 3 
119 334254 3 3 4 2 5 4 
120 341123 3 4 1 1 2 3 
121 342322 3 4 2 3 2 2 
122 342353 3 4 2 3 5 3 
123 343214 3 4 3 2 1 4 
124 343312 3 4 3 3 1 2 
125 343325 3 4 3 3 2 5 
126 344145 3 4 4 1 4 5 
127 344344 3 4 4 3 4 4 
128 345122 3 4 5 1 2 2 
129 345623 3 4 5 6 2 3 
130 411245 4 1 1 2 4 5 
131 412152 4 1 2 1 5 2 
132 413144 4 1 3 1 4 4 
133 413333 4 1 3 3 3 3 
134 413414 4 1 3 4 1 4 
135 413511 4 1 3 5 1 1 
136 414511 4 1 4 5 1 1 
137 414522 4 1 4 5 2 2 
138 415424 4 1 5 4 2 4 
139 421314 4 2 1 3 1 4 
140 422655 4 2 2 6 5 5 
141 423333 4 2 3 3 3 3 
142 423343 4 2 3 3 4 3 
143 423433 4 2 3 4 3 3 
144 424421 4 2 4 4 2 1 
145 424554 4 2 4 5 5 4 
146 424643 4 2 4 6 4 3 
147 425133 4 2 5 1 3 3 
148 425521 4 2 5 5 2 1 
149 431144 4 3 1 1 4 4 
150 431435 4 3 1 4 3 5 
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Serial Number Health state PH RL SF PN MH VT 
151 431443 4 3 1 4 4 3 
152 431623 4 3 1 6 2 3 
153 432255 4 3 2 2 5 5 
154 432623 4 3 2 6 2 3 
155 433142 4 3 3 1 4 2 
156 433333 4 3 3 3 3 3 
157 433433 4 3 3 4 3 3 
158 433541 4 3 3 5 4 1 
159 434654 4 3 4 6 5 4 
160 441132 4 4 1 1 3 2 
161 442343 4 4 2 3 4 3 
162 443144 4 4 3 1 4 4 
163 443215 4 4 3 2 1 5 
164 443222 4 4 3 2 2 2 
165 443335 4 4 3 3 3 5 
166 445321 4 4 5 3 2 1 
167 511114 5 1 1 1 1 4 
168 512242 5 1 2 2 4 2 
169 512551 5 1 2 5 5 1 
170 513354 5 1 3 3 5 4 
171 513531 5 1 3 5 3 1 
172 515332 5 1 5 3 3 2 
173 521424 5 2 1 4 2 4 
174 522321 5 2 2 3 2 1 
175 523554 5 2 3 5 5 4 
176 523634 5 2 3 6 3 4 
177 524442 5 2 4 4 4 2 
178 524644 5 2 4 6 4 4 
179 525112 5 2 5 1 1 2 
180 525311 5 2 5 3 1 1 
181 531635 5 3 1 6 3 5 
182 532124 5 3 2 1 2 4 
183 532455 5 3 2 4 5 5 
184 532554 5 3 2 5 5 4 
185 533331 5 3 3 3 3 1 
186 534133 5 3 4 1 3 3 
187 534544 5 3 4 5 4 4 
188 534555 5 3 4 5 5 5 
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Serial Number Health state PH RL SF PN MH VT 
189 534625 5 3 4 6 2 5 
190 534644 5 3 4 6 4 4 
191 535422 5 3 5 4 2 2 
192 535544 5 3 5 5 4 4 
193 535545 5 3 5 5 4 5 
194 535554 5 3 5 5 5 4 
195 535555 5 3 5 5 5 5 
196 535645 5 3 5 6 4 5 
197 541432 5 4 1 4 3 2 
198 541531 5 4 1 5 3 1 
199 541622 5 4 1 6 2 2 
200 542325 5 4 2 3 2 5 
201 542345 5 4 2 3 4 5 
202 542524 5 4 2 5 2 4 
203 543344 5 4 3 3 4 4 
204 543624 5 4 3 6 2 4 
205 544223 5 4 4 2 2 3 
206 544352 5 4 4 3 5 2 
207 544555 5 4 4 5 5 5 
208 544633 5 4 4 6 3 3 
209 544644 5 4 4 6 4 4 
210 544654 5 4 4 6 5 4 
211 545122 5 4 5 1 2 2 
212 545422 5 4 5 4 2 2 
213 545523 5 4 5 5 2 3 
214 545622 5 4 5 6 2 2 
215 545644 5 4 5 6 4 4 
216 545654 5 4 5 6 5 4 
217 545655 5 4 5 6 5 5 
218 612442 6 1 2 4 4 2 
219 613143 6 1 3 1 4 3 
220 614321 6 1 4 3 2 1 
221 614434 6 1 4 4 3 4 
222 615144 6 1 5 1 4 4 
223 621221 6 2 1 2 2 1 
224 621451 6 2 1 4 5 1 
225 622513 6 2 2 5 1 3 
226 623133 6 2 3 1 3 3 
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Serial Number Health state PH RL SF PN MH VT 
227 624115 6 2 4 1 1 5 
228 624142 6 2 4 1 4 2 
229 624331 6 2 4 3 3 1 
230 624343 6 2 4 3 4 3 
231 625141 6 2 5 1 4 1 
232 625213 6 2 5 2 1 3 
233 631231 6 3 1 2 3 1 
234 631354 6 3 1 3 5 4 
235 631355 6 3 1 3 5 5 
236 632121 6 3 2 1 2 1 
237 633122 6 3 3 1 2 2 
238 634124 6 3 4 1 2 4 
239 634545 6 3 4 5 4 5 
240 635244 6 3 5 2 4 4 
241 635255 6 3 5 2 5 5 
242 635544 6 3 5 5 4 4 
243 635554 6 3 5 5 5 4 
244 641424 6 4 1 4 2 4 
245 641622 6 4 1 6 2 2 
246 642612 6 4 2 6 1 2 
247 644545 6 4 4 5 4 5 
248 645555 6 4 5 5 5 5 
249 645655 6 4 5 6 5 5 
PH Physical functioning, RL Role limitation, SF Social functioning, PN Pain, MH Mental health, VT Vitality. 
 
 
 
 
 
 
 
 
 
 108 
Appendix 5: EQ-5D-3L Health States Selected in Study A 
Serial Number Health State MO SC UA PD AD 
1 11111 1 1 1 1 1 
2 11112 1 1 1 1 2 
3 11113 1 1 1 1 3 
4 11121 1 1 1 2 1 
5 11122 1 1 1 2 2 
6 11131 1 1 1 3 1 
7 11133 1 1 1 3 3 
8 11211 1 1 2 1 1 
9 11312 1 1 3 1 2 
10 12111 1 2 1 1 1 
11 12121 1 2 1 2 1 
12 12211 1 2 2 1 1 
13 12222 1 2 2 2 2 
14 12223 1 2 2 2 3 
15 13212 1 3 2 1 2 
16 13311 1 3 3 1 1 
17 13332 1 3 3 3 2 
18 21111 2 1 1 1 1 
19 21133 2 1 1 3 3 
20 21222 2 1 2 2 2 
21 21232 2 1 2 3 2 
22 21312 2 1 3 1 2 
23 21323 2 1 3 2 3 
24 22112 2 2 1 1 2 
25 22121 2 2 1 2 1 
26 22122 2 2 1 2 2 
27 22222 2 2 2 2 2 
28 22233 2 2 2 3 3 
29 22323 2 2 3 2 3 
30 22331 2 2 3 3 1 
31 23232 2 3 2 3 2 
32 23313 2 3 3 1 3 
33 23321 2 3 3 2 1 
34 32211 3 2 2 1 1 
35 32223 3 2 2 2 3 
36 32232 3 2 2 3 2 
 109 
Serial Number Health State MO SC UA PD AD 
37 32313 3 2 3 1 3 
38 32331 3 2 3 3 1 
39 33212 3 3 2 1 2 
40 33232 3 3 2 3 2 
41 33321 3 3 3 2 1 
42 33323 3 3 3 2 3 
43 33333 3 3 3 3 3 
MO Mobility, SC Self-care, UA Usual activities, PD Pain/Discomfort, AD Anxiety/Depression. 
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Appendix 6: EQ-5D-5L Health States Selected in Study C 
Block Health State MO SC UA PD AD 
1 11221 1 1 2 2 1 
11235 1 1 2 3 5 
54231 5 4 2 3 1 
51451 5 1 4 5 1 
34515 3 4 5 1 5 
35245 3 5 2 4 5 
12514 1 2 5 1 4 
45144 4 5 1 4 4 
12111 1 2 1 1 1 
55555 5 5 5 5 5 
2 12543 1 2 5 4 3 
12121 1 2 1 2 1 
43542 4 3 5 4 2 
34155 3 4 1 5 5 
52215 5 2 2 1 5 
45133 4 5 1 3 3 
32443 3 2 4 4 3 
23514 2 3 5 1 4 
11211 1 1 2 1 1 
55555 5 5 5 5 5 
3 45233 4 5 2 3 3 
55233 5 5 2 3 3 
31525 3 1 5 2 5 
52455 5 2 4 5 5 
12244 1 2 2 4 4 
13313 1 3 3 1 3 
25122 2 5 1 2 2 
11421 1 1 4 2 1 
21111 2 1 1 1 1 
55555 5 5 5 5 5 
4 21112 2 1 1 1 2 
14554 1 4 5 5 4 
12513 1 2 5 1 3 
 111 
Block Health State MO SC UA PD AD 
44345 4 4 3 4 5 
12344 1 2 3 4 4 
53221 5 3 2 2 1 
54342 5 4 3 4 2 
44125 4 4 1 2 5 
11121 1 1 1 2 1 
55555 5 5 5 5 5 
5 43315 4 3 3 1 5 
54153 5 4 1 5 3 
52431 5 2 4 3 1 
24443 2 4 4 4 3 
14113 1 4 1 1 3 
31524 3 1 5 2 4 
15151 1 5 1 5 1 
21315 2 1 3 1 5 
11112 1 1 1 1 2 
55555 5 5 5 5 5 
6 12112 1 2 1 1 2 
11212 1 1 2 1 2 
44553 4 4 5 5 3 
21345 2 1 3 4 5 
34244 3 4 2 4 4 
23152 2 3 1 5 2 
43514 4 3 5 1 4 
55424 5 5 4 2 4 
21111 2 1 1 1 1 
55555 5 5 5 5 5 
7 13122 1 3 1 2 2 
24553 2 4 5 5 3 
51152 5 1 1 5 2 
11425 1 1 4 2 5 
22434 2 2 4 3 4 
42115 4 2 1 1 5 
35332 3 5 3 3 2 
45413 4 5 4 1 3 
 112 
Block Health State MO SC UA PD AD 
11211 1 1 2 1 1 
55555 5 5 5 5 5 
8 33253 3 3 2 5 3 
23242 2 3 2 4 2 
24342 2 4 3 4 2 
32314 3 2 3 1 4 
12334 1 2 3 3 4 
21334 2 1 3 3 4 
55225 5 5 2 2 5 
53412 5 3 4 1 2 
11112 1 1 1 1 2 
55555 5 5 5 5 5 
9 11414 1 1 4 1 4 
25331 2 5 3 3 1 
25222 2 5 2 2 2 
21444 2 1 4 4 4 
31514 3 1 5 1 4 
53243 5 3 2 4 3 
53244 5 3 2 4 4 
35143 3 5 1 4 3 
11121 1 1 1 2 1 
55555 5 5 5 5 5 
10 11122 1 1 1 2 2 
52335 5 2 3 3 5 
35311 3 5 3 1 1 
43555 4 3 5 5 5 
24445 2 4 4 4 5 
13224 1 3 2 2 4 
34232 3 4 2 3 2 
42321 4 2 3 2 1 
12111 1 2 1 1 1 
55555 5 5 5 5 5 
MO mobility, SC self-care, UA usual activities, PD pain/discomfort, AD anxiety/depression. 
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Appendix 7: Post-hoc Analysis of Comparing Valuation Score of 
Mild and Moderate Health States between the Heart 
Disease and Control Groups in Study A. 
# Health states with only one domain at severity level 2 and remaining all the domains at severity 
level 1 are classified as ‘mild,’ health states with at least one domain at severity level 3 are classified 
as ‘severe,’ and remaining health states are classified as ‘moderate.’  
Adjusted mean difference: mean scores of the heart disease patient group minus mean scores of the 
control group, estimated by ordinary least-square regression model, with adjustment for health state 
descriptors, disutility due to severe problems, and sociodemographic covariates (see Methods 
section). 
*** p <0.001.   
 
EQ-5D-3L health states# Control (N = 651) 
Heart diseases 
(N = 44) 
Mild health states  
      Mean (SD) 81.3 (16.7) 89.1 (4.5) 
      Adjusted mean difference (95% CI) 12.8 (8.0, 17.7) *** 
Moderate health states  
     Mean (SD) 68.8 (19.2) 64.9 (15.1) 
     Adjusted mean difference (95% CI) 0.1 (-5.0, 5.2) 
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Abstract
Background: It has been reported that valuation of health states that are close to death, such as the most severe
health state, can be affected by health state valuation procedure, and their utility values are difficult to predict. We
examined how the most severe health states of Short Form-6 dimension (SF-6D) and EuroQoL-5 dimension-3 level
(EQ-5D-3L) were valued by the Singapore general population.
Methods: Overall, 249 SF-6D and 42 EQ-5D-3L states were valued by two separate samples from the Singapore
general population using the visual analogue scale (VAS) method. Ordinary least-square regression model was
employed to explain deficit in the valuation of the most severe state using the health state descriptors.
Results: A total of 1021 participants from the SF-6D sample and 1015 participants from the EQ-5D-3L sample were
included in the analysis. We observed that 67% of the SF-6D participants and 74% of the EQ-5D-3L participants
considered the most severe state worse than dead. The most severe state had mean VAS valuation scores more
than 20–25 points lower than the adjacent states that are better by only one level in only one dimension. SF-6D
VAS valuation score for the most severe state was 27 points and 12 points lower than expected according to the
health state descriptors among the participants who considered the most severe state worse than dead and better
than dead, respectively. Similar results were found for the EQ-5D-3L valuation.
Conclusions: The most severe health state was valued lower than expected according to its descriptors.
Keywords: EQ-5D, SF-6D, Utility, Visual analogue scale, Worse than dead
Background
There is an increasing demand on evaluating the outcome
of health-care interventions using cost utility analysis
(CUA), and various health regulatory bodies consider it the
main approach for evaluating the outcome of health-care
interventions [1]. CUA involves quality adjusted life years
(QALYs), which are estimated as the time spent in a health
state multiplied by its utility. QALYs are very useful as they
capture changes in both quality and quantity of life. Health
states from generic health outcome instruments such as
EuroQoL-5 dimension (EQ-5D), Short Form-6 dimension
(SF-6D) and Health Utility Index Mark 3 (HUI3) are val-
ued by the general population using one or more valuation
methods such as time trade-off (TTO), standard gamble
(SG) and visual analogue scale (VAS) [2]. A number of
health states with a mixture of severity levels, including
perfect health, dead and the most severe health state de-
scribed by the instrument, are valued by each participant.
The utility of perfect health is valued 1 and dead is valued
0. A negative utility value represents that the health state is
considered ‘worse than dead’.
The most severe health state is an important health
state in valuation studies. Usually either the most severe
health state or dead state is the least valued state and
hence decides the lower bound of utility values [3]. For
example, the valuation studies in several European coun-
tries asked participants to value the most severe health
state along with the perfect health and dead state twice
because these states are anchoring states (lower or upper
bound of the utility values) [4]. Some valuation methods,
such as chained TTO and chained SG, also use the most
severe health state as the ‘temporary health state’ and
ask participants to trade-off or gamble the other health
* Correspondence: mihir.gandhi@scri.edu.sg
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states between the perfect health and the most severe
health state [5].
The most severe health state is often labelled as ‘all-
worst’ or ‘pits’ [6-10]. There is a general consensus that
adding a disease label in disease-specific health state de-
scriptions can have an impact on health state value, pos-
sibly due to prior knowledge or preconception of the
disease [11]. However, no study to our knowledge has
investigated the impact of labeling a generic health state.
Valuation of health states based on generic instruments
is the most common method for eliciting the population
preferences in CUA, thus how the most severe health state
(in the presence of a label) is valued needs attention.
Drawing on data from a valuation study of the two
most commonly used generic instruments, namely SF-
6D and EQ-5D-3 level (EQ-5D-3L), we aim to examine
how the most severe health state is valued by the par-
ticipants. In this study, the most severe health state
was labelled as ‘all-worst’ state. A valuation study in
multi-ethnic Asian general population showed that the
majority of participants felt that ‘all-worst’ is a better
description than ‘pits’ for the most severe health state
of EQ-5D [12].
Methods
Valuation survey procedures
A cross-sectional, face-to-face survey of health state
valuation for SF-6D and EQ-5D-3L using the VAS
method was conducted in 2009 from a representative
sample of the general population of Singapore, a multi-
ethnic Asian country. A multi-stage sampling approach
was used to randomly select residential blocks, within
which households were selected. Potential participants
who satisfied the pre-set recruitment quotas for ethnicity
(400 Chinese, 400 Malay, 234 Indian), gender (50%
Female) and age (30% for 21–34 years, 40% for 35–49
years, 30% for 50+ years) were interviewed. Within each
race, there was a quota that half of the participants
would use English and the remaining half would use
their native language for the interviews, i.e. Mandarin
for Chinese, Malay for Malays and Tamil for Indians.
Two separate samples of 1034 participants each were
selected for the SF-6D and EQ-5D-3L health states valu-
ation. The SF-6D consists of 6 dimensions (physical
functioning, role limitations, social functioning, pain,
mental health and vitality) and each dimension has 4 to
6 levels. Thus, SF-6D describes a total of 18,000 health
states. A subset of 249 SF-6D states was selected (out
of 18,000) for the valuation based on the protocol of
Brazier et al. [6]. The most severe state (‘645655’ for
SF-6D) was labeled as ‘all-worst’. Each participant was
asked to compare between ‘dying now’ and ‘living for
the rest of his/her life in all-worst’, from which the less
desirable state was assigned a value 0 on the VAS. Each
participant was then asked to value a unique set of 6
states from the subset of SF-6D states and either dead
or the ‘all-worst’ state, depending on which one was not
valued earlier at 0. The unique set of 6 health states
were assigned to each participant in a way that they
spread widely over the valuation space. A 100-point
“feeling thermometer” with endpoints of 100 (most de-
sirable, i.e. perfect health) and 0 (least desirable) was
used as the VAS. The participants were required to in-
dicate where they would rate each of the assigned states
on the “feeling thermometer” by imagine themselves in
that state for the rest of their life without changing.
The participants were allowed to value more than one
health state at the same level of VAS.
The valuation of EQ-5D-3L states was carried out in a
similar way as SF-6D. The EQ-5D-3L consists of 5 di-
mensions (mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression) with 3 levels each (no
problems, some problems, and extreme problems) and
thus describes 243 health states. A subset of 42 EQ-5D-
3L states was selected based on the protocol of Dolan
[13]. The most severe state (‘33333’) was labeled as ‘all-
worst’. Unconscious state was also valued in addition to
the other 6 assigned states.
The study was approved by SingHealth Centralized
Institutional Review Board.
Analyses
Participants who met the following criteria were ex-
cluded from our analysis: a) valued less than 3 health
states, b) did not value dead or the ‘all-worst’ state, c)
valued dead or the ‘all-worst’ state or unconscious state
higher than all the other states, d) gave the same valu-
ation score to all the health states, e) self-reported or
rated by the interviewers as having poor understanding
of health states description or valuation tasks. The valu-
ation score used in the analyses was ‘raw’ VAS valuation
score ranging from 0 (worst possible score) to 100 (best
possible score). We did not transform the valuation
scores to utility to avoid an impact of the transformation
on the estimated valuation score [3].
Mean valuation scores of the health states are pre-
sented using line graphs for a subset of selected health
states. As the study has valued many health states, to
maintain visual clarity we did not include all the valued
health states. The lowest ten health states with the least
valuation scores near the dead state were included in the
graphs. Health states with higher valuation scores were
systematically skipped for the graphical presentation.
The valuation scores among the participants who con-
sidered the ‘all-worst’ state worse than dead and who
considered the ‘all-worst’ state better than dead were
presented separately in the graphs.
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We performed ordinary least-square (OLS) regression
model for EQ-5D-3L with valuation score as the
dependent variable and indicator variables representing
level of severity for each dimension as the independent
variables, with an intercept [4]. That is, included 2 indi-
cator variables for each of the 5 dimensions of EQ-5D-
3L. We also included an indicator variable (N3) to take
into account of additional disutilities when severe prob-
lem (level 3) is reported on at least one dimension. In
addition to the above commonly used variables, we in-
cluded two indicator variables D1 and D2 and their inter-
action: D1 represented the participant who considered
the ‘all-worst’ state worse than dead and D2 represented
the ‘all-worst’ state. This model helped to assess whether
there was a deficit in the valuation score for the most se-
vere state even after taking the descriptors (levels and di-
mensions) into account. It also assessed possible impact
of considering the most severe state worse than death
on its valuation.
Similar regression analysis model was used to study
SF-6D valuation scores. For the variable N3, the severe
level was defined as levels 4–6 for physical functioning,
levels 3–4 for role limitation, level 4–5 for social func-
tioning, mental health and vitality, and level 5–6 for
pain [6].
All the health states valued in the study were included
in the regression analysis. Perfect health state was not
included in the models, as it was assigned a value 100
on VAS. The dead and unconscious states were also
excluded from the regression analyses as they do not
represent any health states/dimensions of SF-6D or EQ-
5D-3L. Since each of the participants valued 6 health
states, we used the Eicker-Huber-White robust standard
error for clustered data for statistical inference [14]. A
P-value less than 0.05 was considered statistically signifi-
cant. All the analyses were carried out using Stata/MP
10.1 for Windows.
Results
Demographic and health characteristics information was
received from all 1034 participants of the SF-6D sample.
Seven participants valued dead higher than all the other
states; 1 participant valued the ‘all-worst’ state higher
than all the other states; and 5 participants were observed
to have poor understanding of heath states description
and/or valuation tasks. Hence, these 13 participants were
excluded from the SF-6D related analysis. Table 1 shows
demographic and health characteristics of 1021 partici-
pants for the SF-6D valuation that were included in the
analysis. Due to the pre-specified quota for gender, age
and ethnicity, the demographic characteristics of enrolled
participants were similar to what was planned. The major-
ity of the SF-6D participants were married (n = 765, 75%),
employed/self-employed (n = 659, 65%), had at least
secondary education (n = 844, 83%), and self-reported
good to excellent general health (n = 947, 93%).
Similarly in the EQ-5D-3L sample, 12 participants val-
ued dead higher than all the other states; 2 participants
valued the unconscious state higher than all the other
states; 1 participant did not value the ‘all-worst’ state;
and 4 participants were observed to have poor under-
standing of heath states description and/or valuation
tasks. Hence, 19 participants were excluded from the
EQ-5D-3L related analysis. The demographic and health
characteristics of the EQ-5D-3L participants were simi-
lar to the SF-6D participants (Table 1).
In the SF-6D valuation, except the ‘all-worst’ state, no
other health state was valued worse than dead state. The
majority of participants (n = 681, 67%) considered the
‘all-worst’ state worse than dead. The mean valuation
score given to the ‘all-worst’ state was 12.8 (SD = 14.0)
among the participants who considered the ‘all-worst’
Table 1 Demographic and health characteristics of the
study sample participants
Characteristics, n (%)
Participants
completing
the SF-6D
Participants
completing
the EQ-5D-3L
(N = 1021) (N = 1015)
Female 521 (51.0) 512 (50.4)
Age (years)
21-29 190 (18.6) 194 (19.1)
30-39 222 (21.7) 228 (22.5)
40-49 272 (26.6) 269 (26.5)
50-59 206 (20.2) 200 (19.7)
60+ 131 (12.8) 124 (12.2)
Ethnicity
Chinese 392 (38.4) 387 (38.1)
Malay 396 (38.8) 399 (39.3)
Indian 233 (22.8) 229 (22.6)
Education level
Primary (6 years) or less 177 (17.3) 190 (18.7)
Secondary (11 years) 562 (55.0) 576 (56.8)
Diploma/degree or higher 282 (27.6) 249 (24.5)
Married/partner 765 (74.9) 761 (75.0)
Employed or self-employed 659 (64.5) 643 (63.4)
General health status
Poor 4 (0.4) 8 (0.8)
Fair 70 (6.9) 99 (9.8)
Good 443 (43.4) 424 (41.8)
Very good 419 (41.0) 383 (37.7)
Excellent 85 (8.3) 101 (10.0)
Self-reported health on EQ-5D-3L VAS,
Mean (SD)
84.5 (11.2) 83.0 (12.1)
VAS = visual analogue scale.
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state better than dead. On the other hand, dead state was
valued with mean valuation score of 11.2 (SD = 12.5)
among the participants who considered the ‘all-worst’
state worse than dead. The mean valuation scores for se-
lected SF-6D health states are shown in Figure 1. For the
participants who considered the ‘all-worst’ state worse
than dead, there was a difference of more than 30 points
in the mean valuation score between the ‘all-worst’ state
(‘645655’) and its adjacent health states that are only one
level different in one dimension (‘545655’ and ‘645555’).
For the participants who considered the ‘all-worst’ state
better than dead the corresponding difference ranged
from 9 to 17 points.
Similar to the SF-6D results, only the ‘all-worst’ state
was valued worse than dead, and the majority of partici-
pants (n = 753, 74%) considered the ‘all-worst’ state worse
than dead in the EQ-5D-3L valuation. The mean valuation
score of the ‘all-worst’ state was 11.4 (SD = 12.3) among
the participants who considered the ‘all-worst’ state better
than dead; and the mean valuation score of dead was 15.2
(SD = 19.7) among the participants who considered the
‘all-worst’ state worse than dead. Similar to Figures 1, 2
also shows a difference of 25 points in the mean valuation
score between the ‘all-worst’ state (‘33333’) and its adja-
cent state ‘33323’ for the participants who considered
the ‘all-worst’ worse than dead. For the participants
who considered the ‘all-worst’ better than dead the cor-
responding difference was 11 points.
The regression intercept showed that, among the par-
ticipants who considered the ‘all-worst’ state better than
dead in the SF-6D sample, the estimated valuation score
was 80.2 (95% CI: 77.3, 83.1) when all the dimensions
were at its best (level 1) (Table 2). The coefficient D1
showed that the participants who considered the ‘all-
worst’ state worse than dead scored the other health
states higher by 2 points (95% CI: 0.2, 3.8) compared to
the participants who considered the ‘all-worst’ state better
than dead. The participants who considered the ‘all-worst’
state better than dead scored the ‘all-worst’ state 12.3
points lower (95% CI: −15.8, −8.8; P-value < 0.001) than
expected by its descriptors. Furthermore, the participants
who considered the ‘all-worst’ state worse dead scored the
‘all-worst’ state 27.0 points lower (coefficient: −12.3-14.7 =
27.0; 95% CI: −30.2, −24.0; P-value < 0.001) than expected.
For the EQ-5D-3L valuation, the participants who
considered the ‘all-worst’ state better than dead scored
the ‘all-worst’ state 2.1 points lower (95% CI: −5.4, −1.1;
P-value = 0.201) than expected by its descriptors. The
participants who considered the ‘all-worst’ state worse
than dead scored the ‘all-worst’ state 15.8 points lower
(coefficient = −2.1-13.7 = −15.8; 95% CI: −18.8, −12.7;
P-value < 0.001) than expected (Table 3).
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All the coefficients of indicator variables for different
levels of SF-6D and EQ-5D-3L dimensions in the re-
spective regression models were negative and most of
them were statistically significant (Tables 2 and 3).
Discussion
We examined the valuation of the most severe state
(labeled as ‘all-worst’) of two of the most widely used
generic instruments, SF-6D and EQ-5D-3L, using the
VAS method in a general population. We examined
the valuation score in two groups of participants - who
considered the most severe state worse than dead and
who considered it better than dead. We observed a
deficit of 20–25 points in the valuation score of the
most severe state than the adjacent states that are bet-
ter by only one level in only one dimension. The re-
gression analysis showed that this deficit could not be
explained by the differences in the health state descrip-
tors. In the SF-6D valuation, the unexplained deficit
was about 27 points and 12.3 points, respectively,
among participants who considered the most severe
state worse and better than dead. This is practically signifi-
cant, as 3.3 points was considered minimally important
difference [15,16]. In the valuation of the EQ-5D-3L, the
participants who considered the most severe state worse
than dead also scored the most severe state 15.8 points
lower than expected according to its descriptor, which is
bigger than the minimally important difference of 7–8
point [16,17]. The regression models were developed
based on the comparative review and user guide for EQ-
5D value sets [4]. We used raw VAS valuation score in the
analysis without any transformations or rescaling to re-
duce artifact effect on the regression coefficients [3].
We found a deficit in value in the health state labelled
as ‘all-worst’. Participants may have valued the most se-
vere state based on the ‘all-worst’ label rather than the
objective description of it [18]. That is, the valuation
might be affected by prior belief associated with a worst
health condition or an emotional response to the hearing
of ‘all-worst’. Several studies of disease-specific health
states valuation have found that an inclusion of disease
label lowered the health state values [11]. For example, a
study found that using a label ‘breast cancer’ reduced
health state values [19]. Another study found that the
use of mental health labels such as mental handicap,
schizophrenia and dementia was associated with lower
health state values [20]. The present study showed a
similar labeling effect in a generic health state and in a
community context. Thus, we suggest to avoid labeling
health states in valuation studies.
Furthermore, the difference in the degree of deficit in
the values of the most severe state between participants
who considered the state worse than dead and those
who considered it better than dead might have been
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affected by end-aversion bias [21]. Some participants
might be reluctant to value health states at the extreme
end of the VAS scale or the portion of scale near the
end. For the participants who consider the most severe
health state worse than dead, the valuation procedure in-
volved putting the card that represented the state at the
lower end of the VAS scale (score 0). Then, the
remaining health states were valued between the two
ends of the VAS scale. Thus, the other health states near
the lower end of the VAS scale might have been valued
higher than the most severe health state as a result of
end-aversion bias. On the other hand, for the partici-
pants who considered the most severe health state better
than dead, the dead state was anchored at 0 and the
most severe health state and the other health states were
valued similarly between the two ends of the VAS scale.
Our study showed that there was larger unexplained
deficit in the valuation of the most severe state in SF-6D
than EQ-5D-3L. It was likely due to differences in their
descriptive systems. It has been shown by Brazier et al.
[22] that severe SF-6D states are less severe than the se-
vere EQ-5D-3L states. That is, the participants consider
the most severe state of EQ-5D-3L almost like the worst
state based on its descriptors and hence leave less room
for the other factors which can intensify its severity,
whereas in SF-6D there is more scope for other factors,
such as the labeling effect.
It should be noted that we valued the health states
using the VAS method and hence the study findings are
applicable to this valuation method only. Further re-
search would be needed to examine if the present find-
ings are generalizable to other valuation methods like
TTO and SG.
Conclusions
We found that the most severe state was valued signifi-
cantly lower than expected according to its descriptors.
The magnitude of the deficit depended on the valuation
instrument and whether the respondents considered the
most severe state worse or better than dead.
Table 2 Summary of ordinary least-square regression on
valuation score of SF-6D health states
Regressor* Coefficient 95% confidence
interval
P-value
The most severe state worse
than dead (D1)
2.0 [0.2, 3.8] 0.029
The most severe state (D2) −12.3 [−15.8, −8.8] <0.001
Interaction of D1 and D2 −14.7 [−16.6, −12.9] <0.001
At least one severe level (N3) −2.3 [−4.3, −0.4] 0.018
Physical functioning level 2 −7.5 [−16.6, −12.9] <0.001
Physical functioning level 3 −7.9 [−9.7, −6.0] <0.001
Physical functioning level 4 −13.8 [−15.8, −11.7] <0.001
Physical functioning level 5 −13.9 [−15.9, −11.9] <0.001
Physical functioning level 6 −22.1 [−24.4, −19.9] <0.001
Role limitations level 2 −3.7 [−5.2, −2.2] <0.001
Role limitations level 3 −3.1 [−4.6, −1.6] <0.001
Role limitations level 4 −2.7 [−4.3, −1.0] 0.002
Social functioning level 2 −3.1 [−4.6, −1.5] <0.001
Social functioning level 3 −2.1 [−3.8, −0.4] 0.015
Social functioning level 4 −2.9 [−4.8, −1.1] 0.002
Social functioning level 5 −3.2 [−5.1, −1.4] 0.001
Pain level 2 −3.9 [−5.7, −2.2] <0.001
Pain level 3 −6.3 [−8.1, −4.5] <0.001
Pain level 4 −6.8 [−8.6, −4.9] <0.001
Pain level 5 −7.5 [−9.2, −5.7] <0.001
Pain level 6 −11.1 [−13.0, −9.2] <0.001
Mental health level 2 −2.1 [−3.8, −0.4] 0.016
Mental health level 3 −2.8 [−4.7, −1.0] 0.002
Mental health level 4 −4.0 [−5.9, −2.1] <0.001
Mental health level 5 −3.0 [−4.9, −1.1] 0.002
Vitality level 2 −0.3 [−2.1, 1.6] 0.785
Vitality level 3 −5.0 [−6.9, −3.2] <0.001
Vitality level 4 −5.6 [−7.6, −3.6] <0.001
Vitality level 5 −10.6 [−12.6, −8.6] <0.001
Intercept 80.2 [77.3, 83.1] <0.001
R2 = 0.519
*Adjusted for all levels of 6 dimensions of SF-6D.
Table 3 Summary of ordinary least-square regression on
valuation score of EQ-5D-3L health states
Regressor* Coefficient 95% confidence
interval
P-value
The most severe state worse
than dead (D1)
2.2 [−0.0, 4.5] 0.054
The most severe state (D2) −2.1 [−5.4, 1.1] 0.201
Interaction of D1 and D2 −13.7 [−15.8, −11.6] <0.001
At least one severe level (N3) −14.8 [−17.4, −12.1] <0.001
Mobility level 2 −8.2 [−9.4, −6.9] <0.001
Mobility level 3 −15.0 [−17.0, −13.0] <0.001
Self-care level 2 −5.1 [−6.5, −3.7] <0.001
Self-care level 3 −13.9 [−15.7, −12.2] <0.001
Usual activities level 2 −1.6 [−3.5, 0.3] 0.102
Usual activities level 3 −4.2 [−6.3, −2.0] <0.002
Pain/discomfort level 2 −5.1 [−6.3, −3.9] <0.001
Pain/discomfort level 3 −12.4 [−13.6, −11.1] <0.001
Anxiety/depression level 2 −0.3 [−1.8, 1.2] 0.674
Anxiety/depression level 3 −6.1 [−7.9, −4.2] <0.001
Intercept 79.9 [77.5, 82.3] <0.001
R2 = 0.642
*Adjusted for all levels of 5 dimensions.
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disease? A case of a multicultural Asian population
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Abstract
Background: There is conflicting evidence as to whether patients with chronic disease value hypothetical health
states differently from individuals who have not experienced any long-lasting diseases. Furthermore, most studies
regarding this issue have been conducted in western countries, with only one conducted in Asia. We aimed to
evaluate possible systematic differences in the valuation of EuroQol Group five dimensions 3-level (EQ-5D-3L) health
states by chronic disease patients and a population with no chronic disease in Singapore.
Methods: A face-to-face survey for the valuation of the 42 health states of the EQ-5D-3L using the visual analogue
scale (VAS) method was conducted in Singapore. The survey also asked participants to report any chronic diseases
they had. Ordinary least-square regression models were employed to assess possible differences in the valuation
scores of all health states, severe health states and non-severe health states by individual chronic disease patient
groups (diabetes, rheumatism, hypertension, heart diseases and lung diseases) and by a group of participants with
no chronic disease. A difference of 4 to 8 points on the 100-point VAS was considered to be of practical significance.
Results: The analysis included 332 participants with at least one chronic disease and 651 participants with no chronic
disease. After taking health state descriptors and covariates into account, mean valuation scores of the 42 health states
by the heart disease group were higher by 4.6 points (p-value = 0.032) compared to the no chronic disease group.
Specifically, the heart disease group valued severe health states 5.4 points higher (p-value = 0.025) than the no chronic
disease group. There was no practically significant difference in the mean valuation score of non-severe health states
between the heart disease group and the no chronic disease group. No practically significant differences were found in
the mean valuation score of all health states, severe health states and non-severe health states between any other
chronic disease group and the no chronic disease group.
Conclusions: In Singapore, heart disease patients valued EQ-5D-3L severe health states differently from individuals with
no chronic disease. Other chronic disease groups did not value EQ-5D-3L health states differently from the no chronic
disease group.
Keywords: Chronic disease, EQ-5D, Utility, Valuation
Background
There is conflicting evidence as to whether patients with
chronic disease value their own health states differently
from individuals who have not experienced any such dis-
eases [1,2]. Similar conflicting results have been reported
for how patients with chronic disease and individuals with
no such disease experience value hypothetical health states
[1,2]. The difference in valuation of health states between
the patients and individuals with no disease experience
may arise because the patients might have adapted to their
condition or because individuals with no disease experi-
ence overestimate the impact of disease or disability on
quality of life [3]. Most studies that have evaluated differ-
ences in valuations by these two groups have been con-
ducted in western countries; only one study has reported
on an Asian population [1,4]. This is important as there is
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evidence of meaningful differences between populations of
different countries regarding the valuation of health states
[5,6]. In addition, most of the studies that have compared
the valuation by chronic disease patients and that of by
a no chronic disease population have compared the
valuation of only selected disease-related health states,
without covering a range of mild to severe states. Only
a few studies have investigated the potential systemic
difference between valuation by specific chronic disease
patients and individuals with no experience of chronic
disease regarding health states with a wide range of se-
verity [7,8].
Differences in valuation between chronic disease patients
and individual with no chronic disease may affect the out-
comes of analyses of healthcare interventions. Cost-utility
analysis (CUA) is a cost-effectiveness analysis in which the
effect of health-care interventions is measured in terms of
quality-adjusted life-years (QALYs) gained. QALYs are esti-
mated as the time spent in a health state (quantity of life)
multiplied by its utility (quality of life). QALYs are also an
important outcome for monitoring health status in individ-
ual patients, measuring population health and measuring
the impact of health-care intervention in clinical studies
[9]. The question of whose utility (general-population-
derived or patient-derived) should be used in clinical
decision making and economic evaluations of health-care
interventions has been debated in the literature [10,11].
The answer depends on the purpose for which the util-
ity is used and context in which it is used. A general
population-derived utility is desirable when the utility
is needed to inform decisions that allocate societal re-
sources, while a patient-derived utility may be more appro-
priate when making treatment decisions guided by patient
preferences. The Panel on Cost-Effectiveness in Health and
Medicine in the United States and the National Institute
for Health and Care Excellence in England and Wales
recommend that a general-population-derived utility for
health states be used for cost-effectiveness analyses [12,13].
However, the latest systematic review revealed that less than
one-third of published CUAs use a general-population-
derived utility; the remainder used a patient-derived utility, a
clinician- or expert-derived utility, or authors’ judgments
[14]. Many investigators use a patient-derived utility because
they believe that patients who have experienced the disease
conditions can appraise their conditions more accurately
than individuals who have not experienced such conditions
[15]. On the other hand, CUAs using a general population-
derived utility can help broader system-level decision
making to prioritize health care funding in order to
maximize the benefit for patients with different medical
conditions- considering patients’ as well as non-patients’
perspectives [11]. This is a recommended approach when
the health care is funded by the public/tax payers. How-
ever, if the health care costs are mostly paid by patients
themselves, patient-derived utility should be considered.
In Singapore, more than 60% of the health care costs are
borne by patients [16]; and therefore patient-derived utility
is relevant.
Utilities of health states from generic quality of life in-
struments, such as the EuroQoL Group five dimensions
(EQ-5D) or Short Form six dimension (SF-6D), are pre-
ferred over health states from disease-specific quality of
life instrument for CUAs. Utilities of generic health states
allow comparisons of the effects on quality of life of different
health-care interventions in different diseases. Currently, the
EQ-5D is the most commonly used generic instrument for
CUAs [14].
The present study draws on data from a valuation
study of EQ-5D 3-level (EQ-5D-3L) health states in the
Singapore general population which involves self-reporting
of chronic diseases. We aimed to explore whether there
are systematic differences in values for health states elicited
by specific chronic disease patients (CDP) and by the no
chronic disease population (NCDP). We also explored
how the most severe health state and unconscious state
were valued in relation to dead state by specific CDP
and NCDP.
Methods
Valuation survey procedures
In 2009, the EQ-5D-3L—using the visual analogue scale
(VAS) method—was used to conduct a cross-sectional,
face-to-face survey of health state valuation in a repre-
sentative sample of 1034 participants from the general
population of Singapore. Singapore is a multi-ethnic city
state with a rapidly increasing aging population. Its popula-
tion is 75% Chinese, 13% Malay, 9% Indian (mostly Tamil
speaking) and 3% others [17]. A multi-stage sampling
approach was used to randomly select residential blocks,
within which households were selected. We interviewed
potential participants (one per household) who satisfied
the pre-set recruitment quotas for ethnicity (400 Chinese,
400 Malay, and 234 Indians), gender (50% Female) and
age (30% of 21–34 years, 40% of 35–49 years, and 30% of
50+ years). Within each ethnicity, there was a quota that
half of the participants would use English for the interview
and the remaining half would use their native language
(i.e., Mandarin for Chinese, Malay for Malays and Tamil
for Indians).
The EQ-5D-3L consists of 5 dimensions (mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression) with 3 response levels for each dimension
(1: no problems, 2: some problems, and 3: extreme
problems). This instrument thus describes 243 health
states. Each health state is represented by one response
level from each of the 5 dimensions. For example, 11112
describes a health state with no problems on the first 4 di-
mensions and some problem related to anxiety/depression.
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A subset of 42 EQ-5D-3L states was selected based on the
protocol of Dolan [18]. Immediate death and the most se-
vere state (‘33333’) were labeled as ‘dead’ and ‘all-worst’, re-
spectively. Each participant was asked to compare between
‘dying now’ and ‘living for the rest of his/her life in all-
worst’, from which the less desirable state was assigned a
value 0 on the VAS. Each participant was then asked to
value a unique set of 6 states from the subset of EQ-5D-3L
states and either ‘dead’ or the ‘all-worst’ state, whichever
one was not valued earlier at 0. The unique set of 6 health
states that was assigned to each participant included states
that were spread widely over the valuation space. A 100-
point “feeling thermometer” with endpoints of 100 (most
desirable, i.e., perfect health) and 0 (least desirable) was
used as aVAS. For the six assigned states, participants were
required to indicate where they would rate each of the
states on the “feeling thermometer” by imagining them-
selves in that state for the rest of their life without chan-
ging. The participants were allowed to value more than
one health state at the same level of VAS. In addition to
the six assigned states, ‘unconscious’ state was also valued.
Participants were also asked to report their chronic
diseases. The list of chronic diseases included diabetes,
high blood pressure (hypertension), heart diseases, stroke,
asthma or other lung diseases, cancer, rheumatism/back
pain or other bone or muscle illness, mental illness (e.g.,
depression, anxiety neurosis, schizophrenia) and other ill-
ness (e.g., kidney problems or dialysis).
This study was approved by the SingHealth Central-
ized Institutional Review Board.
Analyses
The analysis included participants with diabetes, high
blood pressure/hypertension, heart diseases, asthma/lung
diseases, rheumatism/back pain/other bone-muscle illness,
or no chronic disease. The number of participants with
other chronic diseases was small (<10) and these partici-
pants were not included in the analyses described in this
manuscript.
Participants who met the following criteria were ex-
cluded from our analysis: a) valued less than 3 health
states, b) did not value ‘dead’ or ‘all-worst’ state, c) valued
‘dead’ or ‘all-worst’ or ‘unconscious’ state higher than all of
the other states, d) gave the same valuation score to all the
health states, e) self-reported or rated by the interviewers
as having a poor understanding of the health states de-
scription or valuation tasks. The valuation score used in
the analyses was ‘raw’ VAS valuation score, which ranged
from 0 (worst possible score) to 100 (best possible score).
There is no consensus among researchers or regulatory
bodies regarding the optimal method of transforming the
valuation scores into utility [19].
We performed a separate analysis to compare the val-
uations by participants in each of the CDP groups with
those of the NCDP group. Each analysis included two
ordinary least-square regression models. Model I was
used for the comparison of overall difference in valu-
ation scores (including all the health states) between
each CDP group and the NCDP group. Model II was
used for the comparison of the differences in valuation
scores of non-severe health states and severe health
states by including an interaction term between the in-
dicator variable for severe health state (versus non-severe
health state) and the indicator variable for the specific
CDP group (versus the NCDP group). We considered
health states with at least one dimension at level 3 as
“severe” health states, and the remaining states as “non-
severe”.
Model I was performed for the valuation score with an
indicator variable representing a specific CDP group, the
members of which might have co-morbid conditions,
versus the NCDP group as the independent variable. The
model adjusted for indicator variables that represented the
level of severity in each dimension of the health states.
That is, including 2 indicator variables for each of the 5 di-
mensions of EQ-5D-3L. Furthermore, we included an in-
dicator variable (commonly called ‘N3’ in the cost-utility
analysis literature) to take into account additional disutil-
ities when a severe problem (level 3) was reported on at
least one dimension [20]. Finally, the comparison adjusted
for ethnicity, gender, age, marital status, education level,
religion and house type because the CDP group being ana-
lyzed and NCDP group might differ in these background
characteristics.
Model II further included an interaction term between
the CDP group indicator and the N3 in Model I. In this
model, the coefficient of the CDP group provides an es-
timate of the difference between valuation scores of non-
severe health states; whereas its sum with the interaction
term provides an estimate of the difference between
valuation scores of severe health states by the specific
CDP group and the NCDP group after taking the health
state descriptors and participants’ background character-
istics into account. Perfect health state, ‘unconscious’
state and ‘dead’ state were excluded from Models I and II.
The perfect health state was assigned a valuation score of
100 for each participant. Since each of the participants
valued 6 health states, we used the Eicker-Huber-White
robust standard error for cluster data for statistical in-
ference [21].
We compared the valuation of the ‘all-worst’ and
‘unconscious’ health states with the valuation of ‘dead’
state by each of the CDP groups and the NCDP group.
The mean valuation scores of the ‘all-worst’ state and
‘unconscious’ state were compared with the ‘dead’ state
using a paired t-test.
All the analyses were carried out using Stata/MP 10.1
for Windows. A minimally important difference of 4 to
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8 points on the 100-point VAS was considered to be of
practical significance [22-24].
Results
All 1034 participants provided demographic and health char-
acteristic information. Nine participants had chronic diseases
other than diabetes, high blood pressure/hypertension, heart
disease, asthma/lung disease or rheumatism/back pain/other
bone-muscle illness. Thirty-four participants valued ‘dead’
state higher than all the other states, 3 participants valued
‘unconscious’ state higher than all the other states, 1
participant did not value the ‘all-worst’ state and 4
participants were observed to have a poor understand-
ing of valuation tasks. Hence, a total of 51 participants
were excluded from the analysis. Table 1 shows the
demographic and health characteristics of the 983 partici-
pants that were included in the analysis. The percentage
of participants who had good-to-excellent self-reported
general health varied between 68% and 75% among the
CDP groups (Diabetes: 70/102, Rheumatism: 122/162,
Hypertension: 107/145, Heart diseases: 29/44, Lung dis-
eases: 30/44) as compared to 95% among NCDP group
(621/651). Participants in the CDP groups were older,
had lower education level and lower self-reported general
health compared to participants in the NCDP group.
Table 2 summarizes the comparison of health state
valuation scores between the CDP groups and the NCDP
group. Mean observed differences between the CDP groups
and the NCDP group regarding the valuation score of all
the 42 EQ-5D health states, non-severe health states and
severe health states ranged from −3.3 to 0.5, −3.7 to −1.0
and −2.8 to 2.1, respectively. After taking health state de-
scriptors and covariates into account in the regression ana-
lysis, the mean differences between the CDP groups and
the NCDP group regarding valuation scores of all the
health states ranged from −2.5 to 1.6 (each p-value >0.05),
except for the heart disease group. The adjusted mean valu-
ation score of all the health states for the heart disease
group was 4.6 points higher (95% CI: 0.4 to 8.9; p-value =
0.032) than that of the NCDP group. Similarly, after taking
health state descriptors and covariates into account, the
mean differences between the CDP group and the NCDP
group regarding severe health state valuation scores ranged
from −2.4 to 1.8 (each p-value >0.05), except for the heart
disease group. The adjusted mean valuation score of severe
states for the heart disease group was 5.4 points higher
(95% CI: 0.7 to 10.1; p-value = 0.025) than that of the
NCDP group. After taking health state descriptors and co-
variates into account, there was no practically significant
difference in the mean valuation scores of non-severe
health states between any CDP group and the NCDP
group. The changes in the mean differences after the
adjustment for the covariates could be due to differ-
ences in the distribution of demographic characteristics
between the CDP and NCDP groups (please see Table 1).
For example, the NCDP group had more participants mar-
ried/living with partners, which was associated with higher
value, compared with unmarried participants in multi-
variable analysis. After statistical adjustment, the differ-
ence between NCDP and lung disease groups would
become smaller. Similarly, the NCDP group had differ-
ences in multiple demographic characteristics, such as
more female participants, fewer Indian participants, and
more participants following Buddhism/Taoism, which were
associated with higher value, compared to the heart disease
group. Thus, after statistical adjustment, the heart disease
group had higher valuation score compared to the NCDP
group. Other demographic characteristics did not have
much influence on the valuation score (Details not shown).
Table 3 summarizes the comparison of valuation scores
for the ‘all-worst’ state with those of the ‘dead’ state by dis-
ease group. Except for the heart disease group, the mean
difference in valuation scores of ‘all-worst’ state and ‘dead’
state by the CDP groups and the NCDP group were
within the range of −8.4 points (95% CI: −11.8 to −4.9;
p-value < 0.001) to −5.3 points (95% CI: −8.8 to −1.8;
p-value = 0.003). For the heart disease group, this differ-
ence was −2.3 points (95% CI: −7.3 to 2.8; p-value = 0.370).
Table 4 summarizes the comparison of valuation scores
for ‘unconscious’ state with those of the ‘dead’ state by dis-
ease group. Except for the heart disease group, the mean
difference in valuation scores of ‘unconscious’ state and
‘dead’ state by the CDP groups and the NCDP group were
within the range of −0.1 points (95% CI: −3.0 to 2.7;
p-value = 0.922) to 3.0 points (95%CI: −0.1 to 6.0;
p-value = 0.057). For the heart disease group, this differ-
ence was 4.2 points (95% CI: 0.4 to 8.0; p-value = 0.030).
Discussion
We examined the potential effect of experience with
chronic disease on the valuation of EQ-5D-3L health
states using the VAS method in a multicultural Asian
population. Valuation by participants with five different
types of chronic disease (diabetes, rheumatism, hyperten-
sion, heart disease and lung disease) was compared with
valuation by participants with no chronic disease.
The heart disease group valued the health states 5 points
higher than did the NCDP group (p-value = 0.032), which
is mainly attributed to the heart participants’ valuation of
the severe health states. This difference was statistically
significant and larger than the minimal important differ-
ence of 4 points for the EQ-5D-3L valuation score, which
indicates that the result is practically meaningful. The
mean differences between the valuation by other CDP
groups (diabetes, rheumatism, hypertension and lung
diseases) and the NCDP group were all smaller than
the minimal important difference.
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The ‘all-worst’ state (the most severe state of EQ-5D
with all dimensions at extreme severity) was valued worse
than the ‘dead’ state by the majority of participants across
the different types of chronic diseases and the NCDP
group. Except for the heart disease group, all CDP groups
and the NCDP group valued the ‘all worst’ state statisti-
cally and practically significantly lower than the ‘dead’
state. The heart disease group’s valuation of the ‘all-worst’
state was not statistically and practically significantly
different from their valuation of the ‘dead’ state (differ-
ence = −2.3, p-value = 0.370).
We also found that the mean valuation score of the
‘unconscious’ state was likely to be equivalent to the
‘dead’ state by the NCDP group and all of the CDP
groups except for the heart disease group. The difference
in the mean valuation score of the ‘unconscious’ state
and the ‘dead’ state by heart disease group was statisti-
cally significant and higher than the minimal important
difference (difference = 4.2, p-value = 0.030), whereas the
difference was statistically non-significant and less than
4 (minimal important difference) for the diabetes,
rheumatism, hypertension, asthma/lung disease groups
and the NCDP group.
A possible reason for heart disease patients giving higher
valuation scores could be that a higher proportion of heart
disease patients might have experienced one or more
severe heath states, and this might have changed their
perception regarding these health states. This might
not be the case with other CDP groups and the NCDP
group. On the other hand, the majority of CDP groups
and the NCDP group might have experienced the non-
severe health states, thus leading to their similar valuation
of non-severe health states.
Wang et al. [5] in Singapore found that after adjusting
for health state descriptors and demographic characteris-
tics, there was no meaningful difference in the valuation
of severe health states by diabetes patients and a popula-
tion without diabetes. However, the study reported that
diabetes patients valued the non-severe health states 13
points higher than did the no-diabetes population. Our
Table 3 Comparison of valuation scores between the ‘all-worst’ state and the ‘dead’ state by disease group
Valuation Scores Diabetes
(n = 102)
Rheumatism
(n = 162)
Hypertension
(n = 145)
Heart diseases
(n = 44)
Lung diseases
(n = 44)
No chronic disease
(n = 651)
All-worst#
Mean (SD) 3.3 (8.4) 2.1 (6.0) 3.1 (8.6) 4.8 (9.9) 1.7 (5.2) 3.1 (8.3)
Dead
Mean (SD) 8.6 (13.3) 10.3 (15.9) 11.4 (17.1) 7.1 (10.4) 8.5 (10.9) 9.4 (14.1)
All-worst - Dead
Mean difference (95% CI) −5.3 (−8.8, −1.8)* −8.1 (−11.0, −5.3)* −8.4 (−11.8, −4.9)* −2.3 (−7.3, 2.8) −6.8 (−10.8, −2.7)* −6.3 (−7.6, −4.9)*
#EQ-5L-3L health state with all its domains at severity level 3 is labelled as ‘all-worst’ health state.
*P-value < 0.05.
Table 2 Comparison of valuation of health states between the chronic disease groups and the no chronic disease
group taking into account health state descriptors and covariates
Health States Diabetes
(n = 102)
Rheumatism
(n = 162)
Hypertension
(n = 145)
Heart diseases
(n = 44)
Lung diseases
(n = 44)
No chronic disease
(n = 651)
All health states1
Mean (SD) 43.6 (30.0) 43.4 (30.6) 44.4 (30.0) 43.1 (28.7) 40.6 (29.5) 43.9 (30.6)
Mean difference (95% CI)2,3 1.6 (−1.2, 4.3) 0.4 (−2.0, 2.8) 0.7 (−1.7, 3.1) 4.6 (0.4, 8.9)* −2.5 (−6.2, 1.2) -
Non-severe health states1,4
Mean (SD) 71.6 (18.8) 71.3 (20.0) 71.2 (19.7) 69.8 (16.8) 69.0 (22.1) 72.7 (19.3)
Mean difference (95% CI)2,3 1.0 (−2.5, 4.6) −0.3 (−3.4, 2.9) −1.0 (−4.3, 2.3) 2.6 (−2.4, 7.6) −2.6 (−9.0, 3.8) -
Severe health states1,4
Mean (SD) 31.4 (25.4) 31.9 (26.6) 33.6 (26.5) 33.7 (26.0) 28.7 (23.6) 31.5 (25.8)
Mean difference (95% CI)2,3 1.8 (−1.2, 4.7) 0.7 (−1.9, 3.3) 1.3 (−1.2, 3.9) 5.4 (0.7, 10.1)* −2.4 (−6.1, 1.2) -
1The study included 42 EQ-5D-3L health states, not including perfect health, unconscious and dead states. The perfect health state of EQ-5D-3L was assigned
default value of 100 points on the visual analogue scale.
2Difference: mean scores of participants with chronic diseases minus mean scores of participants with no chronic disease.
3Using ordinary least square regression model adjusted for health state descriptors, disutility due to severe problems, ethnicity, gender, age, marital status,
education level, religion and house type (see Methods section).
4EQ-5D-3L health states with at least one domain at severity level 3 are considered as ‘severe’ health states. Remaining health states are considered as ‘non-severe’
health states.
*P-value <0.05.
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findings do not fully support their results. It should be
noted that Wang et al. included only 3 non-severe health
states; hence their findings have limited applicability.
On the other hand, we used 14 non-severe health states,
which represent more generalized findings.
Our study findings are consistent with those of Pickard
et al. [8]. Using the time trade-off method, Pickard et al.
found no meaningful difference in valuation scores be-
tween CDP (arthritis, diabetes, depression, hay fever,
cancer) and NCDP, except for heart failure patients [8].
Pickard et al. found that after adjusting for covariates, pa-
tients with heart failure only, and patients with heart fail-
ure and at least one other chronic disease, gave valuation
scores higher by 25 points (n = 6, p-value = 0.222) and 7
points (n = 129, p-value = 0.049), respectively, compared
to NCDP.
A possible explanation for no practical differences in the
mean valuation score between individuals with chronic
diseases and individuals without any chronic diseases
might be because in this exercise, individuals with and
without chronic diseases are valuing many hypothetical
health states that are unlikely to reflect the actual health
state(s) that one has experienced. As such, it is probably
not surprising that generally speaking, individuals with
chronic disease might value them similarly to individuals
with no chronic disease.
This study has several potential limitations. First, the
chronic disease conditions were self-reported by the par-
ticipants. We did not collect any further information to
confirm the disease, the severity of the disease or the time
spent with the disease. Hence, there could be a chance of
misclassification regarding reported diseases. A Finnish
study showed that the sensitivity and specificity of self-
reported chronic diseases (diabetes, hypertension, cor-
onary heart disease, asthma and rheumatoid arthritis)
could range from 78% to 96% and 96% to 99%, respectively
[25]. This indicates a relatively large possibility that pa-
tients with chronic diseases could be misclassified into
the NCDP group, but a small possibility that those with
no chronic disease could be misclassified into a chronic
disease group. This should mean that the difference
between CDP and NCDP might be under-estimated but
not over-estimated. Furthermore, this is a secondary
analysis of existing data. The limited information re-
lated to disease conditions does not allow us to inves-
tigate any concrete reasons for the differences or lack
of differences between the CDP and NCDP. Second,
although our study had a sizable CDP group, nearly
80% of the CDP group self-reported their health status
as good to excellent. Hence, our study findings may
not be generalized to patients at a severe or unstable
stage of chronic disease. Third, our study included only
five chronic diseases (with a relatively small number of
participants) and only one life-threatening chronic disease
(heart diseases). Thus, our study findings may not be
assumed to generalize to other life-threatening chronic
diseases. Fourth, we performed separate statistical tests
for comparing valuation by each CDP group with valu-
ation by the NCDP group without multiplicity adjust-
ment. Furthermore, the sample size was not powered
for this analysis. Thus, the statistically significant find-
ings might be due to inflated Type I error and therefore
require further confirmation. Nevertheless, our findings
are based on a random sample of a chronic disease popu-
lation from the Asian general population. It also in-
cluded many health states with a wide range of severity.
It also has potential to generalize the findings for non-
life-threatening chronic disease patients. We encourage
conducting a larger study that includes a greater variety
of life-threatening chronic disease patients, as well as
varying severity levels and the verification of disease
conditions and severity.
Conclusions
Our study findings suggest that heart disease patients value
severe EQ-5D-3L health states differently than individuals
who have no experience with chronic disease when an-
alyzed using the VAS method in a Singaporean popula-
tion. However, the experience of chronic diseases other
than heart disease does not necessarily result in a higher or
lower valuation across all the health states of EQ-5D-3L.
Table 4 Comparison of valuation scores between the ‘unconscious’ state and the ‘dead’ state by disease group
Valuation Scores Diabetes
(n = 102)
Rheumatism
(n = 167)
Hypertension
(n = 147)
Heart diseases
(n = 46)
Lung diseases
(n = 44)
No chronic disease
(n = 667)
Unconscious
Mean (SD) 11.6 (11.1) 10.1 (12.3) 12.0 (13.0) 11.3 (11.7) 10.6 (9.6) 11.8 (12.6)
Dead
Mean (SD) 8.6 (13.3) 10.3 (15.9) 11.4 (17.1) 7.1 (10.4) 8.5 (10.9) 9.4 (14.1)
Unconscious - Dead
Mean difference (95% CI) 3.0 (−0.1, 6.0) −0.1 (−3.0, 2.7) 0.6 (−2.6, 3.8) 4.2 (0.4, 8.0)* 2.1 (−1.4, 5.7) 2.4 (1.2, 3.6)*
*P-value < 0.05.
Gandhi et al. Health and Quality of Life Outcomes  (2015) 13:8 Page 8 of 9
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JT conceived the study, and participated in the study design and coordination.
HLW and LN participated in the study design and coordination. YB participated
in the design of the study, statistical analysis and interpretation of the results.
MG carried out the data analysis and interpretation, and wrote the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
The study was funded by a programme grant 03/1/27/18/226 from the
Biomedical Research Council of Singapore. The last author (YBC) was
supported by Singapore Ministry of Health’s National Medical Research
Council under its Clinician Scientist Award. We acknowledge the medical
editing assistance of Jon Kilner, MS, MA (Pittsburgh, Pennsylvania, USA).
Author details
1Biostatistics, Singapore Clinical Research Institute, Singapore, Singapore.
2Centre for Quantitative Medicine, Duke-NUS Graduate Medical School,
Singapore, Singapore. 3Department of International Health, School of
Medicine, University of Tampere, Tampere, Finland. 4Department of
Rheumatology and Immunology, Singapore General Hospital, Singapore,
Singapore. 5Department of Medicine, Yong Loo Lin School of Medicine,
National University of Singapore, Singapore, Singapore. 6School of Public
Health, National University of Singapore, Singapore, Singapore. 7Department
of Pharmacy, Faculty of Science, National University of Singapore, Singapore,
Singapore.
Received: 9 August 2014 Accepted: 23 December 2014
References
1. Peeters Y, Stiggelbout AM. Health state valuations of patients and the general
public analytically compared: a meta-analytical comparison of patient and
population health state utilities. Value Health. 2010;13(2):306–9.
2. Dolders MG, Zeegers MP, Groot W, Ament A. A meta-analysis demonstrates
no significant differences between patient and population preferences.
J Clin Epidemiol. 2006;59(7):653–64.
3. Bremner KE, Chong CA, Tomlinson G, Alibhai SM, Krahn MD. A review and
meta-analysis of prostate cancer utilities. Med Decis Making. 2007;27:288–98.
4. Wang P, Tai ES, Thumboo J, Vrijhoef HJ, Luo N. Does Diabetes Have an
Impact on Health-State Utility? A Study of Asians in Singapore. Patient 2014
[Epub ahead of print]
5. Luo N, Wang P, Thumboo J, Lim YW, Vrijhoef HJ. Valuation of EQ-5D-3L health
states in Singapore: modeling of time trade-off values for 80 empirically
observed health states. Pharmacoeconomics. 2014;32(5):495–507.
6. Johnson JA, Luo N, Shaw JW, Kind P, Coons SJ. Valuations of EQ-5D health
states: are the United States and United Kingdom different? Med Care.
2005;43:221–8.
7. Krabbe PF, Tromp N, Ruers TJ, van Riel PL. Are patients’ judgments of health
status really different from the general population? Health Qual Life
Outcomes. 2011;9:31.
8. Pickard AS, Tawk R, Shaw JW. The effect of chronic conditions on stated
preferences for health. Eur J Health Econ. 2013;14(4):697–702.
9. Kind P, Lafata JE, Matuszewski K, Raisch D. The use of QALYs in clinical and
patient decision-making: issues and prospects. Value Health. 2009;12
Suppl 1:S27–30.
10. McTaggart-Cowan H. Elicitation of informed general population health state
utility values: a review of the literature. Value Health. 2011;14(8):1153–7.
11. Stamuli E. Health outcomes in economic evaluation: who should value
health? Br Med Bull. 2011;97:197–210.
12. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of
the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253–8.
13. National Institute for Health and Clinical Excellence (NICE): Guide to the Methods
of Technology Appraisal. NICE; 2013 [http://www.nice.org.uk/article/
pmg9/resources/non-guidance-guide-to-the-methods-of-technology-
appraisal-2013-pdf]
14. Brauer CA, Rosen AB, Greenberg D, Neumann PJ. Trends in the measurement of
health utilities in published cost-utility analyses. Value Health. 2006;9(4):213–8.
15. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-
effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in
Health and Medicine. JAMA. 1996;276(14):1172–7.
16. World Health Organization. World Health Statistics 2014. WHO Press. [Internet]
http://apps.who.int/iris/bitstream/10665/112738/1/9789240692671_eng.pdf.
Accessed November 14, 2014
17. Singapore Department of Statistics. Census of Population 2010. Statistical
Release 1. Demographic characteristics, education, language and religion.
Singapore: Department of Statistics 2011 [Internet]. http://www.singstat.gov.
sg/docs/default-source/default-document-library/publications/
publications_and_papers/cop2010/census_2010_release1/cop2010sr1.pdf.
Accessed April 16, 2014
18. Dolan P. Modeling valuations for EuroQol health states. Med Care.
1997;35(11):1095–108.
19. Lamers LM. The transformation of utilities for health states worse than
death: consequences for the estimation of EQ-5D value sets. Med Care.
2007;45(3):238–44.
20. Szende A, Oppe M, Devlin N. EQ-5D value sets: inventory, comparative review
and user guide (EuroQol group monographs, Vol. 2). The Netherlands: Springer;
2007.
21. Williams R. A note on robust variance estimation for cluster-correlated data.
Biometrics. 2000;56:645–6.
22. Walters SJ, Brazier JE. Comparison of the minimally important difference for two
health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14:1523–32.
23. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences
in EQ-5D utility and VAS scores in cancer. Health Qual Life Out. 2007;5:70.
24. Luo N, Johnson JA, Coons SJ. Using instrument-defined health state transitions
to estimate minimally important differences for four preferencebased health-
related quality of life instruments. Med Care. 2010;48:365–71.
25. Oksanen T, Kivimäki M, Pentti J, Virtanen M, Klaukka T, Vahtera J. Self-report
as an indicator of incident disease. Ann Epidemiol. 2010;20(7):547–54.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gandhi et al. Health and Quality of Life Outcomes  (2015) 13:8 Page 9 of 9

PUBLICATION 
III 
Comparison of health state values derived from patients and individuals 
from the general population 
Mihir Gandhi, Ru San Tan, Raymond Ng, Su Pin Choo, Whay Kuang Chia, Chee 
Keong Toh, Carolyn Lam, Phong Teck Lee, Nang Khaing Zar Latt, Kim Rand-
Hendriksen, Yin Bun Cheung, Nan Luo 
Quality of Life Research 2017, 26(12):3353-3363 
https://doi.org/10.1007/s11136-017-1683-5 
Publication reprinted with the permission of the copyright holders. 
 
  
  
 
 
 
 
 

Page 1 of 2 
 
Comparison of Health State Values Derived from Patients and Individuals from the General Population 
Mihir Gandhi1,2,3, Ru San Tan4, Raymond Ng5, Su Pin Choo5, Whay Kuang Chia5, Chee Keong Toh5, Carolyn Lam4, 
Phong Teck Lee4, Nang Khaing Zar Latt4, Kim Rand-Hendriksen6,7, Yin Bun Cheung1,2,3, Nan Luo8*  
1Department of Biostatistics, Singapore Clinical Research Institute, #02-01, 31 Biopolis Way, Singapore 
2Centre for Quantitative Medicine, Duke-NUS Medical School, Level 6, Academia, 20 College Road, Singapore 
3Tampere Center for Child Health Research, University of Tampere and Tampere University Hospital, Arvo 
Building, Lääkärinkatu 1, Tampere, Finland 
4Department of Cardiology, National Heart Centre Singapore, 5 Hospital Drive, Singapore 
5Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 
6Health Services Research Centre, Akershus University Hospital, Forskningsveien 3A, 0373 Oslo, Norway 
7Deptartment of Health Management and Health Economics, University of Oslo, Forskningsveien 3A, 0373 Oslo, 
Norway 
8Saw Swee Hock School of Public Health, National University of Singapore, Tahir Foundation Building (MD1), 12 
Science Drive 2, Singapore 
Email addresses of co-authors: 
MG: mihir.gandhi@scri.edu.sg (ORCID: 0000-0002-8902-2710) 
RST: tan.ru.san@singhealth.com.sg (ORCID: 0000-0003-2086-6517)  
RN: raymond.ng.c.h@singhealth.com.sg (ORCID: 0000-0001-9651-234X)  
SPC: choo.su.pin@singhealth.com.sg (ORCID: 0000-0002-8925-3922)  
WKC: john.chia.w.k@singhealth.com.sg (ORCID: 0000-0003-4198-9831) 
CKT: toh.chee.keong@singhealth.com.sg (ORCID: 0000-0002-5691-6144) 
CL: carolyn.lam.s.p@nhcs.com.sg (ORCID: 0000-0003-1903-0018) 
PTL: phongteck.lee@mohh.com.sg 
NKZL: nangkhaingzar.latt@mohh.com.sg 
KR: kim.rand-hendriksen@medisin.uio.no (ORCID: 0000-0001-7692-4099) 
YBC: yinbun.cheung@duke-nus.edu.sg (ORCID: 0000-0003-0517-7625)  
 
Page 2 of 2 
 
 
* Corresponding author:  
Nan Luo 
Associate Professor, Saw Swee Hock School of Public Health 
National University of Singapore, 12 Science Drive 2, Singapore 
Email: ephln@nus.edu.sg 
Telephone: +65-65164966 
ORCID: 0000-0001-7980-6979 
Running head: Health state values of patients and public 
Funding: The study was supported in part by the EuroQol Research Foundation (EQ Project 2015220), The 
Netherlands, and in part by the Duke-NUS Signature Research Program (WBS R-913-200-040) funded by the 
Agency for Science, Technology and Research (A*STAR), Singapore, and the Ministry of Health, Singapore. The 
funding agreement ensured the authors’ independence in designing the study, interpreting the data, writing, and 
publishing the report. 
Page 1 of 1 
 
ABSTRACT 
Purpose: Utility values are critical for cost-utility analyses that guide healthcare decisions. We aimed to compare 
the utility values of the 5-level EuroQoL-5Dimension (EQ-5D-5L) health states elicited from members of the 
general public and patients with heart disease or cancer. 
Methods: In face-to-face interviews with 157 heart disease patients, 169 cancer patients, and 169 members from the 
general population, participants valued 10 EQ-5D-5L health states using a composite Time Trade-Off method. 
Results: Pooling utility values for all health states, heart disease patients and cancer patients had mean utility values 
lower by 0.11 points (P-value=0.014) and 0.06 points (P-value=0.148), respectively, compared to the general 
population. Adjusting for sociodemographic characteristics, differences in health state utility values between the 
patient and the general populations were rendered non-significant, except that heart disease patients gave higher 
utility values (mean difference=0.08; P-value=0.007) to mild health states than the general population. Difference in 
utility values, defined as utility value of a better health state minus that of a poorer health state, was higher among 
heart disease patients compared to the general population, before and after adjusting for sociodemographic 
characteristics. 
Conclusions: Patients may differ from members of the general population in the strength of their preferences for 
hypothetical health states. Using utility values derived from the general population may under-estimate the 
comparative effectiveness of healthcare interventions for certain diseases, such as heart diseases. 
Keywords: EQ-5D; time trade-off; cancer; heart disease; utility; preference 
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Introduction 
Health state utility values are usually elicited from either the general population or patients [1-3]. General 
population-derived utility values have been recommended for use in cost-effectiveness analysis to inform decisions 
involving allocation of societal resources [4]. Health utility instruments such as the EuroQol 5 dimensions (EQ-5D) 
are designed to generate health state utility values based on the health preferences of the general population. 
Members of the general population, however, may have different health preferences compared to patients, and they 
may lack understanding of what it means to live in impaired health [5]. Therefore, patient-derived utility values are 
desirable for effectiveness analysis to inform clinical decision making from a patient-centered perspective. 
The issue of whose preferences to use is only important insofar as health preferences differ between the populations. 
Some studies indicate that there are important differences between patient-derived and general population-derived 
health state values [6-10]. For example, a meta-analysis found that utility values elicited from patients tend to be 
higher than those elicited from the general population [8]. However, other studies, including a meta-analysis, report 
no or minimal difference in the utility values elicited from general and patient populations [9, 11-13]. The mixed 
findings could be due to multiple factors, including type of condition, severity of condition, and valuation method. 
For example, one study reports that health state values derived using the Visual Analog Scale (VAS) method were 
similar between individuals with and without arthritis, but were different between individuals with and without heart 
disease [9]; utility values elicited from patients with arthritis and the general population using the VAS method were 
similar but values elicited from the two populations using the Time Trade-Off (TTO) method were different [14]. 
The mixed findings may also be due to the fact that some of the studies were underpowered, poorly designed, or 
poorly executed [8].  
In this study, we investigated the impact of chronic diseases on measurement of the utility of health states defined by 
the 5-level EuroQoL-5Dimension (EQ-5D-5L) questionnaire [15]. The EQ-5D-5L is a new version of EQ-5D, and 
has demonstrated better measurement properties than the 3-level EQ-5D (EQ-5D-3L)  [16, 17]. The primary 
objective of this study was to compare two patient populations, heart disease and cancer patients, with the general 
population. The two diseases were selected because of their high disease burden globally [18, 19]. In all three 
groups, we elicited utility values for a set of 10 EQ-5D-5L health states using the TTO method. Both TTO and EQ-
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5D are recommended by the National Institute for Health and Care Excellence (NICE) for generating utility values 
in economic evaluations of health technologies [20].   
Methods 
Participants 
Heart disease and cancer patients attending outpatient clinics at the National Heart Centre Singapore (NHCS) and 
the National Cancer Centre Singapore (NCCS), respectively, were invited to participate during their routine visits. 
The NHCS and NCCS are the largest capacity specialty centers in Singapore for cardiovascular disease and cancer 
patients respectively. The main eligibility criterion for the heart disease patients was hospitalization primarily for a 
heart disease such as coronary heart disease or heart failure treatment in the last five years; this criterion was used to 
screen out patients with mild heart conditions. The main eligibility criterion for the cancer patients was to have 
histologically confirmed cancer of any type and stage in the last five years; this criterion was used to screen out 
cancer survivors. The study also included a sample from the general population recruited from three shopping malls 
in Singapore. All participants were between 21 and 80 years old, able to read and communicate in English or 
Chinese (Mandarin), and well enough for an interview. A quota sampling based on age and gender distributions 
similar to the Singapore census was used to generate the general population sample.  
Valuation interview 
The study design was cross-sectional, and consenting participants were interviewed face-to-face in a computer-
assisted interviewing protocol. All interviews were conducted by the same trained interviewer using the EuroQol 
Valuation Technology (EQ-VT) computer program running from a laptop in either English or Chinese according to 
participant’s preference [21]. The interviews with the patients were conducted in the hospitals in a quiet waiting 
area; the general population participants were interviewed in a quiet place of the malls where they were recruited. 
The study was approved by the SingHealth Centralized Institutional Review Board. 
The interviewer followed a standard interviewer script in all interviews [22]. Both the Chinese and English versions 
of the EQ-VT computer program and the interviewer script were tested among Singaporean general population as 
well as patient populations in pilot studies. The valuation tasks using the EQ-VT computer program were well 
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understood and accepted by all three major local ethnicities (Chinese, Malay and Indian) in the general and patient 
populations [21]. The advantages of using a computer program include reduced interviewer burden, inter-interview 
variation, and errors and violation of interview protocol. The EQ-VT program is designed to collect data on the 
processes of each interview and upload the data daily to the server. By analyzing the process data, we were able to 
identify any errors the interviewer made and intervene timely whenever necessary.   
The interviews started with some warm-up questions asking the participants to describe their own health using the 
EQ-5D-5L questionnaire. Subsequently, the TTO-based valuation task was explained to participants using the state 
of “in a wheelchair” as an example, after which three practice EQ-5D-5L health states were administered to 
familiarize participants with the task and EQ-5D-5L health states of varying severity. The practice states were 
followed by TTO valuation of a 10 EQ-5D-5L health states. The interviews ended with some feedback and 
background questions. 
A detailed description of the TTO and the EQ-VT protocol can be found elsewhere [23]. Briefly, the objective of the 
task was to identify the point of preferential indifference between 10 years of life in the described target state, 
followed by death, and a shorter life (x ≤10 years) in full health, followed by death. With a defined utility value of 1 
for 10 years in full health, the utility value of the target state can be calculated as x/10. For states considered to be 
worse than death (respondent preferred a life of 0 to 10 years in the target state), a lead-time of 10 years was added 
to both alternatives in order to elicit a negative utility value for the state. The utility value of a worse than death 
health state was calculated as (x-10)/10 such that the utility value of each health state is bounded at -1 and 1; 0 
represents value for the ‘dead’ state.  
In addition to the valuation interview, clinical information was collected from patients by interview or directly from 
their medical records. Clinical information included diagnoses, year of diagnosis, and clinical assessment such as 
New York Heart Association (NYHA) functional classification and Canadian Cardiovascular Society (CCS) 
functional classification of angina for heart disease patients; and cancer stage and Eastern Cooperative Oncology 
Group (ECOG) performance status for cancer patients. All participants were also asked to self-report their current 
and past chronic diseases.  
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The EQ-5D-5L health states 
In this study, all participants were asked to value the same set of 10 health states, in random order. All health states 
were defined using the EQ-5D-5L system which contains five dimensions (mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression) and five functional levels for each dimension (broadly corresponding to no 
problems, slight problems, moderate problems, severe problems, and extreme problems). EQ-5D-5L health states 
are conventionally described using a 5-digit index, where the digits represent the functional level of each dimension 
in the conventional order of presentation (mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression). For example, the health state ‘11122’ indicates slight problems (level 2 severity) in both 
pain/discomfort and anxiety/depression and no problems in mobility, self-care, and usual activities. The 10 health 
states were 11122, 21121, 21222, 21232, 32232, 32333, 22224, 31242, 53343, and 33453. The first three health 
states (11122, 21121, 21222) with all dimensions at severity level either 1 or 2 were considered as ‘mild’ health 
states, the last four health states (22224, 31242, 53343, 33453) with at least one dimension at severity level either 4 
or 5 were considered as ‘severe’ health states, and the remaining three health states (21232, 32232, 32333) were 
considered as ‘moderate’ health states. 
Statistical analyses 
The planned sample size for the study was 525 participants (175 heart disease patients, 175 cancer patients and 175 
participants from the general population). The sample size was estimated to detect a difference of 0.1 standardized 
effect size in mean value of the 10 elicited health states from a group of patients and general population using a two-
sided test for 5% type-I error rate and 80% power, assuming 10% participants may provide logically inconsistent 
valuation or do not complete the interviews.  
Participants who met the following criteria were excluded from the analysis: a) gave the same utility value to all the 
health states, b) gave negative or zero utility value to all health states (i.e., considered all health states worse than or 
equal to death). The use of stricter logical inconsistency criteria (i.e., further excluding participants who valued one 
or more mild states as equal to or lower than any severe states) was explored. It led to exclusion of more participants 
but had no material impact on results and therefore was not adopted.  
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We performed ordinary least-square (OLS) regression analysis to compare the mean utility values elicited from the 
patient groups with those of the general population group. The regression model was performed separately for each 
of the 10 health states, across 10 health states, the three mild health states (11122, 21121, 21222), the three moderate 
health states (21232, 32232, 32333), and the four severe health states (22224, 31242, 53343, 33453). Finally, these 
models were repeated by adjusting for ethnicity, gender, age, marital status, education level, employment status, 
religion and household income level because the patient groups and the general population group differed in 
demographic and socioeconomic characteristics.  
Lastly, we compared the differences in utility values between the health states as elicited from members of the 
general population, heart disease patients and cancer patients. As the difference in utility values of two health states 
is usually used to approximate utility gained from transitions between the two health states, this comparison helped 
us to assess whether the different sets of utility values would give similar estimates when used to determine utility 
gained from health state transitions. First, differences in utility were calculated separately for the heart disease 
patient group, cancer patient group, and the general population group for 35 pairs of health states where one is no 
worse than the other in any of the five domains. Second, differences in the differences between a patient group and 
the general population group were presented using a line graph and tested by OLS regression models. The graph also 
presented the differences in differences adjusted for participants’ demographic and socioeconomic characteristics, 
calculated using the regression models performed separately for each pair of health states. 
All the models involving more than one utility value per participant used the Eicker-Huber-White robust standard 
error for cluster data for statistical inference [25].  We also performed both unadjusted and adjusted analysis using 
mixed-effect models with participant specific-intercepts. The results were very similar to those based on OLS 
models with robust standard error. Hence, results of only OLS models were presented. All the analyses were carried 
out using Stata/MP 13.1 for Windows. A minimally important difference of 0.05 points for the utility values was 
considered to be of practical significance [26]. 
Results 
Of 525 participants who completed the interview, 30 were excluded from analyses: 24 participants assigned the 
same value to all 10 health states, and six participants valued all the health states worse than or equal to death. There 
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was no systematic difference in demographic and health characteristics between participants included and excluded 
from the analysis, except that slightly more heart disease patients (n = 18) were excluded compared to the general 
population participants (n = 6) and cancer patients (n = 6) (Appendix Table 1). Table 1 shows the demographic, 
socioeconomic and health characteristics of the 495 participants included in the analyses (169 in the general 
population group, 157 in the heart disease patients group, and 169 in the cancer patients group). Participants in the 
patient groups were older, had lower education level, and poor self-reported general health compared to participants 
in the general population group. A total of 62 (37%) participants in the general population group self-reported to 
have one or more chronic diseases, such as hypertension (15%), hyper/dyslipidemia (12%), and lung diseases (10%). 
The majority of demographic characteristics of the general population sample were similar to the census population 
(Appendix Table 2) [27]. 
The majority of the heart disease patients reported no breathlessness with heavy or moderate exertion (95%), and 
had coronary artery disease (64%), atrial fibrillation (34%), arrhythmias (29%), myocardial infraction (28%), or 
heart failure (20%). Mean time from the most recent episode of symptom onset to the interview date was 1.2 years 
(SD 1.5). The majority of the heart disease patients (85%) had other chronic diseases such as hypertension (57%), 
hyper/dyslipidemia (59%), and diabetes mellitus (29%). Mean time from the most recent hospitalization due to a 
heart disease problem to the interview date was 1.4 years (SD 2.0). (Appendix Table 3) 
The majority of the cancer patients reported ECOG performance status 0-1 (99.4%), and had breast cancer (29%), 
colorectal cancer (21%), or lymphoma (11%). The percentage of patients in cancer stages 0-1, 2-3, and 4 were 21%, 
42% and 36% respectively. Mean time from the diagnosis of the most recent cancer to the interview date was 1.9 
years (SD 1.4). (Appendix Table 4) 
Only 5% of patients in the heart disease group self-reported to have had cancer. Similarly, 4% of patients in the 
cancer group have had heart disease, and less than 5% of participants in the general population group had either 
heart disease or cancer.  
Table 2 summarizes the comparison of utility values between the patient groups and the general population group. 
Pooling all 10 states, heart disease patients displayed a mean utility value that was lower by 0.11 points (P-
value=0.014) than the general population group. Heart disease patients valued moderate and severe health states 
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lower by 0.05 points (P-value=0.353) and 0.25 points (P-value <0.001), respectively, than members of the general 
public. There was no statistically significant difference in mean utility value for mild health states between the two 
groups (difference=0.03). After adjusting for demographic and socioeconomic variables in the regression models, 
the overall difference weakened and became statistically non-significant. However, the mean utility value based on 
heart disease patients was lower by 0.05 (P-value=0.534) for severe health states, and higher by 0.08 points (P-
value=0.007) and 0.09 points (P-value=0.176) for mild and moderate health states, respectively, than that based on 
the general population members.  
Unlike heart disease patients, there was no statistically significant difference in mean utility value for all health 
states including mild, moderate and severe health states between cancer patient group and the general population 
group. After taking the effects of demographic and socioeconomic characteristics into account, the mean differences 
in utility values between the two groups were smaller than the ones without adjustment and statistically non-
significant (Table 2). Among all the covariates adjusted for the analysis, age had strongest association with utility 
(Wald test P <0.0001; see Appendix Table 4). Older age was associated with lower utility value.  
Mean (unadjusted and adjusted) differences in differences between selected health states for the heart disease 
patients versus the general population group are presented in Fig. 1. It shows that the covariate-adjusted differences 
in differences were higher than 0.05, a possibly minimally important difference for utility values, for 21 of 35 pairs 
of health states (60%; P-value <0.05 for 11 pairs), and lower than 0.05 for 8 pairs of health states (23%; P-value 
≥0.05 for all) in heart disease patients than the general population group. Similar analysis comparing cancer patients 
and the general population group (Fig. 2) showed that adjusted differences in differences were greater than 0.05 for 
10 of 35 pairs of health states (29%; P-value ≥0.05 for all), and lower than 0.05 for 3 pairs (9%; P-value ≥0.05 for 
all). 
Discussion 
Overall, both heart disease and cancer patients tended to value the utility of EQ-5D-5L defined health states lower 
than members of the general public. The difference between cancer patients and the general public was consistent 
across health states of different severity, and disappeared after adjusting for the differences in demographics. In 
contrast, the difference between heart disease patients and the general public depended on health state severity, and 
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demographics explained the difference in severe states but did not fully account for the difference in mild and 
moderate states. These results suggest that whether the health preferences of patients and members of the general 
population differ depends on many factors.  
So far two studies, conducted by Pickard et al. [13] and Gandhi et al. [9], compared valuation of 3-level EQ-5D 
(EQ-5D-3L) health states between heart disease patients and the general population. Our study is consistent with the 
two studies in that heart disease patients give mild and moderate EQ-5D-3L health states higher values compared to 
the general population, which could be explained by the theory of adaptation or coping. Patients are more likely to 
have experienced and adapted to mild and moderate health problems defined by EQ-5D-3L than healthy individuals. 
As a result, patients do not perceive those health states as intolerable or undesirable as the general public. A recent 
study of patients with type 2 diabetes mellitus reported similar results [6], suggesting that higher valuation of mild 
health problems may be a common phenomenon in some patient populations. On the other hand, our finding that 
heart disease patients give lower values to severe health states than the general population was not observed in 
previous studies. For example, Gandhi et al. [9] found the opposite – heart disease patients valued severe health 
states higher than the general public, which can be explained by adaptation. However, the adaptation theory could 
also explain low valuation of severe health problems. If the severe health problems are difficult to adapt to and their 
detrimental effects are also difficult to imagine, patients who had the experience could perceive them more 
undesirably than individuals who never had such experience [28]. Coincidentally, a recent study found that, 
compared to the general population, breast cancer and rheumatoid arthritis patients valued EQ-5D-5L defined 
mobility and self-care problems less undesirable but pain/discomfort and anxiety/depression more undesirable [29]. 
In another study comparing value of depression states between individuals with and without depression has shown 
that individual with depression valued depression lower than the individual who have not experienced it [30]. These 
studies might be a good support to the theory we used to explain the low valuation of health problems by patients, 
considering these two facts: 1), physical problems such as partial paralysis are easier to adapt than sensational 
problems such as pain and depression if they are persistent; 2), three of the four severe health states we used in our 
study involved severe or extreme pain/discomfort or anxiety/depression and only one health state involved extreme 
mobility problems (i.e., unable to walk about).  The reasons for not observing this result in previous studies could be 
due to use of small sample size as well as health states characterized mainly by physical health problems.  
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Pickard et al. [13] also compared valuation by cancer patients and the general population. It showed results similar 
to our study that cancer patients give slightly lower but statistically insignificant values than the general population. 
A study conducted by Krabbe et al. [14] showed that cancer patients give a higher value to EQ-5D-3L health states 
than the general population. However, the comparison did not adjust for the effects of demographic and 
socioeconomic characteristics; the patients were significantly older than the general population group in that study. 
It can be reasonably postulated that utility values derived from cancer patients and the general population could be 
similar if the effect of age had been adjusted for in that study. These consistent findings suggest that cancer patients 
and the general population may have very similar preferences for EQ-5D-5L health states. Therefore, the general 
population-based EQ-5D-5L value sets could be sufficient for measuring the utility of various health outcomes when 
the measurement should be based on the preferences of cancer patients such as in clinical decision making.      
There are a few possible reasons for why heart disease and cancer patients were different in valuation of EQ-5D-5L 
health states compared to the general population. For severe health states, it could be due to different levels of 
adaptation. It is possible that cancer patients adapt better to such health states than heart disease patients given that 
most of them have received surgery and/or chemotherapy, both of which have huge impact on patients’ health and 
quality of life. For mild and moderate health states, cancer patients might focus more on their impact on quality of 
life than heart disease patients and therefore they are willing to trade a slightly larger portion of their life expectancy 
(10 years in this study). It is also possible that, compared to members of the general public and heart disease patients 
of the same age, cancer patients are more likely to perceive their actual life expectancy to be shorter than 10 years 
and therefore they are more generous in trading the ‘extra’ life years in the given life expectancy. This trading 
behavior would lead to lower utility values for health states of all severities. It could offset the effect of adaptation 
and as a result make cancer patients similar to the general population in valuation of health outcomes using the TTO 
method. Our finding that older age is associated with lower utility value in this study could be evidence for the effect 
of self-perceived life expectancy on TTO-based valuation using a standardized timeframe. Further studies are 
needed to test the generalizability of the findings on the population/disease-specific valuation outcomes and 
ascertain the underlying valuation behaviors. 
Our analysis of the differences in differences suggests that utility values derived from the general population will 
lead to smaller differences than utility values derived from heart disease patients, if those are used to determine 
Page 10 of 20 
 
utility gained from transitions between the studied health states. This means that the general population-based EQ-
5D-5L value sets are less likely underestimate treatment benefits for heart disease patients if they are used in clinical 
trials or other longitudinal studies. Therefore, it may be worthwhile to develop a heart disease patients based EQ-
5D-5L value set for use in studies for informing clinical decision making or other decision making in which 
patients’ health preferences are most relevant. One the other hand, differences in utility between EQ-5D-5L health 
states based on utility values derived from cancer patients and the general public were found to be quite similar, 
suggesting that the general population based EQ-5D-5L value sets may be sufficient for use in clinical decision 
making for cancer patients. The differing results for heart diseases and cancers in this analysis suggest that patients-
based EQ-5D-5L value sets, if needed for evaluating treatments, should be disease specific.  
Our finding that older age is associated with lower health-state valuation is in concordance with findings of previous 
studies using a similar valuation method [31, 32]. The effect of age on TTO values could be due to the different life 
experience and perceived responsibilities of young and old individuals. For young individuals, they may tend to look 
forward to more life experience and responsibilities in the future and therefore prefer longer life to better quality of 
life; for old individuals, they are likely to have experienced a lot and fulfilled their responsibilities in past lives and 
are willing to trade life years for a healthy life. Further studies are needed to test the generalizability of the finding in 
other patient populations. 
Our study has several potential limitations. First, our study sample did not include inpatients. As inpatients are likely 
to be in worse functional status which was associated with lower utility values in heart disease patients in our study 
(data not shown), the difference in utility values between the heart disease patients and the general population might 
be under-estimated. Nevertheless, it would be difficult to conduct the very cognitively demanding valuation tasks 
with inpatients. Second, our study involved only cardiovascular diseases and cancers. Therefore, our specific study 
findings may not be generalizable to other patient populations. However, the observation that clinical groups differ 
in terms of how they value health is likely to be generalizable. Third, our general population sample was recruited 
from shopping malls. As shopping is generally a pleasant leisure activity which could have an impact on valuation 
of health, the magnitude of the difference observed between the patient populations and the general population 
might be different if a more representative general population sample had been used in the study. Fourth, the sample 
size for the study was powered enough for overall comparison (mean utility of all heath states) between the general 
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population and a patient population. It was not powered for comparison between the populations for mild, moderate, 
and severe health states separately. Therefore, our study findings should be considered exploratory and need to be 
confirmed with a bigger study. Furthermore, due to limited number of health states and sample size, it was not 
possible to evaluate impact of individual dimensions of EQ-5D-5L on differences in health state preferences. And, 
finally, the findings reported here are limited to valuation of hypothetical health states. They may not be generalized 
to valuation of experienced health states. 
Conclusions 
Patients with chronic diseases may differ from members of the general population in the strength of their preferences 
for hypothetical health states. The difference may depend on type of the disease, age of patients and severity of the 
health states being valued. As a result, using utility values derived from the general population may under-estimate 
the comparative effectiveness of healthcare interventions for certain type of diseases, such as heart diseases. Larger 
studies involving more diverse patient groups and a wider range of health states would be required to confirm our 
study findings.  
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Tables 
Table 1 Demographic and health characteristics of the study participants 
Characteristic 
General population 
(N=169) 
Heart disease patients 
 (N=157) 
Cancer patients 
(N=169) 
n (%) n (%) P-value* n (%) P-value* 
Female   89 (52.7) 54 (34.4) 0.001 98 (58.0) 0.381 
Age (years)   <0.001  <0.001 
     21-40 75 (44.4) 13 (8.3)  20 (11.8)  
     41-60 65 (38.5) 61 (38.9)  93 (55.0)  
     >60 29 (17.2) 83 (52.9)  56 (33.1)  
    Mean (SD)# 44.4 (14.2) 58.8 (11.6) <0.001 54.4 (13.0) <0.001 
Ethnicity   0.029  0.079 
     Chinese 140 (82.8) 110 (70.1)  123 (72.8)  
     Malay 10  (5.9) 12 (7.6)  22(13.0)  
     Indian 10 (5.9) 23 (14.7)  10 (5.9)  
     Others 9 (5.3) 12 (7.6)  14 (8.3)  
Education level   <0.001  <0.001 
     Primary (6 years) or less 12 (7.1) 35 (22.3)  25 (14.8)  
     Secondary (7-11 years) 54 (32.0) 88 (56.1)  91 (53.9)  
     Diploma, University or higher 103 (61.0) 34 (21.7)  53 (31.4)  
Married 104 (61.5)      101 (64.3) 0.647 113 (66.9) 0.364 
Employed 109 (64.5) 84 (53.5) 0.055 95 (56.2) 0.148 
Household earnings per month   <0.001  0.010 
     <S$4000 60 (35.5) 98 (62.4)  87 (51.5)  
     >=S$4000 91 (53.9)    44 (28.0)  65 (38.5)  
     Don’t know/refused 18 (10.7) 15 (9.6)  17 (10.1)  
Religion   0.693  <0.001 
     No religious belief 37 (21.9) 26 (16.6)   15 (8.9)  
     Buddhism/Taoism 55 (32.5) 54 (34.4)  66 (39.1)  
     Christians 44 (26.0) 43 (27.4)  46 (27.2)  
     Islam 15 (8.9) 19 (12.1)  34 (20.1)  
     Others 18 (10.7) 15 (9.6)  8 (4.7)  
Self-reported health on VAS# 82.6 (10.4) 73.8 (14.5) <0.001 76.3 (17.3) <0.001 
Self-reported chronic diseases      
    Cancer 1 (0.6) 8 (5.1) 0.016 169 (100) <0.001 
    Heart disease 6 (3.6) 157 (100) <0.001 6 (3.6) 1.000 
    Hypertension 25 (14.8) 90 (57.3) <0.001 48 (28.4) 0.003 
    Hyper/dyslipidemia 20 (11.8) 92 (58.6) <0.001 29 (17.2) 0.216 
    Diabetes mellitus 7 (4.1) 46 (29.3) <0.001 33 (19.5) <0.001 
    Arthritis/gout/joint pain 8 (4.7) 23 (14.7) 0.002 11 (6.5) 0.638 
    Lung disease 16 (9.5) 12 (7.6) 0.693 7 (4.1) 0.082 
    Other 15 (8.9) 37 (23.6) <0.001 19 (11.2) 0.588 
Number of self-reported chronic diseases      
      None 107 (63.3) 0 (0.0) - 0 (0.0) - 
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Characteristic 
General population 
(N=169) 
Heart disease patients 
 (N=157) 
Cancer patients 
(N=169) 
n (%) n (%) P-value* n (%) P-value* 
     One 38 (22.5) 24 (15.3) - 84 (49.7) - 
     More than one 24 (14.2) 133 (84.7) - 85 (50.3) - 
* Comparison with the general population group using Fisher’s exact test or two-sample independent t test 
# Mean (Standard deviation) 
VAS: Visual Analogue Scale (100: Best imaginable health state, 0: Worst imaginable health state)  
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Table 2 Comparison of composite time trade-off utility values between the general and patient populations 
EQ-5D-5L heath states 
General population 
(N=169) 
Heart disease patients 
 (N=157) 
Cancer patients 
(N=169) 
All health states    
     Mean (SD) 0.398 (0.657) 0.291 (0.807) 0.336 (0.723) 
     Mean difference (95% CI)1,4  -0.107 (-0.191, -0.022)* -0.062 (-0.147, 0.022) 
     Adjusted mean difference (95% CI)1,5  0.031 (-0.067, 0.130) -0.007 (-0.058, 0.045) 
Mild health states6    
     Mean (SD) 0.842 (0.255) 0.875 (0.345) 0.829 (0.362) 
     Mean difference (95% CI)1,4  0.033 (-0.018, 0.084) -0.013 (-0.067, 0.041) 
     Adjusted mean difference (95% CI)1,5  0.076 (0.021, 0.131)** -0.009 (-0.072, 0.054) 
Moderate health states6    
     Mean (SD) 0.505 (0.545) 0.452 (0.704) 0.417 (0.651) 
     Mean difference (95% CI)1,4  -0.053 (-0.166, 0.059) -0.088 (-0.196, 0.020) 
     Adjusted mean difference (95% CI)1,5  0.091 (-0.041, 0.223) -0.011 (-0.132, 0.111) 
Severe health states6    
     Mean (SD) -0.016 (0.693) -0.267 (0.764) -0.096 (0.719) 
     Mean difference (95% CI)1,4  -0.251 (-0.380, -0.123)** -0.080 (-0.206, 0.045) 
     Adjusted mean difference (95% CI)1,5  -0.048 (-0.198, 0.103) -0.002 (-0.137, 0.133) 
    
11122    
     Mean (SD) 0.889 (0.189) 0.903 (0.274) 0.879 (0.287) 
     Mean difference (95% CI)1,2  0.013 (-0.038, 0.065) -0.010 (-0.062, 0.042) 
     Adjusted mean difference (95% CI)1,3  0.031 (-0.030, 0.093) -0.020 (-0.079, 0.038) 
21121    
     Mean (SD) 0.879 (0.204) 0.925 (0.256) 0.871 (0.290) 
     Mean difference (95% CI)1,2  0.046 (-0.004, 0.096) -0.008 (-0.062, 0.045) 
     Adjusted mean difference (95% CI)1,3  0.067 (0.007, 0.128)* -0.015 (-0.076, 0.046) 
21222    
     Mean (SD) 0.759 (0.329) 0.798 (0.457) 0.738 (0.464) 
     Mean difference (95% CI)1,2  0.040 (-0.047, 0.126) -0.021 (-0.107, 0.065) 
     Adjusted mean difference (95% CI)1,3  0.129 (0.025, 0.232)* 0.009 (-0.088, 0.106) 
21232    
     Mean (SD) 0.640 (0.436) 0.681 (0.541) 0.592 (0.557) 
     Mean difference (95% CI)1,2  0.041 (-0.066, 0.147)   -0.049 (-0.156, 0.059) 
     Adjusted mean difference (95% CI)1,3  0.148 (0.020, 0.276)* -0.005 (-0.124, 0.115) 
32232    
     Mean (SD) 0.532 (0.523) 0.393 (0.724) 0.433 (0.623) 
     Mean difference (95% CI)1,2  -0.138 (-0.275, -0.001)*   -0.098 (-0.221, 0.025) 
     Adjusted mean difference (95% CI)1,3  -0.001 (-0.162, 0.160) -0.018 (-0.155, 0.119) 
32333    
     Mean (SD) 0.343 (0.622) 0.282 (0.768) 0.227 (0.714) 
     Mean difference (95% CI)1,2  -0.062 (-0.214, 0.090)  -0.117 (-0.260, 0.026) 
     Adjusted mean difference (95% CI)1,3  0.127 (-0.051, 0.304) -0.009 (-0.165, 0.147) 
31242    
     Mean (SD) 0.226 (0.648) 0.035 (0.785) 0.109 (0.726) 
     Mean difference (95% CI)1,2  -0.191 (-0.347, -0.034)* -0.117 (-0.264, 0.031) 
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EQ-5D-5L heath states 
General population 
(N=169) 
Heart disease patients 
 (N=157) 
Cancer patients 
(N=169) 
     Adjusted mean difference (95% CI)1,3  -0.070 (-0.247, 0.107) -0.060 (-0.222, 0.101) 
22224    
     Mean (SD) 0.069 (0.703) -0.069 (0.825) 0.101 (0.742) 
     Mean difference (95% CI)1,2  -0.138 (-0.304, 0.029) 0.032 (-0.123, 0.186) 
     Adjusted mean difference (95% CI)1,3  0.086 (-0.103, 0.274) 0.148 (-0.023, 0.319) 
53343    
     Mean (SD) -0.165 (0.672) -0.545 (0.614) -0.309 (0.645) 
     Mean difference (95% CI)1,2  -0.380 (-0.520, -0.239)** -0.144 (-0.285, -0.003)* 
     Adjusted mean difference (95% CI)1,3  -0.141 (-0.298, 0.016) -0.064 (-0.217, 0.090) 
33453    
     Mean (SD) -0.193 (0.665) -0.490 (0.641) -0.284 (0.649) 
     Mean difference (95% CI)1,2  -0.297 (-0.440, -0.155)** -0.091 (-0.232, 0.049) 
     Adjusted mean difference (95% CI)1,3  -0.065 (-0.226, 0.096) -0.032 (-0.185, 0.122) 
1 Difference: mean utility of the patients group minus mean utility of the general population group 
2 Using ordinary least-square regression model. 
3 Using ordinary least square regression model adjusted for gender, age, ethnicity, education level, employment 
status, household earnings, and religion. 
4 Using ordinary least-square regression model (with robust standard error for cluster data). 
5 Using ordinary least square regression model (with robust standard error for cluster data) adjusted for gender, age, 
ethnicity, education level, employment status, household earnings, and religion. 
6 EQ-5D-5L health states with all dimensions at severity level either 1 or 2 are considered ‘mild’ heath states. EQ-
5D-5L health states with at least one dimension at severity level either 4 or 5 are considered ‘severe’ heath states. 
EQ-5D-5L health states which are neither ‘mild’ or ‘severe’ are considered ‘moderate’ health states.  
* P-value <0.05; ** P-value <0.01 
SD: Standard deviation; CI: Confidence interval 
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Figure Captions 
Fig. 1 Estimated differences in differences in utility values between heart disease patients and the general population 
for pair of health states 
Difference in utility values defined as utility value of a better health state minus that of a poorer health state. 
 
 
Fig. 2 Estimated differences in differences in utility values between cancer patients and the general population for 
pair of health states 
Difference in utility values defined as utility value of a better health state minus that of a poorer health state. 
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Appendix Table 1 Comparison of demographic and health characteristics of participants included and excluded 
from the analysis 
Characteristic, n (%) 
Included 
participants 
(N = 495) 
Excluded 
participants 
(N = 30) 
P-value* 
Population   0.011 
     General population 169 (34.1) 6 (20.0)  
     Heart disease patients 157 (31.7) 18 (60.0)  
     Cancer patients 169 (34.1) 6 (20.0)  
Female  241 (48.7) 15 (50.0) 1.000 
Age (years)   0.198 
     21-40 108 (21.8) 3 (10.0)  
     41-60 219 (44.2) 13 (43.3)  
     >60 168 (33.9) 14 (46.7)  
    Mean (SD)# 52.4 (14.3) 56.8 (12.1) 0.099 
Ethnicity   0.516 
     Chinese 373 (75.4) 21 (70.0)  
     Malay 44 (8.9) 2 (6.7)  
     Indian 43 (8.7) 5 (16.7)  
     Others 35 (7.1) 2 (6.7)  
Education level   0.134 
     Primary (6 years) or less 72 (14.6) 3 (10.0)  
     Secondary (7-11 years) 233 (47.1) 20 (66.7)  
     Diploma, University or higher 190 (38.4) 7 (23.3)  
Married 318 (64.2) 23 (76.7) 0.236 
Employed 288 (58.2) 17 (56.7) 0.507 
Household earnings per month   0.820 
     <S$4000 245 (49.5) 17 (56.7)  
     >=S$4000 200 (40.4) 11 (36.7)  
     Don’t know/refused 50 (10.1) 2 (6.7)  
Religion   0.416 
     No religious belief 78 (15.8) 2 (6.7)  
     Buddhism/Taoism 175 (35.4) 10 (33.3)  
     Christians 133 (26.9) 9 (30.0)  
     Islam 68 (13.7) 4 (13.3)  
     Others 41 (8.3) 5 (16.7)  
Self-reported health on VAS# 77.7 (14.8) 75.6 (16.6) 0.467 
* Comparison with the general population group using Fisher’s exact test or two-sample independent t test 
# Mean (Standard deviation) 
VAS: Visual Analogue Scale (100: Best imaginable health state, 0: Worst imaginable health state)  
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Appendix Table 2 Comparison of demographic characteristics of the study sample with the Singaporean general 
population according to Census 2010. 
Characteristic, % of the population 
Census 2010 Study sample 
Singapore general 
population of 
age 20 – 79 years 
General 
population 
(N=169) 
Heart disease 
patients 
(N=157) 
Cancer  
patients 
(N=169) 
Female 50.9 52.7 34.4 58.0 
Age (years)     
     20-39 40.9 41.4 7.6 11.8 
     40-59 42.5 39.6 36.9 51.5 
     ≥60 16.6 18.9 55.4 36.7 
Ethnicity     
     Chinese 75.8 82.8 70.1 72.8 
     Malay 12.1 5.9 7.6 13.0 
     Indian 8.8 5.9 14.7 5.9 
     Others 3.2 5.3 7.6 8.3 
Education level*     
     Primary (6 years) or less 8.2 7.1 22.3 14.8 
     Secondary (7-11 years) 34.2 32.0 56.1 53.9 
     Diploma, University or higher 57.6 61.0 21.7 31.4 
Married 65.8 61.5     64.3 66.9 
Household earnings per month     
     <S$4000 37.5 35.5 62.4 51.5 
     >=S$4000 62.5 53.9    28.0 38.5 
     Don’t know/refused - 10.7 9.6 10.1 
Religion     
     No religious belief 16.8 21.9 16.6  8.9 
     Buddhism/Taoism 44.8 32.5 34.4 39.1 
     Christians 18.3 26.0 27.4 27.2 
     Islam 14.2 8.9 12.1 20.1 
     Others 5.9 10.7 9.6 4.7 
* Excluded population with no educational qualification. 
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Appendix Table 3 Disease characteristics of heart disease patients 
Characteristic, n (%) Heart disease patients (N=157 ) 
Heart disease type  
     Coronary artery disease  99 (63.1) 
     Arrhythmias 42 (26.8) 
     Heart failure 31 (19.8) 
     Other 7 (4.5) 
  
NYHA functional classification*  
     I 112 (71.3) 
     II 37 (23.6) 
     III 8 (5.1) 
       
CCS functional classification*  
     I 114 (72.6) 
     II 22 (14.0) 
     III 17 (10.8) 
     IV 4 (2.6) 
  
Years from most recent episode of 
symptom onset 
 
     Mean (SD) 1.4 (2.0) 
  
Heart disease treatment received  
     Medicinal therapy 157 (100.0) 
     Surgery  115 (73.3) 
     Cardiac rehabilitation 45 (28.7) 
     Lifestyle changes 22 (14.0) 
  
 
NYHA: New York Heart Association; CCS: Canadian Cardiovascular Society; SD: Standard Deviation 
* All subjects were graded on symptoms of breathlessness and chest pain using these scores regardless of whether 
they had known heart failure or coronary artery disease, respectively. 
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Appendix Table 4 Disease characteristics of cancer patients 
Characteristic, n (%) Cancer patients (N=169) 
Cancer type  
     Breast 49 (29.0) 
     Colorectal 36 (21.3) 
     Lymphoma 19 (11.2) 
     Lung 13 (7.7) 
     Prostate 9 (5.3) 
     Ovary 7 (4.1) 
     Stomach 6 (3.6) 
     Nasopharyngeal 6 (3.6) 
     Other 32 (18.9) 
  
Highest cancer stage  
     0 9 (5.3) 
     1 26 (15.4) 
     2 31 (18.3) 
     3 41 (24.3) 
     4 62 (36.7) 
  
Years from diagnosis of the most 
recent cancer 
 
     Mean (SD) 1.9 (1.4) 
  
ECOG performance status  
    0 95 (56.2) 
    1 73 (43.2) 
    2 1 (0.6) 
  
Cancer treatment received  
     Chemotherapy 124 (73.4) 
     Surgery 113 (66.9) 
     Radiation therapy 71 (42.0) 
     Hormone therapy 33 (19.5) 
     Immune therapy 21 (12.4) 
     Targeted therapy 13 (7.7) 
     Other therapy 13 (7.7) 
  
 
ECOG: Eastern Cooperative Oncology Group 
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Appendix Table 5 Summary of regression model (adjusted for covariates) for comparing utility values of all health 
states between patients and the general populations  
 Comparison of utility values 
between heart disease patients and 
the general population 
Comparison of utility values between 
cancer patients and the general 
population 
Variables Coefficient  (95% CI) 
P-value Coefficient  
(95% CI) 
P-value 
Population     
     General Reference  Reference  
     Patients 0.031 (-0.067, 0.130) 0.535 -0.007 (-0.058, 0.045) 0.803 
Gender     
     Male Reference  Reference  
     Female -0.073 (-0.156, 0.011) 0.089 -0.028 (-0.077, 0.020) 0.253 
Age (years)  [<0.0001]  [<0.0001] 
     21- 40 Reference  Reference  
     41- 60 -0.147 (-0.247, -0.08) 0.004 -0.091 (-0.155, -0.028) 0.005 
        > 60 -0.288 (-0.415, -0.161) <0.001 -0.220 (-0.300, -0.141) <0.001 
Ethnicity  [0.457]  [0.232] 
     Chinese Reference  Reference  
     Malay 0.100 (-0.133, 0.334) 0.398 -0.056 (-0.212, 0.100) 0.482 
     Indian -0.050 (-0.238, 0.138) 0.600 0.101 (-0.040, 0.242) 0.159 
     Others -0.050 (-0.250, 0.150) 0.622 -0.024 (-0.142, 0.095) 0.697 
Education level  [0.053]  [0.054] 
    Primary (6 years) or less Reference  Reference  
    Secondary (11 years) 0.084 (-0.043, 0.211) 0.192 0.071 (-0.009, 0.151) 0.082 
    Diploma, university or higher 0.186 (0.031, 0.341) 0.019 0.117 (0.022, 0.212) 0.016 
Marital status     
    Married Reference  Reference  
    Single -0.068 (-0.154, 0.017) 0.117 -0.061 (-0.111, -0.010) 0.018 
Employment status     
   Unemployed Reference  Reference  
   Employed -0.042 (-0.130, 0.046) 0.346 -0.025 (-0.078, 0.028) 0.362 
Household earning per month  [0.771]  [0.002] 
     < S$4000 Reference  Reference  
     ≥ S$ 4000 0.023 (-0.077, 0.123) 0.647 0.092 (0.035, 0.149) 0.002 
    Don’t know/refused -0.027 (-0.169, 0.114) 0.704 -0.024 (-0.108, 0.059) 0.566 
Religion  [0.037]  [0.001] 
     No religious belief Reference  Reference  
     Buddhism/Taoism 0.130 (0.012, 0.247) 0.030 0.111 (0.037, 0.184) 0.003 
     Christians 0.160 (0.030, 0.290) 0.016 0.139 (0.063, 0.215) <0.001 
     Islam 0.100 (-0.135, 0.334) 0.404 0.163 (0.009, 0.317) 0.038 
     Others -0.028 (-0.217, 0.161) 0.769 -0.022 (-0.149, 0.106) 0.740 
Constant 0.356 (0.155, 0.557) 0.001 0.299 (0.177, 0.421) <0.001 
CI: Confidence Interval. P-values in square brackets were calculated for joint tests of the categorical variables using 
the Wald test.    
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Purpose: The EuroQol 5-Dimension (EQ-5D) is a widely-used health status instrument for cost-utility analysis 
of healthcare interventions. Recently, its 5-Level version (EQ-5D-5L) and a protocol for conducting valuation of 
its health states were developed. We propose four approaches for estimating the sample size for EQ-5D-5L 
valuation according to the standardized procedures of the protocol.  
Methods: The first approach is for estimating mean health state utility values with a desired precision level 
using a regression model. The second approach, empirical in nature, determines a sample size based on mean 
absolute error in predicting health state values using a large-scale reference study. The last two approaches are 
for assessing the significance of regression coefficients of health state descriptors and to estimate the regression 
coefficients with a desired precision for predicting health state utility values.  
Results: Using data from a Singaporean study, we estimated parameters that are useful for sample size 
determination, including the design effect. Each of the approaches was illustrated with examples and pragmatic 
recommendations were provided.  
Conclusions:  Capitalizing on the EQ-5D-5L valuation protocol, we proposed four sample size estimation 
approaches which can help to decide an appropriate sample size for a value set study.  
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Introduction 
The 3-Level EuroQol 5-Dimension (EQ-5D) is a widely used health-status instrument for cost-utility analysis of 
healthcare interventions [1]. Recently, its 5-Level version (EQ-5D-5L) was developed, thereby increasing 
fineness in health-state descriptors and resulting in improved accuracy of measurement [2]. It requires value sets 
for use in economic evaluations. Previous EQ-5D value set studies were conducted using a variety of valuation 
methods, such as standard gamble, time trade-off (TTO), visual analogue scale. Although, TTO has been widely 
used, it was implemented in numerous ways and the value sets developed were not comparable across studies 
[3]. Learning from past experiences and performing pilot studies for optimizing valuation methodology, the 
EuroQol Group has developed a new valuation protocol for the EQ-5D-5L, namely the EuroQol Valuation 
Technology (EQ-VT) protocol [4]. This protocol is currently considered as a ‘gold standard’ for developing EQ-
5D-5L value sets. The protocol has been adopted by many countries including England, Japan, Canada, 
Netherlands, Korea and Singapore in developing their country-specific value sets in a standard manner [5].  
The protocol recommends a sample size of 1000 members of the general public [4]. This recommendation for 
the sample size, however, is based on some assumptions without support from empirical data and provided 
limited theoretical justification. On one hand the EQ-VT protocol addresses the issue of comparability of 
valuation methods, the suggested sample size could be a limiting factor for many countries where resources for 
conducting such studies is a major constrain. So far there is no follow-up evaluation on whether the 
recommended sample size is sufficient or excessive for developing a value set. The selection of an optimal 
sample size is very important from both statistical and feasibility points of view. This article aims to propose 
four sample size estimation methods for an EQ-5D-5L value set study. These sample size methods are illustrated 
using input parameters estimated from a recently completed EQ-5D-5L value set study in Singapore. This article 
will help guide a statistically sound decision on sample size estimation for future value set studies, in order to 
achieve optimal utilization of resources and confidence with the value set results.  
The plan for the article is as follows. In the Methods section, first we described the EQ-VT protocol and current 
practice for the data analysis. Next, based on the EQ-VT protocol, we derived mathematical formula for 
estimating several parameters, which are critical for sample size determination. The Results section provides 
other key parameters that are needed for the use of the proposed methods, estimated from a large-scale study in 
Singapore. It also illustrates the use of the methods. The article ends with Discussion followed by Conclusions 
section.  
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The EQ-VT protocol uses the composite Time Trade-Off (cTTO) for valuation. It also tests the use of discrete-
choice experiment as a potential method [6]. This article focuses on sample size estimation for the cTTO based 
value sets. 
Methods 
The EQ-VT protocol 
The EQ-5D is a generic health status instrument [7]. It contains five dimensions (mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression), and a visual analogue scale (EQ-VAS) of the overall health 
status. The new version of EQ-5D, EQ-5D-5L, describes each dimension with five levels of severity (broadly 
corresponding to no problem, slight problems, moderate problems, severe problems, and extreme problems). 
Thus, it can describe 3125 possible health states.  
According to the EQ-VT protocol, each participant values a randomly selected set (called a block) of 10 
hypothetical EQ-5D-5L health states [4]. Each block involves one very mild health state from five pre-specified 
ones (21111, 12111, 11211, 11121, 11112), the most severe health state (55555), and eight health states from 80 
pre-specified health states (from the remaining 3119 possible health states). Here, the health state '21111' 
indicates slight problems (level 2 severity) in the first dimension - mobility, no problem (level 1 severity) in the 
remaining four dimensions. Similarly, the other health states are defined. The protocol contains a total of 10 
unique blocks (Table 1). Simple random sampling is used to select one of the 10 blocks for each participant; 
hence equal probability of each block being chosen.  
The cTTO method requires participants to identify the point of preferential indifference between 10 years of life 
in the described target health state, followed by death, and a shorter life (x ≤10 years) in full health, followed by 
death. With a defined utility value of 1 for 10 years in full health, the utility value of the target health state can 
be calculated as 𝑥𝑥/10. For health states considered to be worse than death, a lead-time of 10 years is added to 
both alternatives in order to elicit a negative utility value for the health state. The utility value of a worse than 
death health state is calculated as (𝑥𝑥 − 10) 10⁄  such that the utility value of each health state is bounded at -1 
and 1; 0 represents value for the ‘dead’ state. More details on the EQ-VT protocol are published elsewhere [4, 
6].  
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Development of a value set 
A value set provides an algorithm for deriving a utility value for each health state. A value set study conducted 
using the EQ-VT protocol provides values for only 86 directly elicited health states. These values are used to 
estimate values for all 3125 health states of the EQ-5D-5L. There are potentially various ways to achieve it 
using an appropriate statistical model such as an ordinary least squares (OLS) model, OLS model with cluster-
robust standard error (SE), random effects (RE) model, interval regression model, and so on [8]. Currently, there 
is no consensus on which model is ideal for predicting utility values. Usually, a study team performs several 
models and decides upon a final model based on the models’ performance for consistency, bias, precision, and 
parsimony.  
As an initial choice, an OLS model for estimating utility values can be specified as:  
 y = Xβ + ε.             (1) 
We call this model as the Basic OLS model. Here, 𝑦𝑦 = (𝑦𝑦1,𝑦𝑦2, … ,𝑦𝑦𝑛𝑛)′, where 𝑦𝑦𝑖𝑖 = (𝑦𝑦𝑖𝑖1,𝑦𝑦𝑖𝑖2, … ,𝑦𝑦𝑖𝑖10)′ is a 
vector of utility values of 10 health states elicited from the ith participant, and n is the number of participants; 
𝛽𝛽 = (𝛽𝛽0,𝛽𝛽1, … ,𝛽𝛽20)′ is a vector of regression coefficients to be estimated, corresponding to the intercept and 20 
indicator variables representing the four severity levels (2 to 5 levels) of the five dimensions (dummy coding 
scheme); X is an 10n × 21 design matrix with the first column being an identity vector for the intercept and the 
remaining 20 columns for the indicator variables; ε is an 10n × 1 vector of errors. It is assumed that 𝜀𝜀𝑖𝑖𝑖𝑖 (error for 
utility value of jth health state in ith participant) ~ i.i.d. 𝑁𝑁(0,𝜎𝜎2), where i.i.d. stands for independent and 
identically distributed and 𝑁𝑁(0,𝜎𝜎2) denotes a normal distribution with mean 0 and variance 𝜎𝜎2.  
As each participant values 10 health states, values of health states elicited by the same participant might be 
correlated. Furthermore, the variance may not be constant. Thus, it is advisable to use cluster-robust SE 
(considering each participant as a cluster) to make valid statistical inference about the coefficients of the model 
[9].   
Alternatively, one can use a RE model for utility values specified as [10]:  
𝑦𝑦 = 𝑋𝑋𝛽𝛽 + 𝛾𝛾 + 𝜀𝜀.                          (2) 
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We call this model as the Basic RE model. Here, y, X, and β are vectors as mentioned in equation (1); 𝛾𝛾 =(𝛾𝛾1, 𝛾𝛾2, … , 𝛾𝛾𝑛𝑛)′, where 𝛾𝛾𝑖𝑖 = (𝛾𝛾𝑖𝑖1, 𝛾𝛾𝑖𝑖2, … , 𝛾𝛾𝑖𝑖10)′, 𝛾𝛾𝑖𝑖𝑖𝑖 = 𝛾𝛾𝑖𝑖𝑖𝑖 for all 𝑗𝑗 ≠ 𝑘𝑘,  represents a 10 × 1 vector of ith 
participant-specific random intercept which underlines the intra-participant correlation among the 10 health 
states; ε is an 10n × 1 vector of errors. It is assumed that 𝛾𝛾𝑖𝑖𝑖𝑖~𝑁𝑁(0,𝜎𝜎𝛾𝛾2), 𝜀𝜀𝑖𝑖𝑖𝑖~𝑁𝑁(0,𝜎𝜎𝑒𝑒2), and γi’s and 𝜀𝜀𝑖𝑖𝑖𝑖’s are 
independent. Here, 𝜎𝜎𝛾𝛾2 represents the between-participant variance, 𝜎𝜎𝑒𝑒2 is the within-participant 
variance,𝐶𝐶𝐶𝐶𝐶𝐶�𝑦𝑦𝑖𝑖𝑖𝑖 ,𝑦𝑦𝑖𝑖𝑖𝑖� = 𝜎𝜎𝛾𝛾2 for all 𝑗𝑗 ≠ 𝑘𝑘, 𝐶𝐶𝐶𝐶𝐶𝐶�𝑦𝑦𝑖𝑖𝑖𝑖 ,𝑦𝑦𝑙𝑙𝑖𝑖� = 0 for all 𝑖𝑖 ≠ 𝑙𝑙 and 𝑉𝑉𝑉𝑉𝑉𝑉�𝑦𝑦𝑖𝑖𝑖𝑖� = 𝜎𝜎𝛾𝛾2 + 𝜎𝜎𝑒𝑒2 = 𝜎𝜎2. In 
other words, within-participant utility values are correlated, but between-participant utility values are 
uncorrelated. Furthermore, intra-participant correlation does not depend on order of health states being valued.  
The models in equations (1) and (2) may be extended to include additional variables to indicate whether a health 
state is mild (e.g., all dimensions at severity level 1 or 2) or severe (e.g., at least one dimension at severity level 
4 or 5) and possibly adding interactions between the health state descriptor variables to improve model 
performance for the country-specific valuation data [11]. Alternative modeling technique such as a quantiles 
regression should also be considered. Furthermore, indicator variables for health state descriptor may be coded 
with backward difference coding scheme [12] so that regression coefficients of each dimension represent 
estimated mean differences in the utility values compared to their previous level of severity. In this article, we 
have used dummy coding scheme for illustration as it is widely-used. However, relevant information regarding 
the difference coding scheme is provided in Electronic Supplementary Material. 
Prerequisite parameters for sample size estimation 
Inverse of cross-product of design matrix 
As will be shown in the subsequent sections, the inverse of the cross-product of the design matrix 𝐶𝐶 = (𝑋𝑋′𝑋𝑋)−1, 
where X is as defined in equation (1), plays an important role in the sample size determination. We thus derive 
this piece of generic information before discussing specific sample size determination methods.  
It is intuitive to begin with considering the sample size as a multiple of 10. Since the valuation protocol has only 
10 unique blocks of health states (Table 1), each block has 10 health states, and the blocks have equal 
probability of being selected, for 𝑁𝑁𝑠𝑠 = 10 × 𝑀𝑀 participants, each of the 10 blocks on average is to be valued M 
times. Thus, for 𝑁𝑁𝑠𝑠 participants, the matrix X is expected to be 𝑋𝑋 = �𝑋𝑋𝑢𝑢(1),𝑋𝑋𝑢𝑢(2), … ,𝑋𝑋𝑢𝑢(𝑀𝑀)�′, where 𝑋𝑋𝑢𝑢(𝑖𝑖) = 𝑋𝑋𝑢𝑢 
is the ith replicate of the 100 × 21 design matrix based on the 10 unique blocks. Therefore, 
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𝐸𝐸(𝐶𝐶|𝑁𝑁𝑠𝑠 = 10𝑀𝑀) = (𝑋𝑋𝑢𝑢′ 𝑋𝑋𝑢𝑢)−1 𝑀𝑀⁄ = 𝐷𝐷 𝑀𝑀⁄ = 10 𝐷𝐷 𝑁𝑁𝑠𝑠⁄ ,           (3) 
where 𝐷𝐷 = (𝑋𝑋𝑢𝑢′ 𝑋𝑋𝑢𝑢)−1.  
As such, 
𝐸𝐸�𝐶𝐶𝑖𝑖𝑖𝑖� = 𝐷𝐷𝑗𝑗𝑗𝑗𝑀𝑀 = 10𝐷𝐷𝑗𝑗𝑗𝑗𝑁𝑁𝑠𝑠 ,                         (4) 
where Cjj and Djj are the jth diagonal element of the 21×21 matrices C and D, respectively.    
The matrix D for the dummy coding scheme is shown in Table 2, and for the backward difference coding 
scheme in Electronic Supplementary Material Table A.1.  
Design effect 
Standard sample size estimation approaches as well as those described in the subsequent sections assume (or 
begin with assuming) independent observations. However, the EQ-VT protocol requires each participant to 
value 10 health states. Such clustering of observations within participants impact the variance of the estimates. 
On the one hand, utility values (outcome variable) elicited by the same participant are likely positively 
correlated, as some people may generally give higher (or lower) values to health states no matter what these 
health states are. On the other hand, the EQ-VT protocol is developed to ensure that the 10 health states 
(exposure variables) are diverse within each participant, leading to negative correlation in the exposure. Given 
positive correlation in outcomes, the variances of the regression estimates are inflated if the exposures are 
positively correlated (e.g., cluster randomized trials), or deflated if the exposures are negatively correlated (e.g., 
crossover drug trials) [13, 14]. To compensate for the variance inflation or deflation, the sample size should be 
increased (or decreased) by the ‘design effect’ factor (DE) [13-15]. The sample size adjusted for the design 
effect is calculated as, 
𝑁𝑁 = 𝑁𝑁𝑠𝑠 × 𝐷𝐷𝐸𝐸 .              (5) 
For a randomized controlled trial that has one exposure variable, there are formulas for estimation of design 
effect and therefore sample size using the intra-class correlation coefficients as inputs [13-15]. However, 
currently there is no such formula for the complex case of multivariable regression analysis. We propose to 
empirically estimate the design effect using data from a large-scale study, as will be shown in Results section.  
The design effect for predicted utility value of a particular health state HS0 is calculated as  
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𝐷𝐷𝐸𝐸𝑦𝑦0 =  𝑉𝑉𝐶𝐶𝐶𝐶𝐶𝐶𝑠𝑠𝐶𝐶𝐶𝐶𝐶𝐶(𝑦𝑦�0)𝑉𝑉(𝑦𝑦�0) ,            (6)  
where 𝑉𝑉𝐶𝐶𝑙𝑙𝑢𝑢𝑠𝑠𝐶𝐶𝑒𝑒𝐶𝐶(𝑦𝑦�0) and 𝑉𝑉(𝑦𝑦�0) are cluster-robust and OLS variances, respectively, for the predicted utility value 
of HS0. For simplicity, one may consider using simple or weighted mean of 𝐷𝐷𝐸𝐸𝑦𝑦0 values (𝐷𝐷𝐸𝐸����𝑦𝑦) of directly 
valued health states, where weights can be chosen proportional to probability of occurrence of the health states. 
According to the valuation protocol, probabilities of occurrences of very mild health states (21111, 12111, 
11211, 11121, 11112), the most severe health state (55555) and the remaining 80 directly valued health states 
are 0.02, 1.0, and 0.01, respectively (Table 1). 
Similar to equation (5), the design effect for a regression coefficient, βj, is calculated as 
𝐷𝐷𝐸𝐸𝛽𝛽𝑗𝑗 =  𝑉𝑉𝐶𝐶𝐶𝐶𝐶𝐶𝑠𝑠𝐶𝐶𝐶𝐶𝐶𝐶(𝛽𝛽�𝑗𝑗)𝑉𝑉(𝛽𝛽�𝑗𝑗) ,             (7) 
where 𝑉𝑉𝐶𝐶𝑙𝑙𝑢𝑢𝑠𝑠𝐶𝐶𝑒𝑒𝐶𝐶(?̂?𝛽𝑖𝑖) and 𝑉𝑉(?̂?𝛽𝑖𝑖) are cluster-robust and OLS variances of βj, respectively. Similar to 𝐷𝐷𝐸𝐸����𝑦𝑦, one may 
consider using simple or weighted mean of 𝐷𝐷𝐸𝐸𝛽𝛽𝑗𝑗values (𝐷𝐷𝐸𝐸����𝛽𝛽). For example, if we are interested in coefficients 
of health state descriptors (i.e., β1 to β20), weights proportional to probability of occurrence of respective severity 
levels in a sample of randomly allocated blocks can be used for 𝐷𝐷𝐸𝐸����𝛽𝛽. According to the valuation protocol, the 
probability of occurrences of severity levels 2 to 5 in different dimensions range from 0.13 to 0.26 (Table 1). 
As an alternative to 𝑉𝑉𝐶𝐶𝑙𝑙𝑢𝑢𝑠𝑠𝐶𝐶𝑒𝑒𝐶𝐶(𝑦𝑦�0) and 𝑉𝑉𝐶𝐶𝑙𝑙𝑢𝑢𝑠𝑠𝐶𝐶𝑒𝑒𝐶𝐶�?̂?𝛽𝑖𝑖� in equations (6) and (7) respectively, one can use variances 
estimated for predicted utility value of HS0, 𝑉𝑉𝑅𝑅𝑅𝑅(𝑦𝑦�0), and βj, 𝑉𝑉𝑅𝑅𝑅𝑅�?̂?𝛽𝑖𝑖�, respectively, from the Basic RE model in 
equation (2). Empirical estimates of design effects from the Singaporean study will be given in Results section.  
Equations (6) and (7) assume that participants in the study are selected from the population using simple random 
sampling. However, a complex survey design such as multistage sampling and/or quota sampling may be used 
by investigators. In such cases, the design effect for that specific study design should be estimated as per 
standard survey methodology [16, 17], and then multiply it with the sample size (N) calculated in equation (5).  
Sample size estimation approaches for value set studies 
Approach 1 - To achieve desired precision for an estimated mean utility value for a particular health state 
The primary objective of value set studies is to predict utilities with acceptable precision. Suppose the study 
team would like to predict utility value of a particular health state HS0 with tolerated margin of error δ, where δ 
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is a sufficiently small value (e.g., minimal important difference (MID) for utility values) [18]. That is, the 
maximum allowable difference between the predicted value and the true value should be less than δ with 
sufficiently high probability 100×(1-α)%, 0 < α < 1. This is equivalent to targeting the 100×(1-α)% prediction 
interval (PI) to be ± δ. 
Consider the Basic OLS model for estimating the mean utility value of a particular health state, HS0. The 
100×(1−α)% PI for mean utility value of HS0  is [19]: 
�𝑦𝑦�0 − 𝑍𝑍1−𝛼𝛼
2
�𝜎𝜎�2 𝑥𝑥0′𝐶𝐶𝑥𝑥0,  𝑦𝑦�0 + 𝑍𝑍1−𝛼𝛼
2
�𝜎𝜎�2 𝑥𝑥0′𝐶𝐶𝑥𝑥0�,                             (8) 
where 𝑦𝑦�0 is the predicted utility value for HS0,  𝑥𝑥0′ = (1, 𝑥𝑥01, 𝑥𝑥02, … , 𝑥𝑥020) is the vector representing values of 
indicator variables for health state descriptor of HS0, σ�2 is the estimate of error variance, and 𝐶𝐶 = (𝑋𝑋′𝑋𝑋)−1. 
Thus, for the objective of estimating mean utility value of HS0 with desired precision, say 100×(1-α)% PI of 𝑦𝑦�0 
equal to 𝑦𝑦�0 ± 𝛿𝛿, the sample size Ns can be calculated by solving equation, 𝛿𝛿 = 𝑍𝑍1−𝛼𝛼
2
�𝜎𝜎�2 𝑥𝑥0′𝐶𝐶𝑥𝑥0. It can be solved 
using equation (3) as 𝛿𝛿 = 𝑍𝑍1−𝛼𝛼
2
× 𝜎𝜎� × �10 𝑥𝑥0′𝐷𝐷𝑥𝑥0 𝑁𝑁𝑠𝑠⁄  giving: 
𝑁𝑁𝑠𝑠 = 10 𝜎𝜎�2 𝑥𝑥0′𝐷𝐷𝑥𝑥0  𝑍𝑍1−𝛼𝛼/22𝛿𝛿2  .                     (9) 
This approach provides different sample sizes for different health states. The study team may choose the mean 
of these sample sizes. Using the matrix D (Table 2) and 𝑥𝑥0 vectors of the directly valued health states in the EQ-
VT protocol, it can be shown that  𝑥𝑥0′𝐷𝐷𝑥𝑥0 has mean, standard deviation (SD) and coefficient of variation (CV) of 
0.210, 0.062, and 29.3%, respectively. The 𝑥𝑥0′𝐷𝐷𝑥𝑥0 values are same under the dummy and the backward 
difference coding schemes for any 𝑥𝑥0. 
Lastly, as equation (9) also assumes independent observations, it needs to be adjusted for the design effect 𝐷𝐷𝐸𝐸����𝑦𝑦 
using equation (5), and replacing 𝑥𝑥0′𝐷𝐷𝑥𝑥0 by mean of 𝑥𝑥0′𝐷𝐷𝑥𝑥0 values (𝐷𝐷�𝑥𝑥0) of directly values health states, gives 
𝑁𝑁 = 𝑁𝑁𝑠𝑠 × 𝐷𝐷𝐸𝐸 = 10 𝜎𝜎�2 𝐷𝐷�𝑥𝑥0  𝐷𝐷𝑅𝑅����𝑦𝑦  𝑍𝑍1−𝛼𝛼/22𝛿𝛿2  .                 (10) 
Approach 2 - Empirical approach to achieve desired mean absolute error in prediction of utility values relative 
to a reference study 
This is an empirical approach in which mean absolute error (MAE) defined as [20], 
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𝑀𝑀𝑀𝑀𝐸𝐸𝑁𝑁𝑠𝑠 = 110𝑁𝑁 ∑ ∑ �𝑦𝑦�𝑖𝑖𝑖𝑖(𝑁𝑁𝑠𝑠) − 𝑦𝑦𝑖𝑖𝑖𝑖�10𝑖𝑖=1𝑁𝑁𝑖𝑖=1 ,                             (11) 
is calculated, where 𝑦𝑦�𝑖𝑖𝑖𝑖(𝑁𝑁𝑠𝑠) denote predicted utility values based on a regression model fitted with sample size 
Ns, and 𝑦𝑦𝑖𝑖𝑖𝑖 denote observed utility values in a reference study with a larger sample size N, where N > Ns. 
𝑀𝑀𝑀𝑀𝐸𝐸𝑁𝑁𝑠𝑠is to be estimated for a large number of replications of random sampling (with replacement) of Ns 
number of subjects within a reference study with sample size N conducted according to the EQ-VT protocol. A 
plot of mean 𝑀𝑀𝑀𝑀𝐸𝐸𝑁𝑁𝑠𝑠over sample size Ns can provide a visual presentation of how the MAE is reduced with an 
increase in sample size for the model. A sample size 𝑁𝑁𝑠𝑠∗ corresponding to desired MAE, or desired marginal 
gain in MAE as sample size increases, is selected for the study. 
Approach 3 - To assess significance of a regression coefficient of health state descriptors 
A value set study is expected to show that individual regression coefficients of health state descriptors (i.e., β1 to 
β20) are not different from zero by chance. That is, it requires to test the null hypothesis H0: βj  = 0 against the 
alternative hypothesis H1: βj  ≠ 0, for all j = 1, 2..., 20, with sufficient statistical power (1-β) and type-I error rate 
(α). 
Considering the Basic OLS model in equation (1), the SE of ?̂?𝛽𝑖𝑖 is 𝑆𝑆𝐸𝐸(?̂?𝛽𝑖𝑖) = �𝜎𝜎�2𝐶𝐶𝑖𝑖𝑖𝑖, where σ�2 is the estimate of 
error variance, and Cjj is the jth diagonal element of 𝐶𝐶 = (𝑋𝑋′𝑋𝑋)−1 matrix15. Using equation (4), 𝑆𝑆𝐸𝐸�?̂?𝛽𝑖𝑖� =
�𝜎𝜎�2𝐷𝐷𝑖𝑖𝑖𝑖 𝑀𝑀⁄ = �10𝜎𝜎�2𝐷𝐷𝑖𝑖𝑖𝑖 𝑁𝑁𝑠𝑠⁄ , where Djj are available from Table 2. Solving the equation, 𝛽𝛽𝑖𝑖 𝑆𝑆𝐸𝐸(?̂?𝛽𝑖𝑖)⁄ =
𝛽𝛽𝑖𝑖 �10𝜎𝜎�2𝐷𝐷𝑖𝑖𝑖𝑖 𝑁𝑁𝑠𝑠⁄⁄ = (𝑍𝑍1−𝛼𝛼/2 + 𝑍𝑍1−𝛽𝛽) will give sample size: 
𝑁𝑁𝑠𝑠 = 10𝜎𝜎�2𝐷𝐷𝑗𝑗𝑗𝑗(𝑍𝑍1−𝛼𝛼/2+𝑍𝑍1−𝛽𝛽)2𝛽𝛽𝑗𝑗2 ,          (12) 
where 𝑍𝑍1−𝛼𝛼 2⁄   and 𝑍𝑍1−𝛽𝛽  are values of standard normal distribution at 1 − 𝛼𝛼 2⁄  and 1 − 𝛽𝛽, respectively. The σ�2 
can be obtained from a reference study (see Results section).  
The β𝑖𝑖 can be a smallest desired value for the coefficient (e.g., MID for utility values) that the study team would 
consider meaningful. It is clear that the sample size may be different for different coefficients; one can choose 
the mean of coefficients (?̅?𝛽) for simplicity in the sample size estimation. Substituting ?̅?𝛽 for β𝑖𝑖  and 𝐷𝐷� for Djj in 
equation (12) gives,  
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𝑁𝑁𝑠𝑠 = 10 𝜎𝜎�2 𝐷𝐷� (𝑍𝑍1−𝛼𝛼/2+𝑍𝑍1−𝛽𝛽)2𝛽𝛽�2 .         (13) 
Since the sample size formula assumes independent observations, it needs to be adjusted for the design effect 
𝐷𝐷𝐸𝐸����𝛽𝛽 using equations (5), which gives, 
𝑁𝑁 = 10 𝜎𝜎�2 𝐷𝐷� 𝐷𝐷𝑅𝑅����𝛽𝛽 (𝑍𝑍1−𝛼𝛼/2+𝑍𝑍1−𝛽𝛽)2
𝛽𝛽�2
 .          (14) 
Approach 4 - To estimate a regression coefficient of health state descriptors with a desired precision 
Alternative to Approach 3, the study team may desire to estimates the regression coefficients with certain 
precision, say requiring the 100×(1-α)% confidence interval (CI) of βj to be ?̂?𝛽𝑖𝑖 ± 𝛿𝛿𝑖𝑖, where 𝛿𝛿𝑖𝑖  is a sufficiently 
small number (e.g., MID for utility values). For this objective, the sample size is obtained by solving [19] 𝛿𝛿𝑖𝑖 =
𝑍𝑍1−𝛼𝛼
2
𝑆𝑆𝐸𝐸�?̂?𝛽𝑖𝑖� =  𝑍𝑍1−𝛼𝛼
2
�10𝜎𝜎�2𝐷𝐷𝑖𝑖𝑖𝑖 𝑁𝑁𝑠𝑠⁄  . It gives  
𝑁𝑁𝑠𝑠 = 10 𝜎𝜎�2𝐷𝐷𝑗𝑗𝑗𝑗𝑍𝑍1−𝛼𝛼/22𝛿𝛿𝑗𝑗2 .                       (15) 
Alternatively, substituting 𝛿𝛿𝑖𝑖  by 𝛿𝛿̅ = mean of δj (j = 1, 2,.., 20), Djj by 𝐷𝐷� in equation (15) gives  
𝑁𝑁𝑠𝑠 = 10  𝜎𝜎�2 𝐷𝐷�𝑍𝑍1−𝛼𝛼/22𝛿𝛿�2  .                      (16) 
Finally, adjusting the sample size for the design effect 𝐷𝐷𝐸𝐸����𝛽𝛽 using equation (5), gives 
𝑁𝑁 = 10 𝜎𝜎�2 𝐷𝐷� 𝐷𝐷𝑅𝑅����𝛽𝛽 𝑍𝑍1−𝛼𝛼/22
𝛿𝛿�2
.                     (17) 
Results 
Estimates of useful parameters 
We used the cTTO utility values of the EQ-5D-5L value set study in the Singapore general population 
conducted according to the EQ-VT protocol to estimate useful parameters for sample size determination. In a 
cross-sectional national household survey, members of the general public, each from a different household, were 
recruited and interviewed by computer-assisted personal interviewing (CAPI). Quotas were set to make the 
sample representative the general adult Singapore population in distributions of age groups, genders, and ethnic 
groups. After excluding interviews of poor quality, a total of 1000 participants were used to estimate the EQ-
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5D-5L value set for Singapore.  
Using the Basic OLS model in equation (1), the estimate of error variance (𝜎𝜎�2) was 0.365. The mean (β�) of 
regression coefficients (?̂?𝛽1, ?̂?𝛽2, … , ?̂?𝛽20) of health state descriptor defined using the dummy coding scheme was 
−0.196. Using the Basic RE model in equation (2), the estimate of between-participant variance (𝜎𝜎�𝛾𝛾2) and the 
within-participant variance (𝜎𝜎�𝑒𝑒2) were 0.203 and 0.162, respectively. The Basic RE model gave β�  −0.204, which 
was similar to the -0.196 from the Basic OLS model.  
Simple and weighted means of design effects �𝐷𝐷𝐸𝐸����𝛽𝛽� for ?̂?𝛽1, ?̂?𝛽2, … , ?̂?𝛽20, using equation (7) for cluster-robust 
variances, were 0.82 and 0.84, respectively, or approximately 0.8. The Basic RE model was more efficient, in 
the sense that the variance estimates were smaller. Simple and weighted mean design effects based on RE 
variances were both 0.47, or approximately 0.5. Design effects for the intercept, ?̂?𝛽0, were 1.27 and 0.92 based on 
cluster-robust and RE variances, respectively. Detailed results of the Basic OLS and RE models are presented in 
Electronic Supplementary Material Table A.2 and A.3 for the dummy and backward difference coding schemes, 
respectively.  
Pearson’s correlation between predicted utility values based on the Basic OLS and RE models was 0.999 in the 
Singapore study; and mean absolute error in prediction using both the models was 0.499. Mean design effects 
�𝐷𝐷𝐸𝐸����𝑦𝑦0� for predicted values using equation (6) were approximately 1.15 and 0.75 based on cluster-robust and 
RE variances respectively. Weighted means of design effects were similar to their unweighted mean design 
effects. Mean utility values of individual health states in the Singaporean value set study along with their 
predicted values and their standard errors (square root of variances) using the Basic OLS and RE models are 
presented in Electronic Supplementary Material Table A.4.  
Numerical illustration 
For illustration, an MID of 0.05 as reported by Nolan et al. [21] is considered for utility values and regression 
coefficients of health state descriptors.   
Approach 1 - To achieve desired precision of an estimated mean utility value for a particular health state 
Suppose the study team is interested in calculating a sample size such that the predicted utility value of ‘12334’ 
health state, which has 𝑥𝑥0′𝐷𝐷𝑥𝑥0 value approximately equal to the mean of 𝑥𝑥0′𝐷𝐷𝑥𝑥0 values (i.e., 𝐷𝐷�𝑥𝑥0 = 0.210) of all 
directly valued health states in the EQ-VT protocol, is not far from its true value by more than a MID for utility 
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values. That is, the half-width of the 95% PI of the estimated utility value equal to δ = 0.05 (MID). The sample 
size can be calculated using equation (10), assuming 𝜎𝜎�2 = 0.365 and design effect 𝐷𝐷𝐸𝐸����𝑦𝑦 = 0.75 (based on the 
Basic RE model), as 𝑁𝑁 = 10 𝜎𝜎�2 𝐷𝐷�𝑥𝑥0𝐷𝐷𝐸𝐸����𝑦𝑦 𝑍𝑍1−𝛼𝛼/22 𝛿𝛿2⁄   = 10×0.365×0.210×0.75×(1.960)2/(0.05)2 = 2.2084/0.0025 
≈ 883 participants. 
The solid line in Fig. 1 shows the sample sizes calculated as illustrated above for Approach 1 for different MID 
(y-axis on left). It shows a rapid decline in the curve with increase in sample size from 100 to 400 participants. 
However, it decreases by a trivial magnitude with further increase of sample size after 400.  
Approach 2 - Empirical approach to achieve desired mean absolute error in prediction of utility values relative 
to a reference study 
For this approach, Fig. 1 shows the mean of 𝑀𝑀𝑀𝑀𝐸𝐸𝑁𝑁𝑠𝑠 (y-axis on right) for 100 random samples (with 
replacement) of sample sizes 100 to 900 participants based on the Basic OLS model using the Singapore value 
set study data (N=1000). The MAE decreased rapidly between the sample sizes of 100 to 300. After that, 
reduction in the slope is trivial beyond the sample size of 300. That is, gain in prediction accuracy was trivial 
when the sample size was more than 300 participants. Thus, one may consider 300 participants as a sample size 
for developing a value set.  
Approach 3 - To assess significance of a regression coefficient of health state descriptors 
The sample size required to test 𝐻𝐻0: β� = 0 against 𝐻𝐻1: β� ≠ 0, assuming the true value of ?̅?𝛽 = 0.05 (MID) and 𝜎𝜎�2 
= 0.365, at 5% two-sided level of significance (α) and 80% statistical power (1−β), can be calculated using 
equation (14), by inserting value of (𝑍𝑍1−𝛼𝛼/2 + 𝑍𝑍1−𝛽𝛽)2 = (1.960 + 0.842)2 = 7.851, 𝐷𝐷� = 0.131, and adjusting for 
design effect 𝐷𝐷𝐸𝐸����𝛽𝛽 = 0.5 (based on the Basic RE model), as  𝑁𝑁 = 10 𝜎𝜎�2 𝐷𝐷� 𝐷𝐷𝐸𝐸����𝛽𝛽 (𝑍𝑍1−𝛼𝛼/2 + 𝑍𝑍1−𝛽𝛽)2 ?̅?𝛽2⁄  = 
10×0.365×0.131×0.5×7.851/(0.05)2 = 1.8770/0.0025 ≈ 751 participants. Fig. 1 shows sample sizes 
corresponding to values of ?̅?𝛽 (y-axis on left) at 5% of α and 80% statistical power.  
Approach 4 - To estimate a regression coefficient of health state descriptors with a desired precision 
To estimate a regression coefficient with its 95% CI of half-width equal to 𝛿𝛿̅ = 0.05 (MID), using equation (17) 
with 𝜎𝜎�2 = 0.365, 𝐷𝐷� = 0.131 and 𝐷𝐷𝐸𝐸����𝛽𝛽 = 0.5 (as in previous illustration), the required sample size is 𝑁𝑁 =
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10 𝜎𝜎�2 𝐷𝐷� 𝐷𝐷𝐸𝐸����𝛽𝛽 𝑍𝑍1−𝛼𝛼/22 𝛿𝛿̅2⁄  = 10×0.365×0.131×0.5×(1.960)2/(0.05)2 = 0.9184/0.0025 ≈ 367 participants. Fig. 1 
shows sample sizes corresponding to values of 𝛿𝛿̅ (y-axis on left) for 95% CI of a regression coefficient. 
The backward difference coding scheme used for health state descriptors has no impact on sample size 
estimation in Approach 1 and 2, and has only trivial impact in Approach 3 and 4 (Results not shown). 
Discussion 
We illustrated four approaches for estimating sample size for health states valuation studies using the EQ-VT 
protocol – two based on prediction error for utility values, and two based on regression coefficients of an OLS 
regression model for utility values. Among the first two approaches which are directly related to the objective of 
value set studies to predict utility values with acceptable precision, Approach 1 based on PIs of predicted utility 
values has a few advantages over Approach 2 based on MAEs. Using Approach 1, one can control the 
prediction error with desired level of confidence (probability), whereas Approach 2 is only based on the mean 
prediction error. Furthermore, Approach 2 requires access to data of another value set study with sufficiently 
large sample size, and the size of a new study is chosen relative to this bigger study. The last two approaches are 
also relevant for as they are directly related to the analysis strategy and help to achieve an overall objective of 
developing a value set with acceptable precision indirectly. 
A few other sample size estimation approaches, based on comparing mean utility values of two different health 
states and on estimating utility values with desired precision, have been used in EQ-5D-3L value set studies [22, 
23]. However, these approaches were not directly linked to the analysis strategy, which was to develop a 
regression model for estimating utility values, in value set studies. The approaches did not involve the model 
used to predict utility values; therefore, cannot guarantee the precision of utility values estimated using the 
model. The study team should choose an approach which is most relevant to the study objective, analysis 
strategy, and outcome.  
The key objective of the article is to introduce justified approaches for calculating sample size for value set 
studies. We are neither recommending any modeling approach, nor presenting a value set. Thus, no serious 
attempt has been made to improve the model fitting, other than incorporating an intercept and 20 indictor 
variables for health states descriptors in the models. These basic models have not included any interaction terms, 
which might be useful for validity of the model assumptions and performance. This could be also a possible 
reason for a high value of MAE using Approach 2, even at sample size of 1000 participants. How to improve the 
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analysis models and reduce the prediction error in utility values is a complex issue beyond the scope of the 
present manuscript, potentially related to valuation methodology as well as modeling technique. This may 
require research. Furthermore, in the illustrations of sample size determination approaches, we used 0.05 as the 
MID for utility values only for the purpose of illustrating the numerical applications. In some realistic situations 
such as those in the illustration for Approaches 1 and 3, a sample size of 1000 participants was about right. 
However, they were based on specific assumptions and specific level of precision, which may vary from study 
to study. Users should estimate the sample size according to their own requirements.  
We explored how commonly used approaches for statistical inference in clustered data – the cluster-robust 
estimator and RE model – affect the sample size estimation. Both approaches showed deflation in variances for 
regression coefficients of health states descriptors when accounted for within-participant clustering effect. It is 
not surprising to see such results when health states in each block are spread over from very mild to extreme 
severity; that is, the within-person correlation among health state assignments is negative [13, 14]. Regarding the 
choice between clustered-robust estimator and RE model approaches for estimating the design effect, it is not so 
straightforward, and depends on data and study team’s preference for the model selection. The cluster-robust 
estimator approach requires fewer assumptions compared to the RE model approach [24], but it has a larger 
design effect. The RE model approach is more efficient and leads to smaller SEs and design effect compared to 
the other approach, but there is no guarantee that the model assumptions hold. Nevertheless, as reported in the 
Results section, the Pearson’s correlation between predicted utility values based on the Basic OLS and RE 
models was close to 1 in the Singapore study, meaning both the models gave practically the same results.   
It is not uncommon to exclude some participants’ data in value set studies if they seem logically incorrect. 
Currently, there is no consensus on who should be excluded from the analysis [25]. However, value set studies 
usually excludes participants who seem to have not understood the valuation task, and thus provided illogical 
values. For example, participants who have given the same value to all health states or given only negative 
values to all health states can be excluded. In the EQ-5D-3L value set studies conducted in various countries, the 
proportion of unusable data ranged from 0-50% depending on the exclusion criteria used [26]. Thus, depending 
on estimated proportion of unusable data, say p, the sample size should be increased in that proportion, by 
multiplying it to 1 (1 − 𝑝𝑝)⁄  to account for unusable data. Similar adjustments should be made in the sample size 
to account for incomplete interviews, exclusion of data due to interviewer learning effect, and other possible 
reasons which could potentially lead to data exclusion [27].  
Page 14 of 18 
 
Conclusions 
We proposed sample size determination methods for estimating utility values of health states with acceptable 
precision. Capitalizing on the EQ-5D-5L valuation protocol, we calculated the inverse of the cross-product 
matrix, which is critical for the sample size estimation. Based on a Singaporean study, we estimated several 
parameters that are useful for the sample size estimation. We proposed four sample size estimation approaches 
which can help to decide an appropriate sample size for a value set study.  These approaches will be useful for 
developing value sets with a scientifically justified sample size, and thus improve their quality.   
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Figure captions  
Fig. 1 Comparison of sample sizes estimated using different approaches. 
PI: Prediction interval. CI: Confidence interval. Refer to y-axis on left for Approach 1, 3 and 4, and y-axis on 
right for Approach 3. For Approach 2, mean absolute errors are based on 1000 replications for sample sizes 
from 100 to 900 participants (each of the participant valued 10 health states), whereas they are based on a single 
sample for the sample size of 1000 participants.  
 
 
 
 
 
 
Table 1 Unique blocks of EQ-5D-5L health states for the direct valuation with composite time trade-off method. 
  Health state  Health state 
Block MO SC UA PD AD Block MO SC UA PD AD 
1 
 
1 1 2 2 1 6 1 2 1 1 2 
1 1 2 3 5 1 1 2 1 2 
5 4 2 3 1 4 4 5 5 3 
5 1 4 5 1 2 1 3 4 5 
3 4 5 1 5 3 4 2 4 4 
3 5 2 4 5 2 3 1 5 2 
1 2 5 1 4 4 3 5 1 4 
4 5 1 4 4 5 5 4 2 4 
1 2 1 1 1 2 1 1 1 1 
5 5 5 5 5 5 5 5 5 5 
2 1 2 5 4 3 7 1 3 1 2 2 
1 2 1 2 1 2 4 5 5 3 
4 3 5 4 2 5 1 1 5 2 
3 4 1 5 5 1 1 4 2 5 
5 2 2 1 5 2 2 4 3 4 
4 5 1 3 3 4 2 1 1 5 
3 2 4 4 3 3 5 3 3 2 
2 3 5 1 4 4 5 4 1 3 
1 1 2 1 1 1 1 2 1 1 
5 5 5 5 5 5 5 5 5 5 
3 4 5 2 3 3 8 3 3 2 5 3 
5 5 2 3 3 2 3 2 4 2 
3 1 5 2 5 2 4 3 4 2 
5 2 4 5 5 3 2 3 1 4 
1 2 2 4 4 1 2 3 3 4 
1 3 3 1 3 2 1 3 3 4 
2 5 1 2 2 5 5 2 2 5 
1 1 4 2 1 5 3 4 1 2 
2 1 1 1 1 1 1 1 1 2 
5 5 5 5 5 5 5 5 5 5 
4 2 1 1 1 2 9 1 1 4 1 4 
1 4 5 5 4 2 5 3 3 1 
1 2 5 1 3 2 5 2 2 2 
4 4 3 4 5 2 1 4 4 4 
1 2 3 4 4 3 1 5 1 4 
5 3 2 2 1 5 3 2 4 3 
5 4 3 4 2 5 3 2 4 4 
4 4 1 2 5 3 5 1 4 3 
1 1 1 2 1 1 1 1 2 1 
5 5 5 5 5 5 5 5 5 5 
5 4 3 3 1 5 10 1 1 1 2 2 
5 4 1 5 3 5 2 3 3 5 
5 2 4 3 1 3 5 3 1 1 
2 4 4 4 3 4 3 5 5 5 
1 4 1 1 3 2 4 4 4 5 
3 1 5 2 4 1 3 2 2 4 
1 5 1 5 1 3 4 2 3 2 
2 1 3 1 5 4 2 3 2 1 
1 1 1 1 2 1 2 1 1 1 
5 5 5 5 5 5 5 5 5 5 
EQ-5D-5L: 5-Level EuroQol 5-Dimension; MO: Mobility, SC: Self-care; UA: Usual activities; PD: 
Pain/discomfort; AD: Anxiety/depression.
 
 
Table  2 D matrix based on indicator variables defined using the dummy coding scheme for EQ-5D-5L health state descriptors. 
 
INT MO2 MO3 MO4 MO5 SC2 SC3 SC4 SC5 UA2 UA3 UA4 UA5 PD2 PD3 PD4 PD5 AD2 AD3 AD4 AD5 
INT 0.131 
                    MO2 -0.037 0.117 
                   MO3 -0.022 0.052 0.129 
                  MO4 -0.029 0.057 0.058 0.155 
                 MO5 -0.013 0.056 0.059 0.066 0.130 
                SC2 -0.051 0.022 0.007 0.000 -0.008 0.111 
               SC3 -0.011 -0.016 -0.011 -0.052 -0.033 0.045 0.148 
              SC4 -0.020 -0.012 -0.024 -0.034 -0.021 0.051 0.067 0.140 
             SC5 -0.019 -0.013 -0.025 -0.038 -0.042 0.052 0.068 0.074 0.124 
            UA2 -0.050 0.011 -0.008 0.023 -0.018 0.015 -0.031 -0.001 0.001 0.125 
           UA3 -0.041 -0.012 -0.014 -0.001 -0.013 -0.005 -0.018 -0.004 -0.001 0.066 0.136 
          UA4 -0.039 -0.018 -0.011 -0.002 -0.036 0.006 0.005 0.013 0.019 0.063 0.061 0.141 
         UA5 -0.028 -0.001 -0.010 0.001 -0.012 0.002 -0.014 0.000 -0.006 0.053 0.052 0.056 0.123 
        PD2 -0.051 0.011 0.006 0.006 0.004 0.010 -0.004 -0.006 -0.012 -0.002 0.010 -0.006 0.007 0.101 
       PD3 -0.007 -0.020 -0.008 -0.020 -0.022 -0.015 0.017 -0.015 -0.023 -0.037 -0.035 -0.017 0.004 0.036 0.150 
      PD4 0.000 -0.019 -0.008 -0.008 -0.010 -0.013 -0.007 -0.029 -0.018 -0.024 -0.018 -0.018 0.005 0.034 0.059 0.114 
     PD5 -0.035 -0.002 0.003 0.012 -0.034 0.006 -0.016 -0.029 -0.025 0.022 0.021 0.009 -0.019 0.041 0.037 0.040 0.138 
    AD2 -0.063 -0.008 -0.006 0.007 -0.001 0.007 -0.028 -0.012 -0.009 0.019 0.015 0.016 0.005 0.009 -0.006 -0.015 0.008 0.126 
   AD3 -0.050 0.006 -0.008 -0.010 0.013 -0.013 -0.031 -0.033 -0.028 -0.001 0.011 -0.015 -0.019 0.022 -0.011 -0.021 -0.001 0.068 0.156 
  AD4 -0.045 0.000 -0.010 0.000 0.010 -0.010 -0.020 -0.007 -0.006 -0.007 -0.009 -0.022 -0.040 0.009 -0.011 -0.024 0.007 0.063 0.079 0.135 
 AD5 -0.037 -0.009 -0.018 -0.027 -0.020 -0.003 0.003 -0.008 -0.009 -0.010 -0.016 -0.012 -0.034 0.006 0.007 -0.013 -0.012 0.059 0.077 0.071 0.124 
EQ-5D-5L: 5-Level EuroQol 5-Dimension; INT: Intercept; MO2 to MO4, SC2 to SC5, UA2 to UA5, PD2 to PD5, and AD2 to AD5 represent elements corresponding to 
indicator variables for Self-care, Usual activity, Pain/discomfort, and Anxiety/depression dimension at severity level 2 to 4 (Reference: severity level 1), respectively. 
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Table A.1 D matrix based on indicator variables defined using the backward difference coding scheme for EQ-5D-5L health state descriptors.  
 INT MO2 MO3 MO4 MO5 SC2 SC3 SC4 SC5 UA2 UA3 UA4 UA5 PD2 PD3 PD4 PD5 AD2 AD3 AD4 AD5 
INT 0.131                     
MO2 -0.037 0.117                    
MO3 0.015 -0.065 0.141                   
MO4 -0.007 0.005 -0.075 0.167                  
MO5 0.016 -0.001 0.002 -0.090 0.154                 
SC2 -0.051 0.022 -0.015 -0.007 -0.008 0.111                
SC3 0.040 -0.038 0.020 -0.034 0.027 -0.066 0.169               
SC4 -0.010 0.004 -0.017 0.032 -0.007 0.006 -0.087 0.154              
SC5 0.001 -0.001 0.001 -0.004 -0.017 0.001 0.000 -0.066 0.115             
UA2 -0.050 0.011 -0.019 0.031 -0.042 0.015 -0.046 0.030 0.002 0.125            
UA3 0.009 -0.023 0.017 -0.017 0.029 -0.020 0.033 -0.016 0.002 -0.060 0.130           
UA4 0.002 -0.006 0.009 -0.004 -0.021 0.011 0.012 -0.006 0.003 -0.003 -0.072 0.155          
UA5 0.011 0.018 -0.017 0.002 0.021 -0.003 -0.015 0.006 -0.012 -0.010 0.000 -0.075 0.151         
PD2 -0.051 0.011 -0.004 -0.001 -0.001 0.010 -0.015 -0.001 -0.007 -0.002 0.012 -0.016 0.013 0.101        
PD3 0.045 -0.030 0.016 -0.011 0.000 -0.025 0.047 -0.031 -0.001 -0.035 -0.011 0.035 0.007 -0.065 0.179       
PD4 0.007 0.001 -0.001 0.012 0.000 0.002 -0.026 0.010 0.019 0.012 0.004 -0.018 0.002 -0.002 -0.089 0.146      
PD5 -0.035 0.017 -0.006 0.010 -0.045 0.019 -0.027 0.009 -0.007 0.046 -0.007 -0.013 -0.050 0.007 -0.029 -0.052 0.172     
AD2 -0.063 -0.008 0.002 0.013 -0.008 0.007 -0.035 0.016 0.003 0.019 -0.004 0.002 -0.011 0.009 -0.015 -0.009 0.023 0.126    
AD3 0.013 0.014 -0.016 -0.015 0.031 -0.020 0.017 -0.019 0.001 -0.020 0.016 -0.028 0.008 0.013 -0.018 -0.001 -0.003 -0.058 0.147   
AD4 0.005 -0.006 0.003 0.013 -0.012 0.003 0.007 0.016 -0.004 -0.006 -0.014 0.014 -0.015 -0.014 0.014 -0.003 0.010 -0.005 -0.073 0.135  
AD5 0.008 -0.009 0.001 -0.019 -0.003 0.006 0.016 -0.024 -0.002 -0.003 -0.004 0.018 -0.004 -0.003 0.021 -0.007 -0.029 -0.004 0.003 -0.063 0.117 
EQ-5D-5L: 5-Level EuroQol 5-Dimension; INT: Intercept; MO2 to MO4, SC2 to SC5, UA2 to UA5, PD2 to PD5, and AD2 to AD5 represent elements corresponding to 
indicator variables for Self-care, Usual activity, Pain/discomfort, and Anxiety/depression dimension at severity level 2 to 4 (Reference: previous severity level), respectively.  
Table A.2 Summary of Basic OLS and RE models for estimating utility values, using health state descriptors 
defined with the dummy coding scheme, based on the EQ-5D-5L value set study in the Singapore.  
Health state descriptor Basic OLS Model Coefficient (SE; SECluster) 
Basic RE Model  
Coefficient (SERE) 
Mobility Level 2 -0.072 (0.0207; 0.0193) -0.093 (0.0141) 
Mobility Level 3 -0.127 (0.0217; 0.0189) -0.141 (0.0147) 
Mobility Level 4 -0.253 (0.0238; 0.0198) -0.269 (0.0161) 
Mobility Level 5 -0.294 (0.0217; 0.0169) -0.298 (0.0147) 
Self-care Level 2 -0.118 (0.0202; 0.0193) -0.131 (0.0142) 
Self-care Level 3 -0.152 (0.0233; 0.0198) -0.160 (0.0159) 
Self-care Level 4 -0.288 (0.0226; 0.0246) -0.269 (0.0158) 
Self-care Level 5 -0.269 (0.0213; 0.0151) -0.271 (0.0143) 
Usual activities Level 2 -0.081 (0.0214; 0.0195) -0.090 (0.0147) 
Usual activities Level 3 -0.150 (0.0223; 0.0259) -0.156 (0.0157) 
Usual activities Level 4 -0.238 (0.0227; 0.0176) -0.240 (0.0155) 
Usual activities Level 5 -0.182 (0.0211; 0.0156) -0.190 (0.0143) 
Pain/discomfort Level 2 -0.072 (0.0192; 0.0173) -0.086 (0.0132) 
Pain/discomfort Level 3 -0.145 (0.0234; 0.0189) -0.140 (0.0159) 
Pain/discomfort Level 4 -0.260 (0.0203; 0.0202) -0.269 (0.0142) 
Pain/discomfort Level 5 -0.332 (0.0226; 0.0188) -0.343 (0.0153) 
Anxiety/depression Level 2 -0.084 (0.0215; 0.0230) -0.105 (0.0154) 
Anxiety/depression Level 3 -0.174 (0.0239; 0.0273) -0.185 (0.0171) 
Anxiety/depression Level 4 -0.312 (0.0222; 0.0222) -0.325 (0.0156) 
Anxiety/depression Level 5 -0.324 (0.0213; 0.0177) -0.322 (0.0144) 
Intercept 0.840 (0.0219; 0.0247) 0.868 (0.0210) 
R2 (Ordinary least square regression) = 28.9% 
Mean error (𝜎𝜎�2) = Between-participant error (𝜎𝜎�𝑢𝑢2) + Within-participant error (𝜎𝜎�𝑒𝑒2)  = 0.2032 + 0.1616 = 0.3653 
EQ-5D-5L: 5-Level EuroQol 5-Dimension; OLS: Ordinary least square; RE: Random effects; SE: Ordinary least 
square standard error; SECluster: Cluster-robust standard error; SERE: Random effect standard error. 
 
 
 
 
Table A.3 Summary of Basic OLS and RE models for estimating utility values, using health state descriptors 
defined with the backward difference coding scheme, based on the EQ-5D-5L value set study in the Singapore.  
Health state descriptor Basic OLS Model Coefficient (SE; SECluster) 
Basic RE Model  
Coefficient (SERE) 
Mobility Level 2 -0.072 (0.0207; 0.0193) -0.093 (0.0141) 
Mobility Level 3 -0.055 (0.0227; 0.0177) -0.048 (0.0154) 
Mobility Level 4 -0.126 (0.0248; 0.0222) -0.128 (0.0170) 
Mobility Level 5 -0.041 (0.0237; 0.0221) -0.029 (0.0164) 
Self-care Level 2 -0.118 (0.0202; 0.0193) -0.131 (0.0142) 
Self-care Level 3 -0.034 (0.0249; 0.0211) -0.029 (0.0169) 
Self-care Level 4 -0.136 (0.0237; 0.0258) -0.109 (0.0166) 
Self-care Level 5 0.019 (0.0204; 0.0243) -0.001 (0.0146) 
Usual activities Level 2 -0.081 (0.0214; 0.0195) -0.090 (0.0147) 
Usual activities Level 3 -0.069 (0.0219; 0.0239) -0.065 (0.0156) 
Usual activities Level 4 -0.088 (0.0237; 0.0262) -0.084 (0.0168) 
Usual activities Level 5 0.056 (0.0235; 0.0217) 0.050 (0.0164) 
Pain/discomfort Level 2 -0.072 (0.0192; 0.0173) -0.086 (0.0132) 
Pain/discomfort Level 3 -0.073 (0.0256; 0.0242) -0.055 (0.0176) 
Pain/discomfort Level 4 -0.115 (0.0231; 0.0238) -0.129 (0.0161) 
Pain/discomfort Level 5 -0.073 (0.0251; 0.0291) -0.073 (0.0180) 
Anxiety/depression Level 2 -0.084 (0.0215; 0.0230) -0.105 (0.0154) 
Anxiety/depression Level 3 -0.091 (0.0231; 0.0239) -0.080 (0.0163) 
Anxiety/depression Level 4 -0.138 (0.0222; 0.0236) -0.140 (0.0154) 
Anxiety/depression Level 5 -0.012 (0.0208; 0.0219) 0.002 (0.0146) 
Intercept 0.840 (0.0219; 0.0247) 0.868 (0.0210) 
R2 (Ordinary least square regression) = 28.9% 
Mean error (𝜎𝜎�2) = Between-participant error (𝜎𝜎�𝑢𝑢2) + Within-participant error (𝜎𝜎�𝑒𝑒2)  = 0.2032 + 0.1616 = 0.3653 
EQ-5D-5L: 5-Level EuroQol 5-Dimension; OLS: Ordinary least square; RE: Random effects; SE: Ordinary least 
square standard error; SECluster: Cluster-robust standard error; SERE: Random effect standard error. 
 
 
 
 
 
 
Table A.4 Summary of observed and predicted utility values using the Basic OLS and RE models of EQ-5D-5L 
health states elicited using composite time trade-off method in the Singapore value set study. 
Health States n Observed Mean (SD) Basic OLS Model Predicted Value (SE; SECluster) 
Basic RE Model 
Predicted Value (SERE) 
55555 1000 -0.516 (0.566) -0.562 (0.017; 0.020) -0.556 (0.018) 
11121 214 0.893 (0.247) 0.767 (0.022; 0.020) 0.782 (0.021) 
11211 204 0.859 (0.280) 0.759 (0.024; 0.023) 0.778 (0.022) 
11112 201 0.844 (0.318) 0.756 (0.022; 0.018) 0.763 (0.021) 
12111 195 0.770 (0.417) 0.721 (0.023; 0.022) 0.737 (0.021) 
21111 186 0.848 (0.346) 0.768 (0.025; 0.025) 0.775 (0.023) 
21112 110 0.765 (0.392) 0.684 (0.024; 0.025) 0.670 (0.022) 
12513 110 0.321 (0.632) 0.365 (0.027; 0.028) 0.362 (0.024) 
53221 110 0.160 (0.672) 0.241 (0.028; 0.029) 0.234 (0.024) 
12344 110 -0.090 (0.669) -0.001 (0.027; 0.031) -0.013 (0.023) 
44125 110 -0.150 (0.667) -0.097 (0.030; 0.036) -0.078 (0.025) 
54342 110 -0.281 (0.656) -0.236 (0.032; 0.041) -0.230 (0.027) 
14554 110 -0.290 (0.644) -0.276 (0.029; 0.034) -0.259 (0.025) 
44345 110 -0.333 (0.610) -0.435 (0.028; 0.039) -0.418 (0.025) 
11414 104 0.310 (0.591) 0.289 (0.027; 0.028) 0.303 (0.023) 
25222 104 0.263 (0.667) 0.262 (0.033; 0.038) 0.224 (0.027) 
25331 104 0.218 (0.654) 0.203 (0.030; 0.029) 0.209 (0.025) 
31514 104 0.166 (0.608) 0.218 (0.027; 0.029) 0.212 (0.024) 
35143 104 -0.008 (0.643) -0.043 (0.027; 0.034) -0.059 (0.024) 
53243 104 -0.043 (0.660) 0.009 (0.031; 0.038) 0.001 (0.026) 
21444 104 -0.059 (0.657) -0.121 (0.029; 0.036) -0.135 (0.025) 
53244 104 -0.100 (0.648) -0.259 (0.028; 0.039) -0.275 (0.025) 
21315 103 0.211 (0.634) 0.377 (0.028; 0.031) 0.413 (0.024) 
14113 103 0.151 (0.704) 0.294 (0.027; 0.028) 0.297 (0.024) 
52431 103 -0.011 (0.643) 0.238 (0.029; 0.024) 0.255 (0.024) 
31524 103 -0.031 (0.677) 0.146 (0.030; 0.027) 0.126 (0.025) 
43315 103 -0.077 (0.654) 0.045 (0.031; 0.031) 0.059 (0.026) 
15151 103 -0.114 (0.670) -0.039 (0.029; 0.031) -0.039 (0.025) 
24443 103 -0.187 (0.654) -0.193 (0.028; 0.030) -0.188 (0.024) 
54153 103 -0.226 (0.640) -0.249 (0.030; 0.035) -0.228 (0.025) 
12121 102 0.746 (0.369) 0.649 (0.024; 0.023) 0.651 (0.022) 
13122 102 0.619 (0.455) 0.532 (0.028; 0.025) 0.517 (0.024) 
35332 102 0.152 (0.606) 0.205 (0.028; 0.027) 0.220 (0.024) 
23514 102 0.106 (0.618) 0.145 (0.029; 0.030) 0.145 (0.024) 
22434 102 0.093 (0.644) 0.130 (0.030; 0.027) 0.122 (0.025) 
11425 102 0.087 (0.645) 0.105 (0.031; 0.035) 0.093 (0.026) 
45133 102 0.045 (0.634) -0.046 (0.031; 0.036) -0.060 (0.026) 
12543 102 0.038 (0.677) 0.121 (0.029; 0.031) 0.101 (0.024) 
42115 102 0.036 (0.637) 0.023 (0.029; 0.026) 0.026 (0.024) 
32443 102 -0.008 (0.628) -0.078 (0.031; 0.037) -0.098 (0.026) 
52215 102 -0.022 (0.641) 0.065 (0.031; 0.034) 0.055 (0.026) 
43542 102 -0.097 (0.629) -0.002 (0.030; 0.033) 0.003 (0.025) 
45413 102 -0.100 (0.610) -0.095 (0.032; 0.034) -0.096 (0.027) 
34155 102 -0.124 (0.637) -0.232 (0.031; 0.032) -0.208 (0.025) 
24553 102 -0.130 (0.625) -0.091 (0.034; 0.035) -0.125 (0.028) 
51152 102 -0.134 (0.639) -0.209 (0.030; 0.030) -0.212 (0.025) 
Health States n Observed Mean (SD) Basic OLS Model Predicted Value (SE; SECluster) 
Basic RE Model 
Predicted Value (SERE) 
11122 99 0.802 (0.326) 0.684 (0.023; 0.020) 0.677 (0.021) 
35311 99 0.263 (0.579) 0.222 (0.028; 0.030) 0.207 (0.024) 
42321 99 0.219 (0.652) 0.246 (0.035; 0.038) 0.227 (0.028) 
13224 99 0.207 (0.654) 0.293 (0.032; 0.030) 0.300 (0.026) 
34232 99 0.152 (0.624) 0.115 (0.032; 0.035) 0.122 (0.026) 
52335 99 -0.174 (0.631) -0.191 (0.029; 0.032) -0.180 (0.024) 
24445 99 -0.345 (0.601) -0.342 (0.030; 0.030) -0.326 (0.025) 
43555 99 -0.372 (0.583) -0.404 (0.029; 0.031) -0.416 (0.024) 
21334 98 0.189 (0.638) 0.114 (0.028; 0.031) 0.116 (0.024) 
32314 98 0.163 (0.671) 0.160 (0.030; 0.033) 0.154 (0.025) 
12334 98 0.152 (0.646) 0.192 (0.028; 0.033) 0.151 (0.024) 
23242 98 0.083 (0.675) 0.132 (0.030; 0.035) 0.115 (0.025) 
53412 98 0.021 (0.679) -0.014 (0.028; 0.035) -0.024 (0.024) 
33253 98 -0.017 (0.661) 0.072 (0.032; 0.029) 0.065 (0.026) 
24342 98 -0.026 (0.654) -0.027 (0.035; 0.040) -0.052 (0.028) 
55225 98 -0.227 (0.658) -0.200 (0.026; 0.027) -0.200 (0.023) 
11221 96 0.731 (0.391) 0.687 (0.024; 0.021) 0.692 (0.022) 
11421 96 0.496 (0.536) 0.529 (0.026; 0.022) 0.543 (0.023) 
13313 96 0.423 (0.574) 0.363 (0.033; 0.037) 0.367 (0.027) 
25122 96 0.248 (0.662) 0.290 (0.031; 0.032) 0.315 (0.026) 
11235 96 0.159 (0.670) 0.343 (0.028; 0.030) 0.314 (0.024) 
12514 96 0.088 (0.667) 0.068 (0.027; 0.030) 0.052 (0.024) 
31525 96 0.069 (0.644) 0.227 (0.024; 0.022) 0.222 (0.022) 
12244 96 -0.012 (0.680) 0.032 (0.031; 0.036) 0.070 (0.026) 
54231 96 -0.086 (0.680) 0.134 (0.030; 0.026) 0.129 (0.025) 
45233 96 -0.111 (0.666) -0.025 (0.030; 0.026) -0.013 (0.025) 
51451 96 -0.195 (0.644) -0.083 (0.030; 0.034) -0.087 (0.025) 
34515 96 -0.200 (0.658) -0.082 (0.030; 0.033) -0.055 (0.025) 
55233 96 -0.215 (0.667) -0.255 (0.033; 0.037) -0.266 (0.027) 
35245 96 -0.232 (0.636) -0.123 (0.027; 0.033) -0.117 (0.024) 
45144 96 -0.303 (0.632) -0.221 (0.029; 0.035) -0.226 (0.025) 
52455 96 -0.344 (0.630) -0.467 (0.028; 0.033) -0.466 (0.024) 
11212 90 0.746 (0.428) 0.675 (0.027; 0.023) 0.673 (0.023) 
12112 90 0.701 (0.466) 0.638 (0.024; 0.023) 0.632 (0.022) 
23152 90 0.054 (0.698) 0.200 (0.030; 0.035) 0.168 (0.026) 
21345 90 -0.019 (0.670) 0.034 (0.028; 0.026) 0.027 (0.024) 
43514 90 -0.038 (0.680) -0.228 (0.028; 0.036) -0.227 (0.024) 
34244 90 -0.092 (0.687) -0.060 (0.028; 0.028) -0.076 (0.024) 
55424 90 -0.248 (0.681) -0.346 (0.032; 0.035) -0.351 (0.026) 
44553 90 -0.270 (0.673) -0.390 (0.031; 0.036) -0.388 (0.026) 
EQ-5D-5L: 5-Level EuroQol 5-Dimension; n: Number of participants elicited the given health state; SD: Standard 
deviation; OLS: Ordinary least square regression model; SE: Ordinary least square standard error; SECluster: 
Cluster-robust standard error; RE: Random effect model; SERE: Random effect standard error. 
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